Monday Research Poster Presentations

POSTER SESSION I: Poster Display Hours – 8:30AM - 2:00PM
Poster Author Discussion Hour – 1:00PM - 2:00PM

POSTER SESSION II: Poster Display Hours – 3:45PM - 7:45PM
Poster Author Discussion Hour – 6:45PM - 7:45PM

POSTER SESSION I:
PHS: HEALTH SERVICES ROWS A-F
PCV: CARDIOVASCULAR DISORDERS ROWS F-K
PND: NEUROLOGICAL DISORDERS ROWS K-O

POSTER SESSION II:
PRM: RESEARCH ON METHODS ROWS A-H
PRS: RESPIRATORY-RELATED DISORDERS ROWS H-L
PSS: SENSORY SYSTEMS DISORDERS ROWS L-N
PUK: URINARY/KIDNEY DISORDERS ROWS N-P
## Research Poster Presentations – Session I

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS1–PHS14</td>
<td>A10</td>
<td>Health Services – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PHS15–PHS49</td>
<td>A12</td>
<td>Health Services – Cost Studies</td>
</tr>
<tr>
<td>PHS50–PHS565</td>
<td>A18</td>
<td>Health Services – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PHS56–PHS169</td>
<td>A21</td>
<td>Health Services – Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PCV1–PCV26</td>
<td>A39</td>
<td>Cardiovascular Disorders – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PCV27–PCV61</td>
<td>A44</td>
<td>Cardiovascular Disorders – Cost Studies</td>
</tr>
<tr>
<td>PCV62–PCV75</td>
<td>A50</td>
<td>Cardiovascular Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PCV76–PCV108</td>
<td>A53</td>
<td>Cardiovascular Disorders – Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PND1–PND13</td>
<td>A59</td>
<td>Neurological Disorders – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PND14–PND31</td>
<td>A61</td>
<td>Neurological Disorders – Cost Studies</td>
</tr>
<tr>
<td>PND32–PND48</td>
<td>A64</td>
<td>Neurological Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PND49–PND69</td>
<td>A67</td>
<td>Neurological Disorders – Health Care Use &amp; Policy Studies</td>
</tr>
</tbody>
</table>

## Research Poster Presentations – Session II

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRM1–PRM35</td>
<td>A71</td>
<td>Research On Methods – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PRM36–PRM52</td>
<td>A77</td>
<td>Research On Methods – Cost Studies</td>
</tr>
<tr>
<td>PRM53–PRM114</td>
<td>A80</td>
<td>Research On Methods – Database &amp; Management Methods</td>
</tr>
<tr>
<td>PRM115–PRM151</td>
<td>A91</td>
<td>Research On Methods – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PRM152–PRM173</td>
<td>A98</td>
<td>Research On Methods – Statistical Methods</td>
</tr>
<tr>
<td>PRM174–PRM193</td>
<td>A102</td>
<td>Research On Methods – Study Design</td>
</tr>
<tr>
<td>PRM194–PRM219</td>
<td>A105</td>
<td>Research On Methods – Conceptual Papers</td>
</tr>
<tr>
<td>PRS1–PRS17</td>
<td>A109</td>
<td>Respiratory-Related Disorders – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PRS18–PRS38</td>
<td>A112</td>
<td>Respiratory-Related Disorders – Cost Studies</td>
</tr>
<tr>
<td>PRS39–PRS47</td>
<td>A116</td>
<td>Respiratory-Related Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PRS48–PRS568</td>
<td>A118</td>
<td>Respiratory-Related Disorders – Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PSS1–PSS7</td>
<td>A122</td>
<td>Sensory Systems Disorders – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PSS8–PSS19</td>
<td>A123</td>
<td>Sensory Systems Disorders – Cost Studies</td>
</tr>
<tr>
<td>PSS20–PSS31</td>
<td>A125</td>
<td>Sensory Systems Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PSS32–PSS37</td>
<td>A127</td>
<td>Sensory Systems Disorders – Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PUK1–PUK7</td>
<td>A129</td>
<td>Urinary/Kidney Disorders – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PUK8–PUK16</td>
<td>A130</td>
<td>Urinary/Kidney Disorders – Cost Studies</td>
</tr>
<tr>
<td>PUK17–PUK22</td>
<td>A131</td>
<td>Urinary/Kidney Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PUK23–PUK26</td>
<td>A132</td>
<td>Urinary/Kidney Disorders – Health Care Use &amp; Policy Studies</td>
</tr>
</tbody>
</table>
## HEALTH SERVICES - Clinical Outcomes Studies

### PHS1 A1 POST-OPERATIVE PAIN MANAGEMENT ASSOCIATION WITH HEALTH ECONOMIC OUTCOMES

Robinson SB, University of North Carolina, Charlotte, Waxhaw, NC, USA

### PHS2 A2 THE RISK OF CHRONIC PANCREATITIS IN PATIENTS WITH PSORIASIS: A POPULATION-BASED MATCHED COHORT STUDY

Hsieh C1, Chiu H2, Chiang Y3, Tsai T4, Tsai Y4, Huang W5, 1National Yang-Ming University, Taipei, Taiwan, 2National Taiwan University Hospital, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei City, Taiwan, 4Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 5National Yang Ming University, Taipei, Taiwan

### PHS3 A3 RETROSPECTIVE STUDY TO COMPARE MEDICATION UTILIZATION BETWEEN PHYSICIAN-MANAGED AND PHARMACIST-MANAGED GROUPS IN STATE CORRECTIONAL FACILITIES AMONG AN HIV POPULATION

Vu H1, Shaya FT1, Barnes V2, Seo H3, Rodriguez de Bittner M4, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

### PHS4 A4 THE ROLE OF SLEEP QUALITY IMPROVEMENT TRAINING WITHIN WORKPLACE HEALTH PROMOTION

Szaboló J1, Markó Z1, Csákvári T1, Gombos G1, Steinhausz V1, Sió E1, Turcsányi K1, Boncz I1, Pakai A1, 1University of Pécs, Zalaegerszeg, Hungary, 2Geóllnoky Ferenc Hospital, Veszprém, Hungary, 3University of Pécs, Pécs, Hungary

### PHS5 A5 ROLE OF GLYCEMIC CONTROL IN DEVELOPMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Singhal M1, 1George E. Whalen Veterans Health Administration IDEAS Center, Salt Lake City, UT, USA

### PHS6 A6 ASSESSMENT OF WHO/INR PATIENT-CARE AND FACILITY-SPECIFIC INDICATORS IN THE OPHTHALMOLOGY WARDS OF TWO TERTIARY CARE HOSPITALS IN PAKISTAN

Atif M1, Rehan Sarwar M, Azeem M, Qamar-Uz-Zaman M, Arslan B, Nauman A, Zeshan M, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

### PHS7 A7 USE OF REAL-WORLD DATA TO ESTIMATE CARDIOVASCULAR EVENT RATES AMONG ELDERLY HIGH CARDIOVASCULAR RISK PATIENTS WITH MEDICARE SUPPLEMENTAL INSURANCE IN THE UNITED STATES

Quek RG1, Hardin J1, Bonafede MM2, Johnson BH2, Gandra SR3, 1Amgen, Inc., Thousand Oaks, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA

### PHS8 A8 USE OF REAL-WORLD DATA TO ESTIMATE CARDIOVASCULAR EVENT RATES AMONG NON-ELDERLY COMMERCIALLY INSURED HIGH CARDIOVASCULAR RISK PATIENTS IN THE UNITED STATES

Quek RG1, Hardin J1, Bonafede MM2, Johnson BH2, Gandra SR3, 1Amgen, Inc., Thousand Oaks, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA

### PHS9 A9 THE BURDEN OF ATOPIC DERMATITIS IN ADULTS: RESULTS FROM THE 2013 UNITED STATES NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)

Whitley J1, Emir B1, Seitzman R1, Makinson G, Pfizer, New York, NY, USA

### PHS10 A10 KNOWLEDGE, AWARENESS, AND PREVALENCE AMONG COMMUNITY REGARDING HEPATITIS B AND C IN ABBOTTABAD, KPK, PAKISTAN

Azhar S1, Syed A2, Yousaf A1, Khan TK1, Mansoor Z1, Haq N2, 1Comsats Institute of Information Technology, Abbottabad, Pakistan, 2University of Balochistan, Quetta, Pakistan

### PHS11 A11 BIDIRECTIONAL SCREENING OF COMORBID TUBERCULOSIS AND DIABETES AND ITS EFFECT ON TUBERCULOSIS TREATMENT OUTCOMES

Azhar S1, Umer RZ1, Syed A2, Shahid M3, 1Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan, 2DHQ Hospital, Bahawalnagar, Pakistan

### PHS12 A12 EMERGENCY DEPARTMENT VISITS ASSOCIATED WITH ANKLE SPRAINS IN THE UNITED STATES

Shah S1, Thomas AC1, Noone JM2, Blanchette CM3, Wikstrom EW4, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA

### PHS13 A13 POTENTIAL DRUG-DRUG INTERACTIONS IN RENAL IMPAIRMENT PATIENTS IN PAKISTAN

Saleem A1, Masood I1, Khan TM2, Nawaz M2, 1The Islamia University of Bahawalpur, Bahawalpur, Pakistan, 2Monash University Malaysia, Selangor, Malaysia

### PHS14 A14 ASPECTS OF FAMILY LIFE IN YOUNG PEOPLE IN A REGION OF COLOMBIA IN 2014

Alvis Zakzuk JY1, Alvis Zakzuk J2, Salcedo Mejia F3, Alvis Guzman N4, Paz Witches J1, Manrique Mclean J1, 1Mutual Ser EPS, Cartagena, Colombia, 2Alzak foundation, Cartagena, Colombia, 3Alzak Foundation, cartagena, Colombia, 4Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia
HEALTH SERVICES - Cost Studies

PHS15  A15  DEATH BURDEN OF PNEUMOCOCCAL DISEASE ON BRAZILIAN PRIVATE HEALTH SYSTEM
        Santos MC1, Ferreira CN2, Squiassì HB2, Santana CF2, 1Unimed, São José do Rio Preto, Brazil, 2Pfizer, São Paulo, Brazil

PHS16  A16  A BUDGET IMPACT ANALYSIS ESTABLISHING THE ECONOMIC BENEFIT OF THE SANDOSTATIN® LAR® MOBILE ADMINISTRATION PROGRAM IN CANADA
        Panchmatia HR1, Becker DL2, Choe Y3, Gu Q4, Optum, Stoneham, MA, USA, 2Optum, Burlington, ON, Canada, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Optum, Waltham, MA, USA

PHS17  A17  DETERMINATION OF MEDICATION ERRORS AND ECONOMIC IMPLICATIONS TO ONE YEAR OF THE ESTABLISHMENT OF CLINICAL PHARMACY SERVICE IN MEDICAL ONCOLOGY UNIT: EXPERIENCE IN A HOSPITAL OF CANCER IN MEXICO
        Hernández Martínez JF1, Morales Perez M, Toledo Viguera S, Colín Gómez DP, Paredes García P, Sánchez Rodríguez I, Centro Oncológico Estatal, ISSEMyM, Toluca, Mexico

PHS18  A18  IMPACT OF THE ACA: MEDICATION THERAPY MANAGEMENT SERVICES FOR AMERICAN INDIAN PATIENTS ON RESERVATIONS WITH CARDIOVASCULAR DISEASE AND SELF-INSURANCE PLANS
        St. Germaine R, University of Minnesota, Minneapolis, MN, USA

PHS19  A19  A RETROSPECTIVE STUDY TO COMPARE THE MEDICATION COSTS OF AN HIV POPULATION IN STATE CORRECTIONAL FACILITIES BETWEEN THE PHYSICIAN-MANAGED AND PHARMacist-MANAGED GROUPS
        Vu H1, Shaya FT1, Barnes V2, Seo H1, Rodrigo de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

PHS20  A20  TOTAL COST OF CARE IN REAL-WORLD PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH ANTIneOPlastic THERAPY
        Radchenko J1, Korytowsky B2, Bhor M3, Tuell K3, Feinberg B1, 1Cardinal Health, Dublin, OH, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA

PHS21  A21  A RETROSPECTIVE STUDY TO COMPARE MEDICATION COSTS OF A HEPATITIS C POPULATION IN STATE CORRECTIONAL FACILITIES BETWEEN PHYSICIAN-MANAGED AND PHARMacist-MANAGED TREATMENT GROUPS
        Vu H1, Shaya FT1, Barnes V2, Seo H1, Rodrigo de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

PHS22  A22  COST AND CLINICAL OUTCOMES OF A PHARMacist-LED INTERVENTION PROGRAM TO REDUCE UTILIZATION HIGH-RIk Sedative Hypnotics and SkeleTAL Muscle Relaxants in the Elderly Population with Depression
        Yu S, Scott and White Health Plan, Temple, TX, USA

PHS23  A23  TOTAL KNEE ARTHROPLASTY POST ACUTE CARE COSTS BY DISCHARGE STATUS
        Zeng F1, Waldo D2, 1West Health Institute, La Jolla, CA, USA, 2Actuarial Research, Columbia, CA, USA

PHS24  A24  ECONOMIC EVALUATION OF 2014 CHOLERA OUTBREAK IN GHANA: A HOUSEHOLD COST ANALYSIS IN HIGH AND LOW INCIDENCE SETTINGS
        Awalime DK1, Davies-Teye B2, Vanotoo L3, Owoow N4, Nketia-Amponsah E5, 1University of Ghana Legon and Drifney Consult Ltd, Accra, Ghana, 2Drifney Consult Ltd and Ghana Health Service, Accra, Ghana, 3Ghana Health Services and Promise Ghana, Accra, Ghana, 4University of Ghana Legon, Accra, Ghana

PHS25  A25  HEALTH CARE EXPENDITURES, PRESCRIPTION DRUG COST, AND OUT-OF-POCKET SPENDING AMONG ADULTS WITH CHRONIC DISEASE CONDITION COMBINATIONS IN THE UNITED STATES
        Sakharkar P, Roosevelt University College of Pharmacy, Schaumburg, IL, USA

PHS26  A26  ESTIMATING HEALTH BENEFITS AND LIFETIME ECONOMIC COST-SAVINGS FROM PROMOTING BREASTFEEDING TO PREVENT CHILDHOOD LEUKEMIA IN THE UNITED STATES
        Ekwueme D1, Hung M1, Guy G2, Rim SH3, 1US CDC, Atlanta, GA, USA, 2Centers for Disease Control and Prevention, Atlanta, GA, USA

PHS27  A27  EXCESS DIRECT MEDICAL EXPENDITURES ASSOCIATED WITH DEMENTIA AMONG ELDERLY (>=65 YEARS) INDIVIDUALS
        Deb A1, Sambamoorthi U2, Schreurs B3, Iones K4, 1West Virginia University, School of Pharmacy, Morgantown, WV, USA, 2West Virginia University, Morgantown, WV, USA

PHS28  A28  ECONOMIC BURDEN OF MODERATE CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES
        McQueen RB1, Farahbakhshian S2, Bell K2, Nair K3, Saseen J4, 1University of Colorado, Aurora, CO, USA, 2AstraZeneca, Wilmington, DE, USA, 3AstraZeneca, Fort Washington, PA, USA

PHS29  A29  ECONOMIC SURVEILLANCE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ALBERTA, CANADA
        Waye A1, Jacobs P2, Ospina M2, Stickland M3, Mayers I3, 1Institute of Health Economics, Edmonton, AB, Canada, 2Strategic Clinical Network, Edmonton, AB, Canada, 3University of Alberta & AHS, Edmonton, AB, Canada

PHS30  A30  COSTS OF CANCER FROM THE PATIENT/CAREGIVER PERSPECTIVE
PHS31 A31 THE SERVICE UTILIZATION AND COST OF HIV TREATMENT IN MBAGATHI DISTRICT HOSPITAL, KENYA

Owiti EA. The University of Nairobi, Nairobi, Kenya

PHS32 B1 CLINICAL AND ECONOMIC BURDEN OF BLOODSTREAM INFECTIONS FOLLOWING CENTRAL VENOUS CATHETER PLACEMENT IN THE INTENSIVE CARE UNIT

Brunelli SM1, Turetta W1, Sibbel S1, Hunt A1, Pfaffle A2, DaVita Clinical Research, Minneapolis, MN, USA, 2CorMedix Inc, Bedminster, NJ, USA

PHS33 B2 ECONOMIC BURDEN OF HEMATOPOIETIC CELL TRANSPLANT AMONG PATIENTS WITH HEMATOLOGIC MALIGNANCIES

Bonafede MM1, Cai Q1, McMorrow DM1, Garfin P2, Teasell J3, Richhariya A4, Truven Health Analytics, Cambridge, MA, USA, 3Seattle Genetics, Bothell, WA, USA

PHS34 B3 ECONOMIC EVALUATION OF 2014 CHOLERA OUTBREAK IN GHANA: A PATIENT LEVEL AND HEALTH CARE SYSTEM COST ANALYSIS IN AN URBAN SETTING

Davies-Teye B1, Awalime DK2, Davies-Teye S3, Vanootoo L4,1Drifney Consult Ltd and Ghana Health Service, Accra, Ghana, 2University of Ghana Legon and Drifney Consult Ltd, Accra, Ghana, 3Drifney Consult Ltd, Accra, Ghana, 4Ghana Health Services and Promise Ghana, Accra, Ghana

PHS35 B4 OUT-OF-POCKET HEALTH EXPENDITURES IN PATIENTS WITH UNCONTROLLED ASTHMA FROM COLOMBIA

Zakzuk J1, Parra D1, Saucedo Mejia F1, Alvis-Zakzuk JS3, Buendia E1, Caraballo L2, Alvis-Guzmán N2, 1University of Cartagena, Institute for Immunological Research, Cartagena, Colombia, 2University of Cartagena, Health Economics Research Group, Cartagena, Colombia, 3University of Cartagena, CARTAGENA DE INDIAS, Colombia, 4Universidad de Cartagena, Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 5University of Cartagena, Institute for Immunological Research, Fundementb., Cartagena, Colombia

PHS36 B5 OUTCOMES, HEALTH CARE RESOURCES USE, AND COSTS IN PATIENTS WITH POST-MYOCARDIAL INFARCTION: THE HORUS COHORT STUDY IN THE EGB FRENCH CLAIMS AND HOSPITAL DATABASE

Blin P1, Dureau-Pournin C1, Lassalle R1, Jové J1, Thomas-Delecourt F2, Droz-Perroteau C1, Danchin N1, Moore N2, 1Bordeaux PharmacoEpi, INSERM CIC1401, ADERA, Bordeaux University, Bordeaux, France, 2AstraZeneca, Rueil-Malmaison, France, 3European Georges Pompidou Hospital, Paris, France, 4Bordeaux PharmacoEpi, INSERM CIC1401, Bordeaux University, Bordeaux CHU, Bordeaux, France

PHS37 B6 COST ASSESSMENT OF SOJOURN CATHETER USE IN CHRONIC RENAL PATIENTS

Vianna CM1, Souza RC2, Silva FV3, Mosesqu GB1, Peregrino AA1, Silva TN1, 1Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Universidade do Estado do Rio de Janeiro, RIO DE JANEIRO, Brazil, 3Universidade Federal Fluminense, Niterói, Brazil

PHS38 B7 SEVERE HYPOGLYCEMIAS TREATMENT COSTS (INPATIENT) AT INSTITUTIONAL LEVEL IN MEXICO

Camacho-Cordero LM1, Baez-Revelutias FB2, Herran S1, Huicochea-Bartelt JL2, Yamamoto JV1, 1Health Consultings, Distrito Federal, Mexico, 2Boehringer Ingelheim, Distrito Federal, Mexico, 3UMIT, Tirol, Austria

PHS39 B8 COSTS OF END-OF-LIFE TREATMENTS AMONG ELDERLY METASTATIC COLON CANCER PATIENTS

Sieluk J1, Hanna N2, Goto D1, Seal B1, Mullins CD1, 1University of Maryland School of Pharmacy Graduate School, Baltimore, MD, USA, 2University of Maryland Department of Surgery, Division of General and Oncologic Surgery, Baltimore, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA, 4Takeda Pharmaceutical Company, Cambridge, MA, USA

PHS40 B9 OPPORTUNITY COST AND HEALTH IMPACT OF PRENATAL CARE IN PREGNANT WOMEN WITH PUBLIC HEALTH INSURANCE IN COLOMBIA

Gomez de la rosa F1, Barraco Arnedo C1, Florez tanuz A1, Lopez pajarero K1, Mazennet granados E2, Orozco Africano J1, Alvis Guzman N1, 1Grupo de investigació n en economía de la salud, Cartagena, Colombia, 2Universidad de Cartagena, Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 3Centro de investigación e Innovación en Salud - CliSA, Cartagena de Indias, Colombia

PHS42 B10 COST-EFFECTIVENESS ANALYSIS OF NEONATAL SCREENING OF CRITICAL CONGENITAL HEART DEFECTS IN CHINA

Gai R, National Center for Child Health and Development, Tokyo, Japan

PHS43 B11 COST EFFECTIVENESS OF A DIABETES SELF-MANAGEMENT EDUCATION PROGRAMME OF TYPE 2 DIABETES PATIENTS IN RIYADH, SAUDI ARABIA

Alaboudi IS, Buridah Central Hospital, Buridah, Saudi Arabia

PHS44 B12 COST-EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL CARE FOR TYPE 2 DIABETES MELLITUS PATIENTS IN RIBEIRÃO PRETO BRAZIL

Picoli RM1, Pereira LB1, Barros MT1, Nunes AA1, Pereira LR1, Costa AL1, 1University of Sao Paulo, Ribeirao Preto, Brazil, 2Brandeis University, Waltham, MA, USA

PHS45 B13 INCOME GROWTH TRAJECTORY FOR PARENTS OF CHILDREN WITH DOWN SYNDROME IN THE UNITED STATES

Samuelson D1, Kageleiry A1, Duh MS1, Lefebvre P2, Campbell JY3, DerSarkissian M1, Haider BA4, Skotko BG3, 1Analysis Group, Inc., Boston, MA, USA, 2Groupe d'analyse, Ltee, Montreal, QC, Canada, 3Harvard University, Cambridge, MA, USA, 4Analysis
PHS46  B14  CHARACTERISTICS AND HEALTH CARE UTILIZATION AMONG ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACCORDING TO MISSED WORK STATUS: A RETROSPECTIVE ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY  
Dashputre AA, Kamal KM, Covvey JR, Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA

PHS47  B15  COST OF INFLAMMATORY BOWEL DISEASE HOSPITALIZATIONS IN IRELAND  
Bai R, Hogan A, AbbVie Ltd., Dublin 24, Ireland

PHS48  B16  ECONOMIC EVALUATION OF THE FUNCTIONING OF CYTOTOXIC DRUG RECONSTITUTION UNIT  
Diarra Z, Cherrah Y, Meddah B, Ahid S, Mohammed V University, Rabat, Morocco

PHS49  B17  VALUE-BASED HEALTH CARE: COLLABORATION BETWEEN HEALTH CARE PERSONNELS IN A PATIENT-CENTERED SOCIETY  
Okoro KI, University of Nigeria, NSUKKA, ENUGU, Nigeria

HEALTH SERVICES - Patient-Reported Outcomes & Patient Preference Studies

PHS50  B18  ASSESSMENT OF PATIENT ADHERENCE AND UTILIZATION OF SOFOSBUVIR-BASED REGIMENS: A REAL-WORLD DATA ANALYSIS  
Parekh MH1, Kamal K1, Miller R2, Koerner P3, Giannetti V4, Craft Z2, Mylan School of Pharmacy Duquesne University, Pittsburgh, PA, USA, 1Walgreens Specialty Pharmacy, Carnegie, PA, USA, 2Mylan School of Pharmacy Duquesne University, Pittsburgh, PA, USA, 3Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA

PHS51  B19  PATIENT-RELATED BARRIERS TO MEDICATION ADHERENCE IN TYPE 2 DIABETIC PATIENTS: A SYSTEMATIC REVIEW  
Salkar M, Sah J, Pinto S, Vaidya V, University of Toledo, Toledo, OH, USA

PHS52  B20  ASSESSMENT OF PHARMACIST-MEDIATED EDUCATION ON MEDICATION ADHERENCE BEHAVIOUR IN TYPE 2 DIABETES MELLITUS PATIENTS  
Adepu SP1, Ramanath KV1, Bhat S2, SAM S1, Omanakuttan C1, 1SAC COLLEGE OF PHARMACY, MANDYA, India, 2Adichunchangiri Hospital and Research centre, MANDYA, India

PHS53  B21  DEVELOPMENT AND VALIDATION OF PATIENT DECISION AID FOR ANTIDEPRESSANT MEDICATIONS  
Al Jumah K, Al Amal hospital, Riyadh, Saudi Arabia

PHS54  B22  THE IMPACT OF A DECISION AID ON DEPRESSED PATIENTS’ INVOLVEMENT IN SHARED DECISION MAKING: A PILOT RANDOMIZED CONTROLLED DOUBLE-BLINDED STUDY  
Al Jumah K, Al Amal hospital, Riyadh, Saudi Arabia

PHS55  B23  IMPACT OF PHARMACIST INTERVENTION USING SHARED DECISION MAKING ON ADHERENCE AND MEASURABLE DEPRESSED PATIENT OUTCOMES  
Al Jumah K, Al Amal hospital, Riyadh, Saudi Arabia

PHS56  B24  KNOWLEDGE, ATTITUDES, AND PRACTICE TOWARDS USE OF LONG-TERM FAMILY PLANNING METHODS AMONG WOMEN AGED 15-49 YEARS: A COMMUNITY-BASED SURVEY IN AN URBAN UGANDAN SETTING  
Kiyingi R1, Tuehbwe D1, Nalwanga E1, Sseguia E1, Anguzu R2, Nakku-Joloba E1, Makerere University School of Public Health, Kampala, Uganda, 1El-Channun Community Health Initiatives (ELCOHIN), Kampala, Uganda

PHS57  B25  COLORECTAL CANCER PATIENT SATISFACTION WITH THE MULTIDISCIPLINARY TREATMENT IN A HIGH SPECIALTY UNIT AT INSTITUTO MEXICANO DEL SEGURO SOCIAL  
Sat-Muñoz D1, Balderas-Peña L2, Palomares-Chacon U2, Salas-Barragán C2, Martinez-Herrera B2, 1Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, 2UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico

PHS58  B26  BARRIERS AND FACILITATORS TO DIABETES SELF-MANAGEMENT IN A PRIMARY CARE SETTING: PHYSICIAN PERSPECTIVE  
Khairnar R1, Kamal KM2, McConaha J2, Giannetti V2, Dwibedi N2, University of Maryland, Baltimore, MD, USA, 1Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA, 2West Virginia University, Morgantown, WV, USA

PHS59  B27  RACE, SEX, AND GEOGRAPHIC VARIATIONS IN DEPRESSION AMONG CANCER PATIENTS IN THE UNITED STATES  
Adjei Boakye E1, Mohammed KA1, Osazuwa-Peters N2, Buchanan P1, Chen J1, Burroughs T1, 1Saint Louis University Center for Outcomes Research (SLUCOR), Saint Louis, MO, USA, 2Saint Louis University Cancer Center, Saint Louis, MO, USA

PHS60  B28  BARRIERS AND FACILITATORS TO DIABETES SELF-MANAGEMENT IN A PRIMARY CARE SETTING: PATIENT PERSPECTIVE  
Khairnar R1, Kamal KM2, McConaha J2, Giannetti V2, Dwibedi N2, University of Maryland, Baltimore, MD, USA, 1Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA, 2West Virginia University, Morgantown, WV, USA

PHS61  B29  AWARENESS AND IMPACT OF INTERNATIONAL NORMALIZED RATIO MONITORING IN ONGOING ANTICOAGULATION THERAPY IN CARDIAC PATIENTS  
Pal M1, Bandari S1, Sekar MC2, Gier S3, 1St. Peter’s Institute of Pharmaceutical Sciences, Warangal, Telangana, India, 2College of
PHS62  B30  PREDICTORS OF UNHEALTHY DAYS IN PATIENTS WITH METASTATIC BREAST, LUNG, OR COLORECTAL CANCER  
Casebeer AW¹, Draziyich Antol D¹, Hopson S¹, Khoury R², Parikh A³, Michael T⁴, Stemkowski S¹, Bunce M⁵, Humana, Inc., Louisville, KY, USA, ²Genentech, South San Francisco, CA, USA

PHS63  B31  VALIDATION OF THE DHDS: A HYBRID INSTRUMENT TO MEASURE HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH DIABETES, HYPERTENSION, AND DYSLIPIDEMIA  
Bae YH¹, Pham DQ¹, Bounthavong M², Law A³,¹WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA, ²University of Washington, SEATTLE, WA, USA

PHS64  C1  DEPRESSION TREATMENT AND HEALTH-RELATED QUALITY OF LIFE AMONG ADULTS WITH ARTHRITIS AND DEPRESSION IN THE UNITED STATES  
Shah DR, Dwibedi N, Sambamoorthi U, West Virginia University, Morgantown, WV, USA

PHS65  C2  THE IMPACT OF DIFFERENT APPROACHES TO ADDRESSING MISSING ITEMS IN CANCER EXPERIENCE SURVEYS  
Roydhouse JK¹, Gutman R¹, Keating NL², Mor V³, Wilson IB¹,¹Brown University School of Public Health, Providence, RI, USA, ²Harvard University, Boston, MA, USA

HEALTH SERVICES - Health Care Use & Policy Studies

PHS66  C3  CONSEQUENCES OF MEDICARE PART D PLAN SWITCHING: GAIN OR LOSS  
Han J¹, Ko D³, Fairleigh Dickinson University, Florham Park, NJ, USA, ²University of Pittsburgh at Greensburg, Greensburg, PA, USA

PHS67  C4  ASSESSING PATIENT-PERCEIVED BARRIERS TO ROUTINE COUNSELING SERVICES OFFERED BY COMMUNITY PHARMACISTS  
Brinkerhoff A¹, Pinto S²,¹The University of Toledo, Toledo, OH, USA, ²University of Toledo, Toledo, OH, USA

PHS68  C5  UTILIZATION OF CERVICAL CANCER PREVENTIVE CARE SERVICES: DOES MARITAL STATUS MATTER?  
Gunjal SS¹, Mbere O², Wang X³, Essien EJ¹, Mayo Clinic, Rochester, MN, USA, ²Houston Department of Health and Human Services, Houston, TX, USA, ³University of Houston, Houston, TX, USA

PHS69  C6  SYSTEMATIC REVIEW OF INTERNATIONAL MODELS OF CARE ON RARE DISEASES  
Chirveches MA¹, Aroca A¹, Otálora M¹, Quirland-Lazo C², Paccheco B¹, Pollania MJ¹, Zamora M¹, Barrera L¹, Holguín A¹, Castañeda-Cardona C³, Rueda MA¹, González V¹, Cifuentes E¹, Lozano L¹, Díaz J¹, Salinas JG¹, Alfonso K¹, Estupiñán N¹, Lasalvia P¹, Rosselli D¹, Pontificia Universidad Javeriana, Medical School, Bogota, Colombia, ²Universidad de Chile, Santiago, Chile, ³Neuroeconomix, Bogota, Colombia, ⁴Pontificia Universidad Javeriana, Bogota, Colombia

PHS70  C7  PROFILES OF PERFORMANCE OF HEALTH SERVICE PROVIDERS TO IMPLEMENT A PAY-FOR-PERFORMANCE MECHANISM: SIMULATION APPROACH  
Pinzón-Flórez CE¹, Pérez-Gómez AV¹, Castillo-Londoño JS²,¹Instituto de Evaluación Tecnológica en Salud, Bogotá, Colombia, ²Ministry of Health, Bogotá, Colombia

PHS71  C8  AWARENESS OF CATARACT AND AGE-RELATED MACULAR DEGENERATION AMONG KOREAN ELDERLY PATIENTS  
Lee H, Kang H, Yonsei University, Incheon, South Korea

PHS72  C9  ASSOCIATION BETWEEN SELF-MONITORING BEHAVIOR AND SELF-MANAGEMENT EDUCATION AMONG AMERICANS WITH DIABETES  
Adjie Boakye E¹, Rojek RP³, Varble A², Peavler O², Trainer A¹, Hinyard L¹,¹Saint Louis University Center for Outcomes Research (SLUCOR), Saint Louis, MO, USA, ²Saint Louis University College for Public Health and Social Justice, Saint Louis, MO, USA

PHS73  C10  BARRIERS AND FACILITATORS TO ANTICOAGULATION PATIENT SELF-TESTING: NATIONAL SURVEY OF ANTICOAGULATION PROVIDERS IN THE UNITED STATES  
Manzoor B, Goncharenko A, Nutescu EA, University of Illinois at Chicago, Chicago, IL, USA

PHS74  C11  EVALUATION OF AN INTEGRATED CARE PATHWAY FOR RECTAL CANCER TREATMENT IMPLEMENTATION USING A LOGIC MODEL  
Kobayashi ST¹, Campolina AG², Soares PC³, Ribeiro Jr U², Diz MD², Hoff PM²,¹Instituto do Cancer do Estado de Sao Paulo - Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, ²Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, ³Saint Paulo University, Sao Paulo, Brazil, ⁴Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil, ⁵Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

PHS75  C12  THE COST OF SERIOUS ADVERSE EVENTS IN MULTI-DRUG-RESISTANT TUBERCULOSIS TREATMENT: EXPERIENCE FROM ETHIOPIA  
Gama ES, Girma M, Liverpool School of Tropical Medicine, Liverpool, UK

PHS76  C13  UNLOCKING SMARTPHONE POTENTIAL IN HEALTH CARE BY PROVIDING SMARTPHONES TO PATIENTS: A SYSTEMATIC REVIEW  
Namil M¹, White A², Weltman N¹, Carter P³, Trinh J¹, Dsouza K¹, Loving C¹, Dang C¹, Jacob S¹,¹University of North Texas Health
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS77</td>
<td>DEVELOPMENT AND VALIDATION OF PSYCHOLOGICAL INTERVENTION GUIDELINE FOR PATIENTS DIAGNOSED WITH NON-COMMUNICABLE CHRONIC DISEASES</td>
<td>Diaz-Sotelo OD, Orozco AM, Cabrera-Infante KL, Pinzón LV, Universidad El Bosque, Bogotá D.C., Colombia</td>
</tr>
<tr>
<td>PHS79</td>
<td>MONITORING OF HEALTH CARE UTILIZATION 3 MONTHS PRIOR TO A CHRONIC OBSTRUCTIVE PULMONARY DISEASE HOSPITALIZATION</td>
<td>Hur P, Stuart B, Tom S, University of Maryland School of Pharmacy, Baltimore, MD, USA</td>
</tr>
<tr>
<td>PHS80</td>
<td>EVIDENCE-BASED RECOMMENDATIONS FOR PSYCHOLOGICAL INTERVENTION TO PATIENTS DIAGNOSED WITH RHEUMATOID ARTHRITIS</td>
<td>Orozco AM, Diaz-Sotelo OD, Larra-Meléndez PJ, Quintero-Aguirre LM, Universidad El Bosque, Bogotá D.C., Colombia</td>
</tr>
<tr>
<td>PHS82</td>
<td>THE RELATIONSHIP BETWEEN PREVENTIVE CARE VISITS AND SCHOOL ABSENCES AMONG CHILDREN WITH ASTHMA</td>
<td>Rojanasarat S, Carlson AM,   University of Minnesota, Minneapolis, MN, USA,     Data Intelligence Consultants, LLC, Eden Prairie, MN, USA</td>
</tr>
<tr>
<td>PHS83</td>
<td>OVER- AND UNDERUSE OF THERAPEUTIC AND PALLIATIVE CARE SERVICES FOR CANCER PATIENTS AT END OF LIFE: A POPULATION-BASED STUDY</td>
<td>Ramsey S, Goulart B, Shankaran V, Conklin T, McGee R, Lyman GH, Mera C, Smith B, Fred Hutchinson Cancer Research Center, Seattle, WA, USA,     Premera Blue Cross, Moultrie Terrace, WA, USA,     Regence Blue Shield, Portland, OR, USA</td>
</tr>
<tr>
<td>PHS84</td>
<td>OVERVIEW OF ONCOLOGY CENTERS STRUCTURES IN BOTH PUBLIC AND PRIVATE BRASILIAN HEALTH CARE SYSTEM</td>
<td>Nita ME, Mussolino F, Vaz P, Riveros BS, Tolentino AC, IECS, HAOC, and FIPE, Sao Paulo, Brazil,   HEADS, Sao Paulo, Brazil,   University of Glasgow, Glasgow, UK,   UERJ HEALTH ECONOMICS &amp; OUTCOMES RESEARCH, Rio de Janeiro, Brazil</td>
</tr>
<tr>
<td>PHS85</td>
<td>THE STUDY OF UNDERSTANDING OF HEALTH PROFESSIONALS' LIABILITY INSURANCE AMONG MEDICAL DOCTORS IN MONGOLIA</td>
<td>Sambuu T, Byambaa G, Luvsan M,   Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia,   UB City Health Department, Ulaanbaatar, Mongolia</td>
</tr>
<tr>
<td>PHS86</td>
<td>ANALYSIS ON THE UTILIZATION STATUS OF ESSENTIAL MEDICINES IN BEIJING'S COMMUNITY HEALTH INSTITUTIONS</td>
<td>Zhang F, Li SC, Yang Y, Shenyang Pharmaceutical University, Shenyang, China,   University of Newcastle, Callaghan, NSW, Australia</td>
</tr>
<tr>
<td>PHS87</td>
<td>ASSOCIATION BETWEEN AFFORDABLE CARE ACT-COVERED PREVENTIVE CARE USE AND EMERGENCY ROOM VISITS AND COSTS IN ADULTS</td>
<td>Wang Y, Cobran EK,   The University of Georgia, Athens, GA, USA,   University of Georgia, Athens, GA, USA</td>
</tr>
<tr>
<td>PHS88</td>
<td>A CROSS-SECTIONAL SURVEY OF COMMUNITY PHARMACISTS TOWARDS ANTIMICROBIAL STEWARDSHIP IN MALAYSIA</td>
<td>Khan MU, Ahmad A, Hassali MA, Elkalmi RM, Zaidi ST, UCSI University, Kuala Lumpur, Malaysia,   Universiti Sains Malaysia, Penang, Malaysia,   International Islamic University Malaysia, Kuantan, Malaysia,   University of Tasmania, Hobart, Australia</td>
</tr>
<tr>
<td>PHS89</td>
<td>IMPACT OF OUT-OF-POCKET COSTS ON MEDICATION ADHERENCE AMONG PATIENTS WITH TYPE 2 DIABETES</td>
<td>Bibbeau WS, Nelson DR, Eli Lilly, Indianapolis, IN, USA</td>
</tr>
<tr>
<td>PHS90</td>
<td>ASSESSMENT OF ASSOCIATION BETWEEN HEALTH INSURANCE COVERAGE AND DIABETES CARE QUALITY USING DIFFERENCE-IN-DIFFERENCES ANALYSIS</td>
<td>Zhang S, Thomas II, Purdue University, West Lafayette, IN, USA</td>
</tr>
<tr>
<td>PHS91</td>
<td>ECONOMIC EVALUATION OF SCHOOL-BASED HEALTH CENTERS: A COMMUNITY GUIDE SYSTEMATIC REVIEW</td>
<td>Ran T, Chattopadhyay S, Hahn R, CDC, Atlanta, GA, USA</td>
</tr>
<tr>
<td>PHS92</td>
<td>RACIAL AND ETHNIC DIFFERENCES IN THE USE OF PREVENTIVE SERVICES AMONG CANCER SURVIVORS IN THE MEDICARE PROGRAM</td>
<td>Cheng X, Lee MJ, Sallburn R, University of South Carolina, Columbia, SC, USA,   University of South Carolina, COLUMBIA, SC, USA,   University of Florida, Gainesville, FL, USA</td>
</tr>
<tr>
<td>PHS93</td>
<td>EFFECTS OF THE QUALITY BLUE PRIMARY CARE PROGRAM ON HEALTH OUTCOMES IN PATIENTS COVERED BY THE BLUE CROSS BLUE SHIELD OF LOUISIANA</td>
<td></td>
</tr>
</tbody>
</table>
PHS94 D2 GOVERNMENT REIMBURSEMENT VALUES VERSUS REAL CHEMOTHERAPY COSTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: ANOTHER BARRIER TO TREATMENT ACCESS?

Lehment T1, Goes L1, Piedade AD1,2, Evidencias - Kantar Health, Sào Paulo, Brazil, 2Evidencias - Kantar Health, Campinas, Brazil, 3Evidências - Kantar Health, Campinas, Brazil

PHS95 D3 DIFFERENTIAL ACCESS TO CARE BETWEEN DEPRESSED AND NON-DEPRESSED CHILDREN IN A PATIENT-CENTERED MEDICAL HOME

Papademetriou E, Sam Z, Dutta S. Eliassen Group, Somerset, NJ, USA

PHS96 D4 GENERATION AND EVALUATION OF AN INDICATOR OF HEALTH SYSTEM PERFORMANCE FOR MATERNAL AND REPRODUCTIVE HEALTH IN COLOMBIA: AN ECOLOGICAL STUDY

Pinzón Flórez CE1, Fernández-Niño JA2, Cardenas-Cardenas LM3, Diaz-Quijano DM1, Ruiz-Rodriguez M4, Reveiz L1, 2Universidad de La Sabana, Chia, Colombia, 3Instituto Nacional de Salud Pública de México, Cuernavaca, Mexico, 4Universidad Industrial de Santander, Bucaramanga, Colombia, 5Pan American Health Association, Washington D.C, DC, USA

PHS97 D5 TIMELINESS OF CARE AMONG ELDERLY WOMEN WITH BREAST CANCER: A POPULATION-BASED OBSERVATIONAL STUDY

Vyas A1, Madhavan SS2, Sambamoorthi U3, University of Rhode Island, Kingston, RI, USA, 2West Virginia University, Morgantown, WV, USA

PHS98 D6 EMERGENCY DEPARTMENT OPTIMIZATION: IMPROVING TIMELINESS OF PATIENT CARE

Das D, Sir M, Nestler D, Hellmich T, Marisamy G, Pasupathy K, Mayo Clinic, Rochester, MN, USA

PHS99 D7 IMPROVING ACCESS FOR SURGICAL PATIENTS USING VARIOUS POLICIES

Martinez G, Sir M, Pasupathy K, Mayo Clinic, Rochester, MN, USA

PHS100 D8 IMPACT OF INCLUSION OF PROBLEM-BASED LEARNING WITH CONVENTIONAL TEACHING METHOD TO DEVELOP SKILLS IN PHARMACY UNDERGRADUATES: DOES IT REALLY HELPFUL TO ENHANCE THEIR SKILLS?

Kashyap M, Bahari BB, AIMST University, Semeling, Malaysia

PHS101 D9 FINAL YEAR PHARMACY STUDENTS’ PERCEPTION TOWARDS GENERIC MEDICINES: A QUESTIONNAIRE-BASED STUDY FROM YEMEN

AL-Tamimi SK1, Hassali MA1, Shafie AA1, Alrasheedy AA2, 1Universiti Sains Malaysia, Penang, Malaysia, 2Qassim University, Buraidah, Saudi Arabia

PHS102 D10 CHARACTERIZING EMERGENCY DEPARTMENT UTILIZATION AMONG PEDiatric PATIENTS WITH TYMPANostomy TUBES

Tam IM1, Candrilli SD2, Moss JR2, 1Otonomy, Inc., San Diego, CA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Charlotte Eye, Ear, Nose, and Throat Associates, Matthews, NC, USA

PHS103 D11 THE IMPACT OF HIGH-DEDUCTIBLE HEALTH PLANS ON THE FINANCIAL BURDEN OF COMMERCIAly INSURED POPULATION IN THE UNITED STATES

Zhang X, Sood N, University of Southern California, Los Angeles, CA, USA

PHS104 D12 FACTORS ASSOCIATED WITH 30-DAY READMISSION AFTER HIP/PELVIC FRACTURE INPATIENT STAYS

Lin I1, Menzin J1, 1Boston Health Economics, Inc., Waltham, MA, USA, 2Boston Health Economics, Waltham, MA, USA

PHS105 D13 CLINICAL AND ECONOMIC BURDEN OF MENTAL DISORDERS IN CHILDREN WITH CHRONIC PHYSICAL CONDITIONS IN THE UNITED STATES

Suryavanshi M1, Yang Y1, University of Mississippi School of Pharmacy, University, MS, USA, 2University of Mississippi, University, MS, USA

PHS106 D14 IMPACT OF DEPRESSION ON HEALTH EXPENSES AND MEDICAL UTILIZATION IN ADULTS WITH MIGRAINE

Wu J1, Davis-Ajami ML2, Lu K1, 1University of South Carolina, Greenville, SC, USA, 2Virginia Commonwealth University, Richmond, VA, USA, 3University of South Carolina, Columbia, SC, USA

PHS107 D15 IMPACT OF AN AMBULATORY CARE PHARMACY-BASED TRANSITION OF CARE PROGRAM ON HOSPITAL READMISSIONS AND COST

Ni W1, Colayco D2, Hashimoto J2, Komoto K2, Gowda C3, Wearda B3, McCombs J1, 1University of Southern California, Los Angeles, CA, USA, 2Synergy Pharmacy Solutions, Bakersfield, CA, USA, 3Kern Health Systems, Bakersfield, CA, USA

PHS108 D16 NATIONAL TRENDS IN DIRECT HEALTH CARE EXPENDITURES AMONG ADULTS WITH MIGRAINE IN THE UNITED STATES: 2004-2013

Shah A1, Raval A2, 1Virginia Commonwealth University, Richmond, VA, USA, 2Healthcore, Inc., Wilmington, DE, USA

PHS109 D17 ARTHRITIS-RELATED MEDICAL CARE UTILIZATION AND EXPENDITURES UNDER GATEKEEPER AND NON-GATEKEEPER PLANS USING MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA

Ma X1, Park C, Lawson KA, The University of Texas at Austin, Austin, TX, USA
THE ECONOMIC BURDEN OF TYPES OF COMORBIDITY FOR PATIENTS WITH DIABETES MELLITUS
An J, Le Q, Western University of Health Sciences, Pomona, CA, USA

COSTS OF DIABETES-RELATED HOSPITALIZATION AND PERIPHERAL LOWER-EXTREMITY DISEASE-RELATED HOSPITALIZATION IN THE UNITED STATES
Zhao R1, Carlson AM2, 1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH POTENTIAL REFRACTORY EPILEPSY IN TEXAS MEDICAID
Gupte-Singh K, Barner JC, Wilson JP, Hovinga CA, Richards KM, Rascati KL, The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

ECONOMIC BURDEN ATTRIBUTABLE TO OBESITY IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS IN THE UNITED STATES
Kang HA, Makhinova T, Ogunsanya M, Ma X, Lawson KA, The University of Texas at Austin, Austin, TX, USA

THE ECONOMIC COST OF A DEATH EVENT IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
Santos MC1, Ferreira CN1, Squiassì HB2, Santana CF2, 1Unimed, São José do Rio Preto, Brazil, 2Pfizer, São Paulo, Brazil

COMPOUNDING PHARMACIES: WORKERS’ COMPENSATION COST
Iyengar R1, Henderson R2, Nelson B2, 1Express Scripts, Malvern, PA, USA, 2Express Scripts, St. Louis, MO, USA, 2Express Scripts, St. Louis, MO, USA

EVALUATION OF ASTHMA OUTCOMES IN OLDER AND YOUNGER ADULTS
Hines DM1, Sery P1, Blanchette CM2, 1UNC Charlotte, Charlotte, NC, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA

PROVIDER AND PAYER-RELATED INDICATORS OF COMMERCIAL PRICE VARIATION IN PROFESSIONAL SERVICES IN VERMONT
Erten MZ1, London K2, Grenier M2, Jones C1, Ohler T2, 1University of Vermont - College of Medicine, Burlington, VT, USA, 2University of Massachusetts Medical School, Charlestown, MA, USA

DEMOGRAPHIC CHARACTERISTICS OF HIGH MEDICATION SPENDERS IN A STATE CORRECTIONAL SYSTEM
Vu H1, Shaya FT1, Barnes V2, Seo H2, Rodriguez de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

FACTORS ASSOCIATED WITH HEALTH CARE UTILIZATION BY MEMBERS OF QUALIFIED HEALTH PLANS: EMERGENCY ROOM VERSUS PRIMARY CARE PROVIDER VISITS
Pulungan Z, Teigland C, Parente A, Kilgore K, McClellan M, Avalere Health - An Inovalon Company, Bowie, MD, USA

NATIONAL TRENDS IN DIRECT HEALTH CARE COSTS ASSOCIATED WITH ENDOMETRIOSIS AMONG FEMALES IN THE UNITED STATES: 2004-2013
Shah A1, Raval A1, Thakker D1, 1Virginia Commonwealth University, Richmond, VA, USA, 2Healthcore, Inc., Wilmington, DE, USA, 3Capita India Pvt. Ltd., Mumbai, India

LOWER COSTS AND RESOURCE USE IN PATIENTS WHO USE ONSITE HEALTH CLINICS
Lalla D1, Hilu K2, Niecko T2, Kaszpurenko J2, Shreeve S2, 1Palo Alto Outcomes Research, Palo Alto, CA, USA, 2Crossover Health, Aliso Viejo, CA, USA, 3Necko Health Economics, Tierra Verde, FL, USA

ESTIMATING THE ARTHROPLASTIES REVISION RATES AND LIFETIME OF KNEE AND HIP PROSTHESIS IN THE STATE OF SÃO PAULO, BRAZIL
Oliveira FM1, Barbosa EG1, Junqueira Junior SM1, Oliveira D1, Luque A1, Cabra HA2, 1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson & Johnson Medical, México DF, Mexico

CHARACTERISTICS OF A HIGH MEDICATION COST GROUP IN STATE CORRECTIONAL FACILITIES
Vu H1, Shaya FT1, Barnes V2, Seo H2, Rodriguez de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

HEALTH TECHNOLOGY ASSESSMENT ON AN AUTOMATED BLOOD TRANSPORT SYSTEM FOR INPATIENT WARDS: FIRST STEP IN SUPPORTING THE DECISION-MAKING PROCESS IN UNIVERSITY HOSPITALS OF THAILAND
Thaweethamcharoen T, Noparatayaporn P, Nopmaneejumruslers C, Luenee P, Mahidol University, Bangkok, Thailand

COST COMPARISON BETWEEN THE MANUAL SYSTEM AND AUTOMATED DISPENSING SYSTEMS; HOW TO USE EFFECTIVE HEALTH TECHNOLOGY AT A LARGE ACADEMIC HOSPITAL IN THAILAND
Noparatayaporn P1, Thaweethamcharoen T2, Sakulbumrungsil R1, Sangseenil Wc, Chulalongkorn University, Bangkok, Thailand, 1Mahidol University, Bangkok, Thailand

A DESCRIPTIVE STUDY OF MEDICATION EXPENDITURES AND CONSUMPTION IN STATE CORRECTIONAL FACILITIES
Vu H1, Shaya FT1, Barnes V2, Seo H2, Rodriguez de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

ASSESSMENT AND CHARACTERIZATION OF GAPS IN LITERATURE OF RESOURCE UTILIZATION AND ECONOMIC RELATED HOSPITALIZATION AND PERIPHERAL LOWER-EXTREMITY DISEASE-RELATED HOSPITALIZATION IN THE UNITED STATES
Zhao R1, Carlson AM2, 1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH POTENTIAL REFRACTORY EPILEPSY IN TEXAS MEDICAID
Gupte-Singh K, Barner JC, Wilson JP, Hovinga CA, Richards KM, Rascati KL, The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

ECONOMIC BURDEN ATTRIBUTABLE TO OBESITY IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS IN THE UNITED STATES
Kang HA, Makhinova T, Ogunsanya M, Ma X, Lawson KA, The University of Texas at Austin, Austin, TX, USA

THE ECONOMIC COST OF A DEATH EVENT IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
Santos MC1, Ferreira CN1, Squiassì HB2, Santana CF2, 1Unimed, São José do Rio Preto, Brazil, 2Pfizer, São Paulo, Brazil

COMPOUNDING PHARMACIES: WORKERS’ COMPENSATION COST
Iyengar R1, Henderson R2, Nelson B2, 1Express Scripts, Malvern, PA, USA, 2Express Scripts, St. Louis, MO, USA, 2Express Scripts, St. Louis, MO, USA

EVALUATION OF ASTHMA OUTCOMES IN OLDER AND YOUNGER ADULTS
Hines DM1, Sery P1, Blanchette CM2, 1UNC Charlotte, Charlotte, NC, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA

PROVIDER AND PAYER-RELATED INDICATORS OF COMMERCIAL PRICE VARIATION IN PROFESSIONAL SERVICES IN VERMONT
Erten MZ2, London K2, Grenier M2, Jones C1, Ohler T2, 1University of Vermont - College of Medicine, Burlington, VT, USA, 2University of Massachusetts Medical School, Charlestown, MA, USA

DEMOGRAPHIC CHARACTERISTICS OF HIGH MEDICATION SPENDERS IN A STATE CORRECTIONAL SYSTEM
Vu H1, Shaya FT1, Barnes V2, Seo H2, Rodriguez de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

FACTORS ASSOCIATED WITH HEALTH CARE UTILIZATION BY MEMBERS OF QUALIFIED HEALTH PLANS: EMERGENCY ROOM VERSUS PRIMARY CARE PROVIDER VISITS
Pulungan Z, Teigland C, Parente A, Kilgore K, McClellan M, Avalere Health - An Inovalon Company, Bowie, MD, USA

NATIONAL TRENDS IN DIRECT HEALTH CARE COSTS ASSOCIATED WITH ENDOMETRIOSIS AMONG FEMALES IN THE UNITED STATES: 2004-2013
Shah A1, Raval A1, Thakker D1, 1Virginia Commonwealth University, Richmond, VA, USA, 2Healthcore, Inc., Wilmington, DE, USA, 3Capita India Pvt. Ltd., Mumbai, India

LOWER COSTS AND RESOURCE USE IN PATIENTS WHO USE ONSITE HEALTH CLINICS
Lalla D1, Hilu K2, Niecko T2, Kaszpurenko J2, Shreeve S2, 1Palo Alto Outcomes Research, Palo Alto, CA, USA, 2Crossover Health, Aliso Viejo, CA, USA, 3Necko Health Economics, Tierra Verde, FL, USA

ESTIMATING THE ARTHROPLASTIES REVISION RATES AND LIFETIME OF KNEE AND HIP PROSTHESIS IN THE STATE OF SÃO PAULO, BRAZIL
Oliveira FM1, Barbosa EG1, Junqueira Junior SM1, Oliveira D1, Luque A1, Cabra HA2, 1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson & Johnson Medical, México DF, Mexico

CHARACTERISTICS OF A HIGH MEDICATION COST GROUP IN STATE CORRECTIONAL FACILITIES
Vu H1, Shaya FT1, Barnes V2, Seo H2, Rodriguez de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

HEALTH TECHNOLOGY ASSESSMENT ON AN AUTOMATED BLOOD TRANSPORT SYSTEM FOR INPATIENT WARDS: FIRST STEP IN SUPPORTING THE DECISION-MAKING PROCESS IN UNIVERSITY HOSPITALS OF THAILAND
Thaweethamcharoen T, Noparatayaporn P, Nopmaneejumruslers C, Luenee P, Mahidol University, Bangkok, Thailand

COST COMPARISON BETWEEN THE MANUAL SYSTEM AND AUTOMATED DISPENSING SYSTEMS; HOW TO USE EFFECTIVE HEALTH TECHNOLOGY AT A LARGE ACADEMIC HOSPITAL IN THAILAND
Noparatayaporn P1, Thaweethamcharoen T2, Sakulbumrungsil R1, Sangseenil Wc, Chulalongkorn University, Bangkok, Thailand, 1Mahidol University, Bangkok, Thailand

A DESCRIPTIVE STUDY OF MEDICATION EXPENDITURES AND CONSUMPTION IN STATE CORRECTIONAL FACILITIES
Vu H1, Shaya FT1, Barnes V2, Seo H2, Rodriguez de Bittner M1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Correct Rx Pharmacy Services, Hanover, MD, USA

ASSESSMENT AND CHARACTERIZATION OF GAPS IN LITERATURE OF RESOURCE UTILIZATION AND ECONOMIC
BURDEN IN INFLAMMATORY MYOPATHIES

Gaia S, Mwamburi M, Market Access Solutions LLC, Raritan, NJ, USA

PHS128 E8 DETERMINING THE VALUE OF A HEALTH SYSTEM/SCHOOL PARTNERSHIP TO PROVIDE SCHOOL HEALTH AND PEDIATRIC CARE IN SCHOOL: A COST-BENEFIT ANALYSIS
Mueller JM1, Johnson S2, Connor K3, Calderon Velazquez G4, Padula WV5, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 1Johns Hopkins University, Baltimore, MD, USA

PHS129 E9 THE CONCENTRATION OF HEALTH CARE EXPENDITURE OF A COLOMBIAN PUBLIC HEALTH INSURANCE COMPANY
Marrugo Arnedo C1, Florez tanuz A2, Gomez de la rosa F3, Lopez pajaz K4, Orozco Africano J5, Alvis Guzman N6, Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 1Grupo de investigación en economía de la salud - GIES, Cartagena, Colombia, 2Centro de investigación e Innovación en Salud - CiSA, Cartagena de Indias, Colombia

PHS130 E10 IMPACT OF PATIENT NONADHERENCE TO DIABETES TREATMENT ON COMPLICATION RISKS AND HEALTH CARE COSTS
Mizobe M, Fukuda H, Kyushu University, Fukuoka, Japan

PHS131 E11 EFFECT OF FINANCIAL INCENTIVES ON HEALTH PROMOTION PARTICIPATION
Navratil Strawn J, Optum, Minneapolis, MN, USA

PHS132 E12 FINAL YEAR MEDICAL STUDENTS’ PERCEPTION TOWARDS GENERIC MEDICINES IN SOUTHEAST YEMEN
Al-Tamimi SK1, Hassali MA2, Shafie AA3, Alrasheedy AA4, Universiti Sains Malaysia, Penang, Malaysia, 2Qassim University, Buraidah, Saudi Arabia

PHS133 E13 REDUCING YOUNG INVINCIBLES’ HEALTH CARE SPENDING THROUGH THE ACA EXPANSION OF DEPENDENT COVERAGE
Chen J1, Vargas-Bustamante A2, Novak P3, University of Maryland, College Park, MD, USA, 1UCLA, Los Angeles, MD, USA, 2School of Public Health, University of Maryland, College Park, MD, USA

PHS134 E14 PREVALENCE AND RISK FACTORS OF ALCOHOL CONSUMPTION IN YOUNG POOR PEOPLE WITH PUBLIC HEALTH INSURANCE FROM A REGION OF COLOMBIA
Salcedo Mejia E1, Alvis Zakzuk J2, Alvis Guzman N3, Alzak Foundation, cartagena, Colombia, 2Alzak foundation, Cartagena, Colombia, 3University of Cartagena, Cartagena, Colombia

PHS135 E15 COSTS OF NON-ADHERENCE IN HYPERTENSIVE PATIENTS AFFILIATES TO HEALTH INSURANCE IN CARTAGENA
Alvis Estrada L1, Alvis Guzman N2, Paz Wilches J3, Universidad de Cartagena, Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 1Mutual Ser EPS, cartagena, Colombia

PHS136 E16 A DESCRIPTION OF THE ADULT POPULATION’S MEDICATION EXPERIENCES IN THE UNITED STATES USING AN AGGLOMERATIVE HIERARCHICAL CLUSTERING METHOD
Olson AW1, Schommer JC2, Tierg PD3, Brown LM4, University of Minnesota, Minneapolis, MN, USA, 2University of Minnesota College of Pharmacy, Minneapolis, MN, USA, 3SpeedReading People, Hartford, CT, USA, 4Chapman University, Irvine, CA, USA

PHS137 E17 ASSOCIATION OF PATIENT-CENTERED CARE AND SEEKING INSURANCE FROM HEALTH EXCHANGES BY THE LOW-INCOME PEOPLE: EVIDENCE FROM THE HEALTH INFORMATION NATIONAL TREND SURVEY
Haider MR, Qureshi Z, Khan MM, University of South Carolina, Columbia, SC, USA

PHS138 E18 KNOWLEDGE, ATTITUDE, AND PERCEPTION OF FUTURE PHARMACISTS REGARDING PHARMACOVIGILANCE IN PAKISTAN
Syed A1, Azhar S2, Jamshed S3, Dawood M4, Asghar MJ5, Comsats Institute of Information Technology, Abbottabad, Pakistan, 2International Islamic University, Malaysia, Kuantan, Malaysia

PHS139 E19 INDEPENDENT FACTORS AFFECTING PATIENT COMPLIANCE TO PRIVATE INSURER-FUNDED HEALTH CARE MANAGEMENT IN CANADA
Chen W1, Krupitsky Y2, Currie B3, Luny R4, Baumgartner A5, Molloy-Whaley E6, Anderson S7, Innocom Strategies, Oakville, ON, Canada, 1Health Forward, Oakville, ON, Canada, 2The Great-West Life Assurance Company, Winnipeg, MB, Canada

PHS140 E20 EXTRINSIC FACTORS OF BLOODSTREAM INFECTIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS
Oláh A1, Demeterné Medve É2, Pakai A3, Váradyné Horváth A4, Müller A5, Buncz I6, Fusz K7, Szabó L8, Fullér N9, University of Pécs, Pécs, Hungary, 1University of Pécs, Zalaegerszeg, Hungary

PHS141 E21 PHARMACY-LED MEDICATION RECONCILIATION PROGRAMS AT HOSPITAL TRANSITIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Mekonnen AB1, McLachlan AJ2, Brien JE3, Gondar University, Gondar, Ethiopia, 2University of Sydney, Sydney, Australia

PHS142 E22 MONITORING SYSTEM OF PATIENTS WITH CHRONIC NEUROLOGICAL DISORDERS
Blavatska O1, Grynkiv I2, Blavatskyj I3, Danylo Galatskyj Lviv National Medical University, Lviv, Ukraine, 1National University Lviv Polytechnic, Lviv, Ukraine

PHS143 E23 MEDICATION THERAPY MANAGEMENT INTERVENTIONS IN EMERGENCY AND AMBULATORY CARE IN NORTHWEST
ETIOPIA

Bhagavathula AS. Melaku T, Getaye Y, Getachew H.University of Gondar, Gondar, Ethiopia

PHS144 E24 ASSOCIATION BETWEEN NEIGHBORHOOD SOCIOECONOMIC STATUS, STROKE CENTER ADMISSION, AND MORTALITY AFTER ISCHEMIC AND ILL-DINE STROKE

Ohnimma A1, Zheng Y2, Jeerakathil T3, Klarenbach S1, Hakkinen U1, Nguyen T1, Chuck A1, Friesen D2, Ruseski J3, Kaul P1, Ariste R1, Jacobs P3, University of Alberta, Edmonton, AB, Canada, 2Institute of Health Economics, Edmonton, AB, Canada, 3Alberta Health Services, Edmonton, AB, Canada, 4National Institute for Health and Welfare, Helsinki, Finland, 5Alberta Medical Association, Edmonton, AB, Canada, 6West Virginia University, Morgantown, WV, USA, 7Canadian Institute for Health Information, Ottawa, ON, Canada

PHS145 E25 FACTORS INFLUENCING ACCESS TO MEDICINES IN NIGERIA: VIEWS AND EXPERIENCES OF RESIDENTS OF THE FEDERAL CAPITAL TERRITORY

Umoru A, Alfa J, Adigwe OP, National Assembly, Abuja, Nigeria

PHS146 E26 SATISFACTION OF CLIENTS WITH THE SERVICES OF AN OUTPATIENT PHARMACY AT A UNIVERSITY HOSPITAL IN NORTHERN ETHIOPIA: A CROSS-SECTIONAL STUDY

Surur AS1, Teni FS2, Girmay G1, Tesfa M1, Moges E1, Abraha M1, University of Gondar, Gondar, Ethiopia, 2Addis Ababa University, Addis Ababa, Ethiopia

PHS147 E27 INCENTIVES TO HONOR MATERNL HEALTH REFERRALS IN A SETTING WITH INEQUITABLE ACCESS TO HEALTH CARE IN THE AMANISIE WEST DISTRICT IN ASHANTI REGION

Nuamah GB1, Agyei-Baffour P2, Akohene KM1, Boateng D1, Dobin D1, Donkor KA1, Kwame Nkrumah University of Science and Technology, Ghana, Kumasi, Ghana, 2Kwame Nkrumah University of Sciences and Technology (KNUST), Kumasi, Ghana, 3Ghana Health Service, Manso Nkwanta, Ghana, 4Ghana Health Service, Accra, Ghana

PHS148 E28 DRUG THERAPY OF EPILEPTIC SEIZURES IN ADULT EPILEPTIC OUTPATIENTS OF UNIVERSITY OF GONDAR TEACHING HOSPITAL, GONDAR, NORTH WEST ETHIOPIA

Birru EM. University of Gondar, Gondar, Ethiopia

PHS149 E29 A TRANSITIONS OF CARE COLLABORATION BETWEEN PHARMACY ACADEMIA AND A COMMUNITY HEALTH SYSTEM

Bradford C, Thanh D, Kwong M, Chang L, Shah BM, Sui L, Young G, Sharp HealthCare, San Diego, CA, USA, 2Touro University California, Vallejo, CA, USA

PHS150 E30 ASSESSMENT OF DRUG UTILIZATION PRACTICE IN OPHTHALMOLOGY DEPARTMENT OF UNIVERSITY OF GONDAR REFERRAL AND TEACHING HOSPITAL, NORTH WEST ETHIOPIA

Eshete Melese Birru ME. University of Gondar, Gondar, Ethiopia

PHS151 E31 A CROSS-SECTIONAL ASSESSMENT OF KNOWLEDGE, ATTITUDE, AND PRACTICE ON HEPATITIS B AND C PATIENTS IN AYUB MEDICAL COMPLEX ABBOTTABAD, PAKISTAN

Azhar S, Syed A, Mansoor Z, Yousaf A,Comsats Institute of Information Technology, Abbottabad, Pakistan

PHS152 E32 DEVELOPMENT AND IMPLEMENTATION OF THE MEDICAL AUDIT PROCESS IN HEALTH SERVICES AT THE FIRST LEVEL OF CARE: A CONTEXTUALIZED MODEL ADAPTED TO ECUADOR

Torres Toala FG. Makroscopio, Quito, Ecuador

PHS153 E33 A SYSTEMATIC ANALYSIS OF THE REGULATORY PROCESS OF DRUG DELIVERY IN SOCIAL NETWORKS AND THE IMPACT ON HEALTH CARE RUSSIA

Starostina I. Krupnova I.Federal Service for Surveillance in Healthcare (Roszdravnadzor), Moscow, Russian Federation

PHS154 E34 EROSION OF EMPATHY IN PRIMARY CARE TRAINEES

McRae J, Calusi G, Liu M, Scognamiglio V, Messina E, Polenzani L, Maio V, Thomas Jefferson University, Philadelphia, PA, USA, 2AUSL 4 Prato, Prato, Italy

PHS155 F1 CAESARIAN SECTION RATE IN HUNGARY BETWEEN 1960-2013

Kovacs G, Nagy S, Endrei D, Boncz I, Széchenyi István University, Győr, Hungary, 2University of Pécs, Pécs, Hungary

PHS156 F2 HEALTH INSURANCE COVERAGE AND UTILIZATION OF PRENATAL CARE IN THE UNITED STATES

Zelle L. GfK Custom Research, Wayland, MA, USA

PHS157 F3 SOCIAL IMPACT OF A PRENATAL HEALTH CARE PROGRAM AT A HEALTH INSURER IN COLOMBIA

Arevalo HO, Guarín NE, Muñoz-Galindo IM, Moreno JA, Diaz JA, Salud Total EPS, Bogotá D.C., Colombia, 2Universidad Nacional de Colombia, Bogotá D.C., Colombia

PHS158 F4 PREVENTIVE CARE SCREENING PATTERNS AMONG WOMEN WITH MEDICAID

Bonafede MM, Miller JD, Cai Q, Troeger KA, Pohlman S, Truven Health Analytics, Cambridge, MA, USA, 2Hologic, Inc., Marlborough, MA, USA

PHS159 F5 HEALTH TECHNOLOGY ASSESSMENT: A TRAILBLAZER IN BETTER PATIENT CARE

Manchikalapudi Pk. Chalapathi institute of pharmaceutical sciences, Guntur, India

PHS160 F6 DEVELOPING BELIEFS THAT SUPPORT VACCINATION: RESULTS FROM THE PHARMACISTS' PNEUMONIA PREVENTION PROGRAM
PNH161 F7 A REVIEW OF CURRENT QUALITY METRICS FOR EVALUATING PATIENT-CENTERED MEDICAL HOMES
Varga S, Lombardi M, Maio V, Thomas Jefferson University, Philadelphia, PA, USA

PNH162 F8 OVERVIEW OF NATIONAL LEADING ORGANIZATIONS INVOLVED IN QUALITY OF CARE IN ONCOLOGY
Wen L, Divers C, Lingohr-Smith M, Lin J, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, Novosys Health, Green Brook, NJ, USA

PNH163 F9 USING CLINICAL DATA TO MONITOR HIGH-COST, PERFORMANCE CODING ISSUES ASSOCIATED WITH PRESSURE ULCERS: A MULTILEVEL ANALYSIS
Padula WV, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PNH164 F10 REVIEW OF CARDIOVASCULAR QUALITY-OF-CARE METRICS ACROSS DIFFERENT ORGANIZATIONS IN THE UNITED STATES
Podlogar VL, Robinson Jr. D, Saadi R, Rutgers University, Flemington, NJ, USA, University of Illinois at Chicago, Raritan, NJ, USA, Dhaka Medical College, Yale University, Raritan, NJ, USA

PNH165 F11 IMPACT OF MISSING DATA IN CRITERIA OF LEAST CONSENSUS ON ACMG NEWBORN SCREENING RECOMMENDATIONS FOR SHORT-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY
Yang K, Rittenhouse B, Biogen/MCPHS, Weston, MA, USA, MCPHS University, Boston, MA, USA

PNH166 F12 EXAMINING UNCERTAINTY AROUND THE AMERICAN COLLEGE OF MEDICAL GENETICS RECOMMENDATIONS FOR NEWBORN SCREENING FOR GALACTOSE EPIMERASE DEFICIENCY
Bojan B, Rittenhouse B, MCPHS University, Boston, MA, USA

PNH167 F13 PNEUMOCONIOSIS COSTS AT THE SOCIAL SECURITY OF PERU
More Yupanqui GE, EsSalud, Lima, Peru

PNH168 F14 EXAMINING UNCERTAINTY AROUND THE AMERICAN COLLEGE OF MEDICAL GENETICS RECOMMENDATION FOR NEWBORN SCREENING FOR 2-METHYLBUTYRYLL-COA DEHYDROGENASE DEFICIENCY (2MBG)
Algatan R, Rittenhouse B, MCPHS University, Boston, MA, USA

PNH169 F15 RECEIPT OF GUIDELINE-CONCORDANT SURVEILLANCE CARE IN ELDERLY PATIENTS WITH COLORECTAL CANCER
Goyal RK, Davis KL, RTI Health Solutions, Research Triangle Park, NC, USA

DISEASE- SPECIFIC STUDIES

CARDIOVASCULAR DISORDERS - Clinical Outcomes Studies

PCV1 F16 HMG-COA REDUCTASE INHIBITORS (STATINS) ASSOCIATED TENDON RUPTURE: AN ANALYSIS OF REPORTS FROM THE FOOD AND DRUG ADMINISTRATION'S ADVERSE REPORTING SYSTEM
Rafi JA, Arabyat R, Chen C, Raisch DW, University of New Mexico College of Pharmacy, Albuquerque, NM, USA

PCV2 F17 ASSOCIATIONS OF COMORBIDITIES AND CO-MEDICATIONS WITH ANGIOEDEMA DURING THE USE OF ANGIOTENSIN CONVERTING ENZYME-INHIBITORS WITHIN THE UNITED KINGDOM CLINICAL PRACTICE RESEARCH DATALINK
Mahmoudpour SH, Baranova EV, Souverein PC, Asselbergs FW, de Boer A, Maitland-van der Zee A, Utrecht University, UTRECHT, The Netherlands, University Medical Centre Utrecht, UTRECHT, The Netherlands

PCV3 F18 CREATING AN INVENTORY OF RISK FACTORS FOR PREDICTING STROKE AMONG ATRIAL FIBRILLATION PATIENTS: A SYSTEMATIC REVIEW
Oehrlein EM, Perfetto EM, Chung Y, Ghafoori P, Harris R, University of Maryland School of Pharmacy, Baltimore, MD, USA, University of Maryland, School of Pharmacy, Baltimore, MD, USA, University of Maryland, Health Sciences and Human Services Library, Baltimore, MD, USA

PCV4 F19 PREVALENCE OF INAPPROPRIATE PRESCRIBING OF ANTIITHROMBOTIC THERAPY IN ETHIOPIAN ELDERLY POPULATION USING UPDATED 2015 STOPP/START CRITERIA
Getachew H, Bhagavathula AS, Befekadu T, Admasu S, University of Gondar, Gondar, Ethiopia

PCV5 F20 MONO- AND COMBINATION ANTIHYPERTENSIVE THERAPY WITH OLMESARTAN IS ASSOCIATED WITH ENTEROPATHY RISK
Ali AK, Eli Lilly and Company, Indianapolis, IN, USA

PCV6 F21 EXAMINING THE MORTALITY AND READMISSION RATES OF PATIENTS DIAGNOSED WITH STROKE IN THE UNITED STATES MEDICARE POPULATION
Bashyal R, Du H, Wang L, Yuce H, Baser O, StatinMED Research, Plano, TX, USA, New York City College of Technology-CUNY and StatinMED Research, New York, NY, USA, Columbia University and StatinMED Research, New York, NY, USA

PCV7 F22 INSULIN AND HIGHER ODDS OF A POSITIVE HISTORY OF CARDIOVASCULAR DISEASE AMONG DIABETIC INDIVIDUALS
McRae J, Prioli K, Schafer JJ, Cannon-Dang E, Harris LF, Pizzi LT, Thomas Jefferson University, Philadelphia, PA, USA, Center in the Park, Philadelphia, PA, USA
PCV8 F23 ACCELERATED/MALIGNANT HYPERTENSION WITH A DIAGNOSTIC AMBUCITY: A RETROSPECTIVE COHORT STUDY

Geneus CJ, Davis RE, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

PCV9 F24 CHARACTERIZATION OF STATIN EFFECTIVENESS USING REAL-WORLD DATA IN A CANADIAN POPULATION

Shoaie S1, McCurdy S1, Thiele S1, Ching Chau L1, Martin L1, Charland K2, Dobson-Belaire W1, Duclos M1, Borrelli R1, IMS Health Brogan., Mississauga, ON, Canada, 1IMS Health Brogan, Kirkland, QC, Canada, 2IMS Health Brogan, Mississauga, ON, Canada

PCV10 F25 ASPIRIN VERSUS CLOPIDOGREL IN PREVENTION OF ISCHEMIC STROKE RECURRENT: AN EVALUATION OF EFFECTIVENESS AND SAFETY FROM BEIJING MEDICAL INSURANCE DATABASE

Yang L1, Wen L1, Wu J2, Peking University, Beijing, China, 1Bayer, Beijing, China

PCV11 F26 COMPARATIVE EFFECTIVENESS OF ACEI VERSUS ARB IN ELDERLY PATIENTS WITH HEART FAILURE

Ramachandran S, Yang Y, University of Mississippi, University, MS, USA

PCV12 F27 IMPACT OF THERAPEUTIC GUIDELINES ON UTILIZATION PATTERN OF LOW MOLECULAR WEIGHT HEPARINS AT A SOUTH INDIAN TERTIARY CARE TEACHING HOSPITAL

Adepup R, Ariyappallil AJ, G S, JSS University, India, India

PCV13 F28 COMPARATIVE EFFECTIVENESS AND SAFETY OF NOVEL ORAL ANTICOAGULANTS (NOACs) VERSUS VITAMIN K ANTAGONISTS (VKA) IN ATRIAL FIBRILLATION: A META-ANALYSIS OF OBSERVATIONAL STUDIES

Almutairi A, Zhou L, Lee JK, Marion S, Martin JR, Lo-Ciganic W, University of Arizona, Tucson, AZ, USA

PCV14 F29 EFFECTIVENESS OF THERAPEUTIC WATER-ONLY FASTING IN LOWERING BLOOD PRESSURE: A REVIEW

Eziyi A, Florida A & M University, Tallahassee, FL, USA

PCV15 F30 ADHERENCE TO DABIGATRAN AND THE RISK OF STROKE

Cheetham TC,meiner Reynolds K, Kaiser Permanente Southern California, Pasadena, CA, USA

PCV16 F31 TRENDS IN ER VISITS DUE TO HYPERKALEMIA IN THE UNITED STATES

Aggarwal S1, Topaloglu H1, NOVEL Health Strategies, Chevy Chase, MD, USA

PCV17 F32 SYSTEMATIC REVIEW OF BURDEN OF HYPERKALEMIA DUE TO ANGIOTENSIN ENZYME CONVERTING INHIBITORS

Aggarwal S1, Kumar S2, Topaloglu H1, NOVEL Health Strategies, Chevy Chase, MD, USA, 1Institute for Global Policy Research, Washington, DC, USA

PCV18 F33 LIVER FUNCTION STATUS AMONG US ADULTS HAVING BOTH HYPERLIPIDEMIA AND HYPERGLYCEMIA: A CROSS SECTIONAL STUDY

Sakharkar P, Deb S, Roosevelt University College of Pharmacy, Schaumburg, IL, USA

PCV19 F34 TRENDS IN THE UTILIZATION OF WARFARIN AND NON-VITAMIN K ORAL ANTICOAGULANTS IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION

Alalwan A, Voils S, Hartzema A, University of Florida, Gainesville, FL, USA

PCV20 G1 USE OF REAL-WORLD DATA TO ESTIMATE PREVALENCE OF COMMERCIALLY-INSURED HIGH CARDIOVASCULAR RISK PATIENTS IN THE UNITED STATES

Hardin J1, Quek RG1, Roehl K2, Richhariya A3, Gandra SR1, Amgen, Inc., Thousand Oaks, CA, USA, 2Amgen, Thousand Oaks, CA, USA, 3Seattle Genetics, Southeast Bothell, WA, USA

PCV21 G2 RELATIONSHIP BETWEEN LIPOPROTEIN(A) AND CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW

Quek RG1, Forbes CA2, Deshpande S2, Worthy G2, Wolff R2, Stirk L2, Kleijnen J1, Gandra SR1, Djedjos S1, Wong N2, Amgen Inc., Thousand Oaks, CA, USA, 1Kleijnen Systematic Reviews Ltd., York, UK, 2Kleijnen Systematic Reviews Ltd., York, CA, USA, 3Maastricht University, Maastricht, The Netherlands, 4University of California, Irvine, Irvine, CA, USA

PCV22 G3 VARIATION IN MEDICATION ADHERENCE ACROSS THE HEALTH CARE SYSTEM IN COMPARATIVE-EFFECTIVENESS RESEARCH STUDIES

Franklin JM1, Donnegyong MM1, Desai R1, Markson L2, Girman C3, McKay C2, Patel MD2, Mavros P2, Schneeweesis S1, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 2Merck, North Wales, PA, USA, 3CERob's Consulting LLC, Chapel Hill, NC, USA

PCV23 G4 DEPRESSION AND CORONARY HEART DISEASE RISK: AN OVERVIEW OF SYSTEMATIC REVIEWS

Reyes JM1, Gutierrez-Ardila MV2, Lopez-Cabra C3, Pfizer SAS, Bogota, Colombia, 2Pfizer Chile S.A., Santiago, Chile, 3Universidad del Rosario, Bogota, Colombia

PCV24 G5 CARDIOVASCULAR RISKS OF EXOGENOUS TESTOSTERONE USE AMONG MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS

Alexander GC1, Iyer G1, Lucas E1, Lin D1, Singh S1, Johns Hopkins Bloomberg School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA

PCV25 G6 ASSOCIATION BETWEEN EXOGENOUS TESTOSTERONE AND CARDIOVASCULAR EVENTS: AN OVERVIEW OF SYSTEMATIC REVIEWS
PCV26 G7 MORTALITY AND REHOSPITALIZATION RATES AMONG HOSPITALIZED CONGESTIVE HEART FAILURE PATIENTS IN THE UNITED STATES MEDICARE POPULATION

Pandya S1, Du H1, Wang L1, Yuce H2, Basar O3, STATinMED Research, Plano, TX, USA, 1New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, 2Columbia University and STATinMED Research, New York, NY, USA

PCV28 G8 ECONOMIC IMPACT OF TREATMENT WITH NOVEL ORAL ANTICOAGULANTS VERSUS WARFARIN IN BRAZILIAN PRIVATE HEALTH SYSTEM

Ferreira CN1, Squassi HB1, Paloni Ed2, Nogueira F1, Santana CF1, Paiva EC1, Pfizer, Sao Paulo, Brazil, 1Orizon, Barueri, Brazil

PCV29 G9 ECONOMIC BURDEN OF UNMANAGED CHRONIC CARDIOVASCULAR DISEASES IN BRAZILIAN SUPPLEMENTARY HEALTH CARE PERSPECTIVE

Ferreira CN1, Santana CF1, Squassi HB1, Paloni Ed2, Paiva EC1, Pfizer, Sao Paulo, Brazil, 1Orizon, Barueri, Brazil

PCV30 G11 PHARMAECONOMIC ANALYSIS OF NAFTIDROFURYL IN PATIENTS WITH CHRONIC OBLITERATING DISEASES OF LOWER LIMB ARTERIES

Belousov D, Cheberda A, Center of Pharmacoeconomic Research LLC, Moscow, Russia

PCV31 G12 PHARMAECONOMIC ANALYSIS OF NAFTIDROFURYL FOR ISCHEMIC STROKE TREATMENT

Belousov D, Cheberda A, Center of Pharmacoeconomic Research LLC, Moscow, Russia

PCV32 G13 IMPACT OF A LIMB SALVAGE PROGRAM ON THE ECONOMIC BURDEN OF AMPUTATION IN THE UNITED STATES

Palli S1, Gunnarsson C1, Kotlzar H1, Martinsen BJ1, Zhao R2, Rizzo JA3, CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 1Cardiovascular Systems, Inc., St. Paul, MN, USA, 2Cardiovascular Systems, Inc., Saint Paul, MN, USA, 3Stony Brook University, Stony Brook, NY, USA

PCV33 G14 AN INCREMENTAL COST ANALYSIS OF ORBITAL ATERESECTION PLUS ANGIPLASTY COMPARED TO ANGIOPLASTY ALONE FOR THE TREATMENT OF CRITICAL LIMB ISCHEMIA

Zhao R1, Gunnarsson C1, Kotlzar H1, Martinsen BJ1, Palli S1, Bell E1, Rizzo JA3, Cardiovascular Systems, Inc., Saint Paul, MN, USA, 1CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 2Cardiovascular Systems, Inc., St. Paul, MN, USA, 3One Tall Tree Consulting LLC, Seattle, WA, USA, 4Stony Brook University, Stony Brook, NY, USA

PCV34 G15 COSTS ASSOCIATED WITH CHOICE OF PERIOPERATIVE INTRAVENOUS CRYSTALLOID AMONG ADULTS UNDERGOING CARDIAC SURGERY

Raghunathan K1, Khangulov VS2, Peyeri FW2, Shaw AD3, Durham VA Medical Center, Duke University Medical Center, Durham, NC, USA, 1Boston Strategic Partners, Inc., Boston, MA, USA, 2Vanderbilt University School of Medicine, Nashville, TN, USA

PCV35 G16 CLINICAL AND ECONOMIC BURDEN OF PERIPHERAL ARTERY DISEASE AMONG PATIENTS RECEIVING ENDOVASCULAR INTERVENTIONS: A RETROSPECTIVE COHORT STUDY OF COMMERCIALLY INSURED PATIENTS IN THE UNITED STATES

Meyers J1, Chaudhari P1, Madhwan S1, Candrilli SD1, RTI Health Solutions, Research Triangle Park, NC, USA, 2Takeda Pharmaceuticals, Deerfield, IL, USA

PCV36 G17 HEALTH CARE COSTS AMONG PATIENTS DIAGNOSED WITH DEEP VEIN THROMBOSIS IN THE OUTPATIENT SETTING AND TREATED WITH RIVAROXABAN VERSUS LOW-MOLECULAR-WEIGHT HEPARIN AND WARFARIN

Deitelzweig S1, Laliberte F1, Raut R1, Germain G2, Bookhart BK1, Olson WH2, Schein J1, Lefebvre P3, 1Ochsner Medical Center, New Orleans, LA, USA, 2Groupe d'analyse, Ltee, Montreal, QC, Canada, 3Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 4Groupe d'analyse, Ltee, Montreal, QC, Canada

PCV37 G18 COST STUDY OF CARDIOVASCULAR DISEASES

Gantugs Y1, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

PCV38 G19 ANNUAL FATAL AND NON-FATAL CARDIOVASCULAR EVENT COSTS AMONG NON-ELDERLY COMMERCIAL INSURED ADULTS WITH HYPERLIPIDEMIA IN THE UNITED STATES

Bonafede MM1, Johnson BH1, Paoli CJ2, Gandra SR2, Truven Health Analytics, Cambridge, MA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA

PCV39 G20 REAL-WORLD COSTS OF ISCHEMIC STROKE BY DISCHARGE STATUS

Mu F1, Hurley D2, Betts K1, Messali A1, Paschoalin M2, Wu EQ1, 1Analysis Group, Inc., Boston, MA, USA, 2Genentech, Inc., South San Francisco, MA, USA

PCV40 G21 EXAMINATION OF THE ECONOMIC BURDEN OF DYSLIPIDEMIA IN THE VETERANS HEALTH ADMINISTRATION POPULATION

Keshishian A1, Tan H1, Xie L1, Baser O1, 1STATinMED Research, Ann Arbor, MI, USA, 2Columbia University and STATinMED Research, New York, NY, USA

PCV41 G22 RETROSPECTIVE ANALYSIS OF THE ECONOMIC BURDEN OF PATIENTS DIAGNOSED WITH CONGESTIVE HEART
FAILURE IN THE CALIFORNIA MEDICAID POPULATION
Ogbomo A1, Zhao Y1, Kariburyo MF1, Xie L1, Yuce H2, Baseri O3; STATinMED Research, Ann Arbor, MI, USA, 2New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, 3Columbia University and STATinMED Research, New York, NY, USA

PCV43 H3 EVALUATING THE ECONOMIC BURDEN AND HEALTH CARE UTILIZATION OF CORONARY ARTERY DISEASE IN THE US MEDI-CAL POPULATION
Zhang Q1, Zhao Y1, Keshishian A1, Xie L1, Yuce H2, Baser O3; STATinMED Research, Ann Arbor, MI, USA, 2New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, 3Columbia University and STATinMED Research, New York, NY, USA

PCV44 H4 OPERATING ROOM VARIABLE COST OF TRANSCATHETER AORTIC VALVE REPLACEMENT
Clancy S1, Womeldorff J2, Ryan MP2; Edwards Lifesciences, Irvine, CA, USA, 3CITI Clinical Trial and Consulting Services, Cincinnati, OH, USA

PCV45 H5 COST EFFECTIVENESS OF SIMVASTATIN PLUS EZETIMIBE FOR CARDIOVASCULAR PREVENTION IN UNITED STATES POPULATION: RESULTS OF THE IMPROVE-IT TRIAL
Almalki ZS1, Guo JJ, University of Cincinnati, Cincinnati, OH, USA

PCV46 H6 COST CONSEQUENCE ANALYSIS OF TWO DIFFERENT ACTIVE FLOWABLE HEMOSTATIC MATRICES IN CARDIAC SURGERY PATIENTS (US HOSPITAL PROVIDER PERSPECTIVE)
Makhija D1, Rock M1, Xiong Y1, Ikeme S1, Rubinstein M1, Arnold MR2; Baxter Healthcare Corporation, Deerfield, IL, USA, 3Stratevi Consulting, Santa Monica, CA, USA, 4Baxter Healthcare Corporation, Westlake Village, CA, USA

PCV47 H7 COST EFFECTIVENESS OF APIXABAN (NOVEL ORAL ANTI-COAGULANT) COMPARED WITH CONVENTIONAL THERAPY FOR STROKE PROPHYLAXIS AMONG RENAL IMPAIRED PATIENTS WITH ATRIAL-FIBRILLATION FROM PERSPECTIVE OF US THIRD PARTY PAYER
Kumar A1, Wu W2, Nili M1; College of Pharmacy and Health Sciences, St. John’s University, New York, NY, USA, 2College of Pharmacy and Health Sciences, St Johns University, New York, NY, USA

PCV48 H8 COST-EFFECTIVENESS ANALYSIS OF ANTIHYPERTENSIVE COMBINATION THERAPY AMONG PATIENTS WITH MODERATE TO SEVERE HYPERTENSION
Wang X1, Aboughosh S; University of Houston, Houston, TX, USA

PCV49 H9 THE REAL-WORLD COST-EFFECTIVENESS OF CORONARY ARTERY BYPASS GRAFTING VERSUS STENTING IN HIGH-RISK PATIENTS: PROPENSITY SCORE ANALYSIS OF A SINGLE CENTRE EXPERIENCE
Ariyaratne T1, Ademi Z2, Huq M2, Duffy S2, Billah B1, Rosenfeldt F2, Parkinson B2, Yap C2, Yan B2, Smith J1, Brennan A1, Tran L2, Reid C1; Monash University, Melbourne, Australia, 2University of Basel, Basel, Australia, 3University of Melbourne, Melbourne, Australia, 4Alfred Hospital, Melbourne, Australia, 5Macquarie University, Sydney, Australia, 6Geelong Hospital, Geelong, Australia, 7Chinese University of Hong Kong, Shatin, Hong Kong, 8Monash Medical Centre, Melbourne, Australia

PCV50 H10 REEVALUATING THE VALUE OF EZETIMIBE IN THE UNITED STATES FOR PATIENTS WITH HISTORY OF CVD BASED ON THE IMPROVE-IT RESULT
Davies GM1; Baxter C2, Vyas A3, 1Merck and Co., Inc., North Wales, PA, USA, 2Merck and Co., Inc., Hoddeston, UK, 3Merck and Co., Inc., Rahway, NJ, USA

PCV51 H11 COST EFFECTIVENESS ANALYSIS APIXABAN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP OR KNEE REPLACEMENT IN ADULTS IN COSTA RICA IN 2015
Peralta-Acon M1; Poveda-Fernandez J2, 3Pfizer Central America and Caribbean, San José, Costa Rica, 4Caja Costarricense de Seguro Social, San Jose, Costa Rica

PCV52 H12 CLINICAL EVENTS AVOIDED WITH APIXABAN COMPARED TO EDOXABAN FOR THE INITIAL TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM
Lanitis T1, Hamilton M2, Quon P3, Browne C1, Cohen A4; Evidera, London, UK, 2BMS, Princeton, NJ, USA, 3Evidera, Bethesda, MD, USA, 4King’s College Hospital, London, UK

PCV53 H13 COST EFFECTIVENESS OF INTENSIVE LOWERING OF LDL CHOLESTEROL WITH PCSK9 INHIBITORS AS AN ADJUNCT TO HIGH-INTENSITY STATIN THERAPY FOR PREVENTION OF MAJOR VASCULAR EVENTS
Lee H1, Watkins J2, Danielson D3; University of Washington School of Pharmacy, Seattle, WA, USA, 2Premera Blue Cross, Mountlake Terrace, WA, USA

PCV54 H14 DEVELOPMENT OF A PHARMACOECONOMIC MODEL TO ASSESS THE COST EFFECTIVENESS OF PHARMACOGENOMICS TESTS IN CHRONIC HEART FAILURE: THE CASE OF IVABRADINE
Iliza AC1, Fanton Aita F1, Mitchell D1, Guertin JR2, Matteau A3, Lelorier J1; University of Montreal, Montreal, QC, Canada, 2St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada, 3Centre hospitalier de l’Université de Montréal (CHUM), Montréal, QC, Canada

PCV55 H15 COST-UTILITY ANALYSIS OF ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITOR SACUBITRIL/VALSARTAN COMPARED WITH ACE INHIBITORS FOR THE TREATMENT OF CHRONIC HEART FAILURE IN THE UNITED STATES
Harrington RL1; Zueger PM, Kumar VM, Rigoni G, Atwood AM, DiDomenico RJ, Touchette DR, University of Illinois at Chicago, Chicago, IL, USA
### CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

**PCV62** 12  PATTERNS AND PREDICTORS OF DISCONTINUATION AND SWITCH IN ATRIAL FIBRILLATION PATIENTS TREATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS  
Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA, Mayo Clinic, Rochester, MN, USA

**PCV63** 13  ADHERENCE, COMPLIANCE, AND PERSISTENCE WITH LIPID-LOWERING THERAPIES: A SYSTEMATIC REVIEW  
Xu Y, Worden C, University of Southern California, Los Angeles, CA, USA, Amgen Inc., Thousand Oaks, CA, USA

**PCV64** 14  PERSISTENCE AND COMPLIANCE WITH CARDIOVASCULAR DRUG THERAPY AMONG SENIORS  
Rioux J, Hunt J, Canadian Institute for Health Information, Ottawa, ON, Canada

**PCV65** 15  EFFECT OF PATIENT-REPORTED SYMPTOMS ON MEDICATION ADHERENCE IN HYPERTENSIVE PATIENTS  
Fu M, Mehas N, Jaynes H, Hudmon K, Zillich A, Department of Pharmacy Practice, Purdue University, West Lafayette, IN, USA

**PCV66** 16  COMPARISON OF PERSIAN VERSION OF THE HILL-BONE AND MORISKY MEDICATION ADHERENCE SCALES IN HYPERTENSIVE PATIENTS  
Saleh S, Gholami K, Sarayani A, Jahangard-rafsanjani Z, Hadjibabae M, Rajabi M, Morisky DE, Azad University of Pharmaceutical Sciences, Tehran, Iran (Islamic Republic of), Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), Research Center for Rational Use of Drugs, Tehran, Iran (Islamic Republic of), UCLA Fielding School of Public Health, Los Angeles, CA, USA

**PCV67** 17  ASSESSMENT OF ADHERENCE TO HYPERTENSION TREATMENT IN PRIMARY CARE PHYSICIAN IN UKRAINE  
Korzh O, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine

**PCV68** 18  FOCUS GROUPS EXPLORING EXPERIENCES WITH AND PREFERENCES FOR ORAL ANTICOAGULANTS IN PEOPLE WITH NONVALVULAR ATRIAL FIBRILLATION  
Barrett A, DiBenedetti D, Phatak H, Masseria C, Kamble S, RTI Health Solutions, Research Triangle Park, NC, USA, 1Bristol-Myers Squibb, Princeton, NJ, USA, 1Pfizer Inc., New York, NY, USA

**PCV69** 19  HOW DO UTILITIES VARY FOR CARDIOVASCULAR EVENTS? A SYSTEMATIC REVIEW  

**PCV70** 10  IMPACT OF DEPRESSION ON HEALTH STATUS AND HEALTH CARE UTILIZATION IN PATIENT WITH HYPERTENSION  
Shao H, Mir MU, Ye X, Thomas N, Babazadeh S, Tulane University, New Orleans, LA, USA, Fresenius Medical Care/Renal Research Institute, New York, NY, USA

**PCV71** 11  HEALTH-RELATED QUALITY OF LIFE OF PATIENTS SUFFERING AN ACUTE CORONARY SYNDROME: AN ANALYSIS USING MULTINATIONAL EQ-5D OUTCOMES FROM THE PGRX-3 REAL-WORLD DATASET  

**PCV72** 12  REPORTED PSYCHOLOGICAL SYMPTOMS AND QUALITY OF LIFE IN PATIENTS SUFFERING AN ACUTE CORONARY SYNDROME: NEW INSIGHTS FROM THE PGRX-3 REAL-WORLD DATASET  
PCV73  I13 DEVELOPMENT AND CONTENT VALIDATION OF A PATIENT-REPORTED OUTCOME MEASURE TO EVALUATE STATIN INTOLERANCE IN THE REAL WORLD
Jacobson T1, Edelman S2, Davidson M3, Galipeau N4, Shields A5, Mallya UG6, Koren A7, Emory University, Atlanta, GA, USA, 2University of California San Diego, San Diego, CA, USA, 3The University of Chicago Medicine, Chicago, IL, USA, 4Adelphi Values USA, Boston, MA, USA, 5Sanofi US, Inc., Bridgewater, NJ, USA

PCV74  I14 HYPERTROPHIC CARDIOMYOPATHY: A HEART BURDEN AND CHALLENGING DIAGNOSIS
Salberg L1, Schroeder E2, McKinley G3, Hypertrophic Cardiomyopathy Association (HCMA), Denville, NJ, USA, 2Medical Writer, San Mateo, CA, USA, 3MyoKardia, South San Francisco, CA, USA

CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studies

PCV76  I16 IDENTIFICATION AND MANAGEMENT OF PATIENTS WITH SYMPTOMS OF STATIN INTOLERANCE: RESULTS FROM A SURVEY OF BRAZILIAN CLINICIANS
McKendrick J1, Gandra SR2, Hovingh GK3, Dent R4, Wiefker HM5, Catapano AL6, Oh P7, Rosenson RS8, Stroes ES9, 1PRMA Consulting Ltd, Fleet, UK, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Academic Medical Center, Amsterdam, The Netherlands, 4University of Milano and IRCCS Multimedica, Milan, Italy, 5Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Mount Sinai School of Medicine, New York, NY, USA

PCV77  J1 IDENTIFICATION AND MANAGEMENT OF CANADIAN PATIENTS WITH SYMPTOMS OF STATIN INTOLERANCE: RESULTS FROM A REAL-WORLD CLINICAL PRACTICE SURVEY
Oh P1, Hovingh GK2, Gandra SR3, McKendrick J4, Dent R5, Wiefker HM6, Catapano AL7, Rosenson RS8, Stroes ES9, 1Toronto Rehabilitation Institute, Toronto, ON, Canada, 2Academic Medical Center, Amsterdam, The Netherlands, 3Amgen, Inc., Thousand Oaks, CA, USA, 4PRMA Consulting Ltd, Fleet, UK, 5University of Milano and IRCCS Multimedica, Milan, Italy, 6Mount Sinai School of Medicine, New York, NY, USA

PCV78  J2 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS ON THE EFFICACY OF EVOLOUCUMAB AND OTHER LIPID-LOWERING THERAPIES FOR THE MANAGEMENT OF LIPID LEVELS IN HYPERLIPIDEMIA
Worthy G1, Gandra SR2, Bridges I3, Worth G4, Dent R5, Forbes CA6, Deshpande S7, Cheng L8, Ross J9, Kleijnjen J10, Stroes ES11, 1Kleijnjen Systematic Reviews Ltd., York, UK, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Amgen, Inc, Cambridge, UK, 4Amgen Ltd. Zug, Switzerland, 5Maastricht University, Maastricht, The Netherlands, 6Academic Medical Center, Amsterdam, The Netherlands

PCV79  J3 IDENTIFYING AND MANAGING PATIENTS WITH SYMPTOMS OF STATIN INTOLERANCE: RESULTS FROM A SURVEY OF CLINICIANS IN THE UNITED STATES
Rosenson RS1, Gandra SR2, McKendrick J3, Dent R4, Wiefker HM5, Catapano AL6, Oh P7, Hovingh GK8, Stroes ES9, 1Mount Sinai School of Medicine, New York, NY, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3PRMA Consulting Ltd, Fleet, UK, 4University of Milano and IRCCS Multimedica, Milan, Italy, 5Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Academic Medical Center, Amsterdam, The Netherlands

PCV80  J4 A GRAPHICAL AND ANALYTICS APPROACH TO UNDERSTANDING HOSPITAL READmissions IN NORTH CAROLINA
Saunders W1, Blanchette CM2, UNC Charlotte College of Health and Human Services – Health Informatics, Charlotte, NC, USA, 1University of North Carolina at Charlotte, Charlotte, NC, USA

PCV81  J5 ESTIMATING THE FUTURE BURDEN OF CARDIOVASCULAR DISEASE IN CHINA AND THE POTENTIAL VALUE OF UNIVERSAL LIPID AND BLOOD PRESSURE CONTROL
Stevens W1, Peneva D2, Li JZ3, Liu LZ4, Liu GG5, Gao R6, Lakdawalla DN7, 1Precision Health Economics, Oakland, CA, USA, 2Precision Health Economics, Los Angeles, CA, USA, 3Pfizer, Inc., San Diego, CA, USA, 4Weill Medical College of Cornell University, New York, NY, USA, 5Peking University, Beijing, China, 6Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 7University of Southern California, Los Angeles, CA, USA

PCV82  J6 IMPACT OF LDL-C GOAL ATTAINMENTS AND COST OF MANAGEMENT FOLLOWING THE 2013 ACC/AHA GUIDELINE AMONG STATIN USERS IN HONG KONG CHINESE: REAL-WORLD RESULTS
Lee VV1, Wang Y2, Nichol MB3, Wu J4, Tang HC5, Mak CP6, Yan BP7, 1The Chinese University of Hong Kong, Shatin, Hong Kong, 2University of Southern California, Los Angeles, CA, USA

PCV83  J7 REGIONAL VARIATIONS IN US HOSPITAL UTILIZATION OF GP IIb/IIIa INHIBITORS
Fan W1, Werner R, Mitchell M, The Medicines Company, Parsippany, NJ, USA

PCV84  J8 TREND AND CLINICAL CHARACTERISTICS OF STATIN INITIATION IN PATIENTS DISCHARGED FROM HOSPITAL FOR A NEW AHEROSCLEROTIC CARDIOVASCULAR DISEASE EPISODE FROM 2006 TO 2012 IN TAIWAN: A POPULATION-BASED STUDY
Huang S1, Shau W2, Lai C3, Chen S4, Li JZ5, Fung S6, Lai M7, College of Public Health, National Taiwan University, Taipei, Taiwan, 2Pfizer Inc., New Taipei, Taiwan, 3National Taiwan University, Taipei, Taiwan, 4Pfizer, Inc., San Diego, CA, USA, 5Pfizer, Inc., Hong Kong, Hong Kong

PCV85  J9 COMPARING THE VALUE OF EVIDENCE OVER TIME FOR CLOPIDOGREL PHARMACOGENOMICS VERSUS
PCV86  J10  TRENDS IN ORAL ANTICOAGULANT USE IN QATAR: A 5-YEAR EXPERIENCE
Elewa H, Alhaddad A, Al-Rawi S, Nounou A, Mahmoud H, Qatar University, Doha, Qatar, "Hamad Medical Corporation, doha, Qatar

PCV87  J11  BOLUS PLUS INFUSION REMAINS PREDOMINANT MODE OF GP IIb/IIIa UTILIZATION: A 2015 US HOSPITAL PURCHASING STUDY

PCV88  J12  DEMOGRAPHIC AND SOCIOECONOMIC CHARACTERISTICS THAT IMPACT SELECTION OF ORAL ANTICOAGULANTS AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
Keshishian A, Du J, Xie L, Yuce H, Baso O, STATinMED Research, Ann Arbor, MI, USA, "New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, "Columbia University and STATinMED Research, New York, NY, USA

PCV89  J13  RACIAL DISPARITIES IN AMPUTATION RATES AMONG NATIVE AMERICANS WITH PERIPHERAL ARTERY DISEASE: ANALYSIS OF THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE
Rizzo JA, Chen J, Kotlarz H, Martensens BJ, Ryan MP, Gunnarsson C, Stony Brook University, Stony Brook, NY, USA, "University of Maryland, College Park, MD, USA, "Cardiovascular Systems, Inc., St. Paul, MN, USA, "CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA

PCV90  J14  RACIAL DISPARITIES IN AMPUTATION RATES FOR PATIENTS WITH PERIPHERAL ARTERY DISEASE: LONG-TERM TRENDS AND PROJECTIONS TO 2020
Rizzo JA, Chen J, Kotlarz H, Martensens BJ, Ryan MP, Pali S, Gunnarsson C, Stony Brook University, Stony Brook, NY, USA, "University of Maryland, College Park, MD, USA, "Cardiovascular Systems, Inc., St. Paul, MN, USA, "CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA

PCV91  J15  RACIAL DISPARITIES IN AMPUTATION RATES FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE USING THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE
Mustapha JA, Fisher, Sr. BT, Rizzo JA, Chen J, Martensens BJ, Kotlarz H, Ryan MP, Gunnarsson C, Metro Health Hospital, Wyoming, MI, USA, "The Surgical Clinic, Pllc, Nashville, TN, USA, "Stony Brook University, Stony Brook, NY, USA, "University of Maryland, College Park, MD, USA, "Cardiovascular Systems, Inc., St. Paul, MN, USA, "CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA

PCV92  J16  STATIN SELECTION IN QATAR BASED ON MULTI-INDICATION PHARMACOTHERAPEUTIC MULTI-CRITERIA SCORING MODEL AND CLINICIAN PREFERENCE
Al-Badriyeh D, Fahey M, Alabbadi I, Al-Khal A, Zaidan M, Qatar University, Doha, Qatar, "Hamad Medical Corporation, Doha, Qatar, "Jordan University, Amman, Jordan, "Aspetar hospital, Doha, Qatar

PCV93  K1  OUTCOMES RELATED TO VARIATION IN HOSPITAL PULMONARY EMBOLUS OBSERVATION STAY UTILIZATION
Weeda ER, Bunz TJ, Coleman CI, Schein JR, Ashton V, Crivera C, Wildgoose P, Peacock WF, Ferrmann GJ, "University of Connecticut, Storrs, CT, USA, "Janssen Scientific Affairs, LLC, Harriton, NJ, USA, "Baylor College of Medicine, Houston, TX, USA, "University of Cincinnati, Cincinnati, OH, USA

PCV94  K2  CO-OCCURRING CHRONIC CONDITIONS AND THE ECONOMIC BURDEN AMONG COMMUNITY-DWELLING STROKE SURVIVORS IN THE UNITED STATES: A PROPENSITY SCORE MATCHED ANALYSIS
Chinthammit C, Nimworapan M, Bhattacharjee S, University of Arizona, Tucson, AZ, USA, "Chiang Mai University, Chiang Mai, Thailand

PCV95  K3  VARIATION IN IRISH GMS PHARMACEUTICAL EXPENDITURE BY ATC CLASSIFICATION

PCV96  K4  ANTIHYPERTENSIVE AND ANTILIPEMIC MEDICATION USE AND EMERGENCY ROOM EXPENDITURES AMONG ADULTS WITH COEXISTING HYPERTENSION AND HYPERLIPOIDEMIA
Chopra I, Sambamoorthi U, West Virginia University, Morgantown, WV, USA

PCV97  K5  THE PRESENCE OF MENTAL HEALTH CONDITIONS AMONG PATIENTS WITH CONGESTIVE HEART FAILURE AND THE IMPACT ON HEALTH OUTCOMES: A PROPENSITY SCORE MATCHED STUDY
Bhattacharya R, Ruble M, Renda AM, Gresky D, Trevino L, "Humana Inc, Irving, TX, USA, "Humana, Louisville, KY, USA

PCV98  K6  AGE- AND GENDER- SPECIFIC IN DIRECT HOSPITALIZATION COSTS FOR HEMORRHAGIC STROKE INPATIENTS WITH BASIC MEDICAL INSURANCE SCHEME FOR EMPLOYEES IN CHINA
Ma Y, Xiong X, Li J, Jie Z, Fang Y, "Beijing University of Chinese Medicine, Beijing, China, "China Health Insurance Research Association, Beijing, China

PCV99  K7  BURDEN OF CEREBROVASCULAR DISEASE IN COLOMBIA
PCV100 K8 THE UPTAKE OF NON-VITAMIN K ORAL ANTICOAGULANTS IN IRELAND: BALANCING COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT
Barry M1, Clarke S2, Geraghty N1, National Centre for Pharmacoeconomics, Dublin, Ireland, 1HSE Medicines Management Programme, Dublin, Ireland

PCV101 K9 PCSK9 INHIBITORS - ALIROCUMAB AND EVOLUCUMAB: KEY INSIGHTS ON DIFFERENTIATION IN A GENERIC MARKET
Ramesh V, Kochel S, Mwamburi M, Market Access Solutions LLC, Raritan, NJ, USA

PCV102 K10 DEMOGRAPHIC VARIANCE OF INPATIENT HOSPITALIZATIONS FROM STROKE IN THE STATE OF MISSOURI FROM 2000-2012
Behera A, Vogt C, Armbrtrecht E, St. Louis University, St. Louis, MO, USA

PCV103 K11 A COMPARISON OF CARDIOVASCULAR DRUGS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION AND HEALTH CANADA (1980-2014)
Alasmari MS1, Seoane-Vazquez E1, Rodriguez-Monguito R2, Equale T1, Szeinbach S3, Heath N4, 1MCPHS University, Boston, MA, USA, 2University of Massachusetts, Amherst, MA, USA, 3Ohio State University, Columbus, OH, USA, 4Takeda Pharmaceuticals International Co., Cambridge, MA, USA

PCV104 K12 LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AMONG PATIENTS WITH CLINICAL ATHEROSEQLETIC CARDIOVASCULAR DISEASE AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA POST STATIN THERAPY
Johnson BH1, Bonafede MM1, Princlin N1, Harrison DJ2, Boatman B2, Patel J2, 1Truven Health Analytics, Cambridge, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA

PCV105 K13 ASSESSMENT OF DISEASE-STATE KNOWLEDGE IN HYPERTENSIVE PATIENTS IN QUETTA, PAKISTAN
ul Haq N1, Fatima A1, Nasim A1, Razaq O1, Ahmed N1, Zeeshan M1, Mohammad S1, 1University of Balochistan, Quetta, Pakistan, 2University of The Punjab, Lahore, Pakistan

PCV106 K14 WHO WERE THE EARLY ADOPTERS OF DABIGATRAN? AN APPLICATION OF GROUP-BASED TRAJECTORY MODELS
Lo-Ciganic W1, Gellad WF2, Hiskamp HA3, Choudhry Nk4, Zhang R5, Chang C5, Jones BL6, Richards-Shubik S1, Gucul H3, Donohue JM7, University of Arizona, Tucson, AZ, USA, 2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, 3Harvard Medical School, Boston, MA, USA, 4Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 5University of Pittsburgh, Pittsburgh, PA, USA, 6Carnegie University, Tuscon, AZ, USA, 7Leigh University, Bethesda, PA, USA

Qato D1, Wilder J1, Schumm P2, Gillet V1, Alexander C1, 1University of Illinois, Chicago, IL, USA, 2University of Chicago, Chicago, IL, USA, 3Johns Hopkins Bloomberg School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA

PCV108 K16 TREATMENT PATTERNS AMONG PATIENTS PRESCRIBED PDE-5 INHIBITOR MONOTHERAPY FOR PULMONARY HYPERTENSION
Yeaw J1, Hickert C2, Drake W2, De AP3, Wade RL3, 1IMS Health, San Francisco, CA, USA, 2Actelion Pharmaceuticals, Inc., South San Francisco, CA, USA, 3IMS Health, Plymouth Meeting, PA, USA

NEUROLOGICAL DISORDERS - Clinical Outcomes Studies

PND1 K17 PSYCHIATRIC SAFETY PROFILE OF SUVOREXANT, A FIRST-IN-CLASS OREXIN RECEPTOR ANTAGONIST
Alki AK1, Eli Lilly and Company, Indianapolis, IN, USA

PND3 K18 PREDICTIVE MODEL OF PARKINSON’S DISEASE IN LARGE ELECTRONIC HEALTH RECORDS DATABASE
Kabadi S1, Lee A1, Kuhn M2, Gray D3, Pfizer, Inc., Groton, CT, USA, 1University of Florida, Gainesville, FL, USA, 2Pfizer, Inc., Cambridge, MA, USA

PND4 K19 SEVERITY OF MEMORY IMPAIRMENT AND FUNCTIONAL LIMITATIONS IN THE UNITED STATES AND ASSOCIATION WITH HEALTH CARE RESOURCE USE: AN NHANES ANALYSIS
Sanon Aigbogun M1, Stellhorn R1, Krasa HB2, Kostic D1, 1Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA, 2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA

PND5 K20 LINGUISTIC VALIDATION OF THE FREE AND CUED SELECTIVE REMINDING TEST WITH IMMEDIATE RECALL (FCSRT-IR) IN 3 LANGUAGES FOR 3 COUNTRIES WITH ALZHEIMER’S DISEASE PATIENTS
Brandt B1, McKown S, Gawlicki M, Yohe Moore E, Corporate Translations Inc, East Hartford, CT, USA

PND6 L1 CAN INDIRECT COMPARISON METHODS MITIGATE EVOLVING TRIAL POPULATIONS IN ADJUNCTIVE ANTIPEEPTIC DRUG TRIALS? A PROPENSITY-SCORE MATCHED INDIRECT COMPARISON OF BRIVARACETAM AND LEVETIRACETAM
Swallow E1, Fang A1, Signorovitch J1, Plumb J1, Borghs S1, 1Analysis Group, Inc., Boston, MA, USA, 2UCB Pharma, Brussels, Belgium, 3UCB Pharma, Slough, UK

PND7 L2 RAPID RELIEF OF PAIN IN EPISODIC MIGRAINE WAS ASSOCIATED WITH LOWER SELF-REPORTED DISABILITY AND LOWER RATES OF MIGRAINE-ASSOCIATED SYMPTOMS: A SECONDARY ANALYSIS OF THE COMPASS TRIAL

Colombia, 2Pontificia Universidad Javeriana, Bogota, Colombia
PND8 L3 A NETWORK META-ANALYSIS ON COMPARATIVE EFFICACY AND SAFETY OF INVESTIGATIONAL AND APPROVED THERAPIES FOR THE TREATMENT OF NARCOLEPSY
Taneja A, Sahabri P, Chadha N, Rajput A, Goel A,IMS Health India Pvt. Ltd, Gurgaon, India

PND9 L4 A SYSTEMATIC REVIEW OF BENZODIAZEPINE USE FOR THE TREATMENT OF SEIZURE EMERGENCIES
Haut S1, Seinfeld S2, Pellock JM2, Halvorsen MB3, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA, 1Virginia Commonwealth University, Richmond, VA, USA, 2Upsher-Smith Laboratories, Inc., Maple Grove, MN, USA

PND10 L5 HOSPITALIZATION BURDEN ASSOCIATED WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY IN THE UNITED STATES
Suryavanshi M, Khanna R,University of Mississippi School of Pharmacy, University, MS, USA

PND11 L6 BURDEN OF DISEASE AND HEALTH CARE COSTS OF PATIENTS OVER 50 WITH PARKINSON’S DISEASE IN A BIG REAL-WORLD DATABASE (ARCO)
Pedrini A1, Dondi L1, Calabria S1, Rielli R2, Martini N1, 1CORE srl - Collaborative Outcome Research, Bologna, Italy; 2CINECA Interuniversity Consortium, Casalecchio di Reno, Italy

PND12 L7 ANTIPEILEPTIC DRUGS, RISK OF SUICIDE ATTEMPTS, AND THE IMPACT OF UNDERLYING MEDICAL CONDITIONS: RESULTS FROM THE PGRX INFORMATION SYSTEM
Grimaldi L1, Nordon C2, Rossignol M2, Rouillon F3, Kurz X4, Abenhaim L5, 1CNAM Paris University and LASER Analytica France, Paris, France; 2LASER Analytica, Paris, France; 3McGill University, Montreal, QC, Canada; 4Sainte Anne Hospital, Paris, France; 5European Medicines Agency, London, UK; 6LASER Analytica, London, UK

PND13 L8 FINDING POTENTIAL PREDICTORS OF ALZHEIMER’S DISEASE USING MEDICARE CLAIMS DATA
Miyasato G, Zhang Q, Wang Z, Small D, Chiu GR, Trinity Partners, LLC, Waltham, MA, USA

NEUROLOGICAL DISORDERS - Cost Studies

PND14 L9 BUDGETARY IMPACT ANALYSIS OF LEVETIRACETAM USE FOR FOCAL EPILEPSY PATIENTS’ TREATMENT WITH OR WITHOUT SECONDARY GENERALIZATION FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Carmo E1, Nite ME2, Motta R1, Lima F1, 1UCB Biopharma, São Paulo, Brazil; 2IECS, HAOC, and FIPE, Sao Paulo, Brazil

PND15 L10 COST-UTILITY ANALYSIS OF DIMETHYL FUMARATE AS A FIRST SWITCH TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Fahham L1, Murta L1, Teich V1, Machado M2, Serafini P3, 1Sense Company, Sao Paulo, Brazil; 2Biogen, Sao Paulo, Brazil

PND16 L11 HEALTH CARE UTILIZATION AND COSTS IN TREATED AND NON-TREATED PATIENTS NEWLY DIAGNOSED WITH ALZHEIMER'S DISEASE IN THE UNITED STATES
Sanon M1, Xie L1, Bent-Ennakhi N2, Hartry A1, Wang Y1, Kariburyo MF3, Neumann PJ3, Fillit HM3, 1Otsuka America Pharmaceutical, Princeton, NJ, USA; 2STATinMED Research, Ann Arbor, MI, USA; 3Lundbeck, Issy-les-Moulineaux, France; 4Lundbeck Pharmaceuticals Services, LLC, Deerfield, IL, USA; 5Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA; 6Alzheimer’s Drug Discovery Foundation, New York, NY, USA

PND17 L12 COST AND RESOURCE UTILIZATION ASSOCIATED WITH HOSPITALIZED MULTIPLE SCLEROSIS PATIENTS
Craver CW1, Belk K2, Ernst FR3, 1MedAssets, Inc., Huntersville, NC, USA; 2MedAssets, Mooresville, NC, USA; 3Indegene TTM, Kansasav, GA, USA

PND18 L13 PRICE ANALYSIS OF MULTIPLE SCLEROSIS DISEASE-MODIFYING DRUGS: COMPARISON BETWEEN SAUDI ARABIA AND THE UNITED STATES
Bin Sawad A1, Alkaya M2, MCPHS University, Boston, MA, USA; 1King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia

PND19 L14 COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Bin Sawad A1, Seoane-Vazquez E1, Rodriguez-Mongiuo R2, Turkistani F1, 1MCPHS University, Boston, MA, USA; 2University of Massachusetts Amherst, Amherst, MA, USA

PND20 L15 HOSPITALIZATION COST OF CHIARI MALFORMATION TYPE I SURGERY IN PEDIATRIC PATIENTS
Pan L, Mayer RR, Luerssen TG, Lam S, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, USA

PND21 L16 ANTIPEILEPTIC DRUG PILL BURDEN DURING THE FIRST YEAR FOLLOWING MONOTHERAPY INITIATION ASSOCIATED WITH INCREASED EPILEPSY COSTS IN THE UNITED STATES
Velez FF1, Korsnes JS2, 1Sunovion Pharmaceuticals Inc, Marlborough, MA, USA; 2RTI Health Solutions, Research Triangle Park, NC, USA

PND22 L17 PROJECTING THE POTENTIAL COST EFFECTIVENESS OF OCHELIZUMAB VERSUS STANDARD CARE IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS PATIENTS UNDER ALTERNATIVE PRICING SCENARIOS
Suh K, Carlson JJ, Garrison LP, University of Washington, Seattle, WA, USA
PND42 M15 DERIVING UTILITY WEIGHTS FROM PATIENT-REPORTED OUTCOMES IN EPILEPSY
Hendrix N, Devine B, University of Washington, Seattle, WA, USA

PND43 M16 THE BURDEN OF MULTIPLE SCLEROSIS IN JAPAN

PND44 M17 LEVODOPA/CARBIDOPA INTESTINAL GEL TREATMENT AND ITS IMPACT ON QUALITY OF LIFE AND WORK ABILITY IN PATIENTS WITH PARKINSON'S DISEASE IN CZECH REPUBLIC
Poljakova N, Lipovska S, Bielik J, Melus V, Midler M, Liptakova A, Trencin University, Trencin, Slovak Republic, Constantine the Philosopher University, Nitra, Slovak Republic, AbbVie Slovakia, Catholic University Ruzomberok, Ruzomberok, Slovak Republic

PND45 M18 AN EVALUATION OF DISABILITY PROGRESSION AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS IN BRAZIL AND MEXICO
Serafini P, Pike J, Jones E, Machado M, Biogen, Sao Paulo, Brazil, Adelphi Real World, Manchester, UK

PND46 M19 HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS TREATED WITH ONABOTULINUMTOXINA FOR CERVICAL DYSTONIA IN A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL STUDY: POSTURE
Petitclerc M, Bhogal M, Dhani S, Belle Blagrove L, Clinique des Ponts, Levis, QC, Canada, Allergan plc, Markham, ON, Canada

PND47 M20 A SYSTEMATIC REVIEW OF THE IMPACT OF ADJUVANT ANTIPARKINSON MEDICATIONS ON DISABILITY AND QUALITY OF LIFE OF PATIENTS WITH PARKINSON'S DISEASE
Chekani F, Bali V, Aparasu R, Mullen PD, University of Houston, Houston, TX, USA, University of Texas Health Science Center at Houston, Houston, TX, USA

PND48 N1 ASSESSING THE VALUE OF TREATMENT TO ADDRESS VARIOUS SYMPTOMS ASSOCIATED WITH MULTIPLE SCLEROSIS
Lin P, Saret CJ, Neumann PJ, Sandberg EA, Cohen JT, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA

NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies

PND49 N2 GENDER DIFFERENCES IN THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN ADULTS WITH MIGRAINES/SEVERE HEADACHES IN THE UNITED STATES
Rhee TG, Harris IM, University of Minnesota College of Pharmacy, Minneapolis, MN, USA, University of Minnesota School of Medicine, Minneapolis, MN, USA

PND50 N3 GENDER-SPECIFIC IMPACT OF HTA BODIES ON DRUG PRESCRIPTIONS: EVIDENCE FROM ALZHEIMER’S DISEASE DRUGS IN FRANCE
Chauvin P, Sirven N, Rapp T, Bellanger MM, University of Paris Descartes, Paris, France, EHESEP French School of Public Health, Rennes, France

PND51 N4 A LIFE-COURSE ASSESSMENT OF MEDICATION USE AND MEDICAL COSTS OF LENNOX-GASTAUT SYNDROME (LGS)
Montouris G, Piña-Garza Je, Vekeman F, Cheng WY, Tuttle EG, Giguere-Duval P, Duh MS, Isjoarvi J, Boston University School of Medicine, Boston, MA, USA, The Children's Hospital at Tristar Centennial Medical Center, Nashville, TN, USA, Groupe d'analyse, Ltee, Léon, QC, Canada, Analysis Group Inc., Boston, MA, USA, Analysis Group, Inc, Menlo Park, CA, USA, Groupe d'analyse, Montreal, QC, Canada, Analysis Group, Inc., Boston, MA, USA, Analysis Group, Inc, Deerfield, IL, USA

PND52 N5 FACTORS ASSOCIATED WITH A HISTORY OF FAILURE AND SWITCHING MIGRAINE PROPHYLAXIS TREATMENT: AN ANALYSIS OF CLINICAL PRACTICE DATA FROM THE UNITED STATES, GERMANY, FRANCE, AND JAPAN

PND53 N6 CHARACTERIZING PATIENT-REPORTED HEALTH-RELATED QUALITY-OF-LIFE MEASURES AMONG USERS AND NON-USERS OF MIGRAINE PROPHYLAXIS TREATMENT: AN ANALYSIS OF CLINICAL PRACTICE DATA FROM THE UNITED STATES, GERMANY, FRANCE, AND JAPAN

PND54 N7 PREVALENCE, PATTERNS, AND PREDICTORS OF PSYCHOTROPIC POLYPHARMACY AMONG COMMUNITY-DWELLING ELDERLY INDIVIDUALS WITH PARKINSON'S DISEASE IN THE UNITED STATES
Bhattacharjee S, Goldstone L, Bhattacharyya R, Warholak T, University of Arizona, Tucson, AZ, USA, The University of Arizona, Tucson, AZ, USA, Independent Consultant, Tucson, AZ, USA

PND55 N8 THE USE OF MIGRAINE PROPHYLAXIS TREATMENT: ANALYSIS OF CLINICAL PRACTICE DATA FROM THE UNITED STATES, GERMANY, FRANCE, AND JAPAN
PND56 N9  DRUG UTILIZATION EVALUATION OF ANTIEPILEPTIC DRUGS IN PEDIATRIC POPULATION AT A SECONDARY CARE HOSPITAL
Nalluri Kk, Acharya nagarjuna university, guntur. India

PND57 N10  COMPARISON OF CHARACTERISTICS OF PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS AND TAKING SUBCUTANEOUSLY ADMINISTERED DISEASE MODIFYING THERAPIES: INTERFERON BETA 1B VERSUS 1A
Greene M1, Greene N2,Health Economics & Outcomes Research and Market Access Researcher, Medford, MA, USA, 1Massachusetts College of Pharmacy and Health Sciences University, Medford, MA, USA

PND58 N11  IMPACT OF NEW ENTRANTS TO THE MARKET FOR MULTIPLE SCLEROSIS DISEASE-MODIFYING DRUGS IN CANADA
Bennetts L, Khoury H, O’Neil B, LASER Analytica, Montreal, QC, Canada

PND59 N12  COST ANALYSIS OF PATIENTS WITH MULTIPLE SCLEROSIS NEWLY INITIATING SUBCUTANEOUS INTERFERON β-1A VERSUS ORAL DISEASE-MODIFYING DRUGS
Kozma CM1, Munschauer FE, Phillips AL, CK Consulting Associates, LLC, Saint Helena Island, SC, USA, 2EMD Serono, Inc., Rockland, MA, USA

PND60 N13  FINGOLIMOD VERSUS TEIFLUNOMIDE: HEALTH CARE COSTS ASSOCIATED WITH PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TAKING DISEASE MODIFYING THERAPIES IN THE UNITED STATES
Greene M1, Greene N2, Health Economics & Outcomes Research and Market Access Researcher, Medford, MA, USA, 1Massachusetts College of Pharmacy and Health Sciences University, Medford, MA, USA

PND61 N14  HEALTH ECONOMIC EVALUATION OF ORALLY VERSUS SUBCUTANEOUSLY ADMINISTERED DISEASE MODIFYING THERAPIES FOR PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
Greene M1, Greene N2, Health Economics & Outcomes Research and Market Access Researcher, Medford, MA, USA, 1Massachusetts College of Pharmacy and Health Sciences University, Medford, MA, USA

PND62 N15  HEALTH ECONOMIC EVALUATION OF INTERFERON BETA 1B VERSUS 1A FOR PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
Greene M1, Greene N2, Health Economics & Outcomes Research and Market Access Researcher, Medford, MA, USA, 1Massachusetts College of Pharmacy and Health Sciences University, Medford, MA, USA

PND63 N16  FINGOLIMOD VERSUS TEIFLUNOMIDE: CHARACTERISTICS OF PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS AND TAKING ORAL DISEASE MODIFYING THERAPIES
Greene M1, Greene N2, Health Economics & Outcomes Research and Market Access Researcher, Medford, MA, USA, 1Massachusetts College of Pharmacy and Health Sciences University, Medford, MA, USA

PND64 N17  ORALS VERSUS SUBCUTANEOUS ADMINISTRATION OF DISEASE MODIFYING THERAPIES: A COMPARISON OF CHARACTERISTICS OF PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
Greene M1, Greene N2, Health Economics & Outcomes Research and Market Access Researcher, Medford, MA, USA, 1Massachusetts College of Pharmacy and Health Sciences University, Medford, MA, USA

PND65 N18  CURRENT STATUS OF MULTIPLE SCLEROSIS IN COLOMBIA
Jiménez-Pérez CE1, Zarco-Montero LA2, Castañeda-Cardona C2, Otálora-Esteban M1, Martínez A1, Rosselli D3, Pontificia Universidad Javeriana, Medical School, Bogota, Colombia, 1Neuroeconomix, Bogota, Colombia, 3Pontificia Universidad Javeriana, Bogota, Colombia

PND66 N19  A RETROSPECTIVE STUDY OF UNITED STATES HEALTH CARE UTILIZATION AND COSTS FOR PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH DISEASE-MODIFYING THERAPY
Selzer M, Hashemi L, Sanofi Genzyme, Cambridge, MA, USA

PND67 N20  TRENDS IN DESIGN, CONDUCT, AND OUTCOMES MEASURES FOR PATIENT REGISTRIES FOR MULTIPLE SCLEROSIS
Aggarwal S1, Kumar S2, Topaloglu H1, NOVEL Health Strategies, Chevy Chase, MD, USA, 1Institute for Global Policy Research, Washington, DC, USA

PND68 O1  PREDICTORS AND PREVALENCE OF SLEEP DISTURBANCE AND HYPNOTIC USE IN PERSONS WITH CANCER
Scalo JF, Rascati KL, The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

PND69 O2  TREATMENT PATTERNS OF ANTIEPILEPTIC DRUGS IN PATIENTS WITH POTENTIAL REFRACTORY EPILEPSY IN THE TEXAS MEDICAID PROGRAM
Gupte-Singh K, Wilson JP, Barner JC, Hovinga CA, Rascati KL, Richards KM, The University of Texas at Austin, College of Pharmacy, Austin, TX, USA
# RESEARCH POSTER PRESENTATIONS - SESSION II

## RESEARCH ON METHODS - Clinical Outcomes Methods

<table>
<thead>
<tr>
<th>PRM1</th>
<th>A1</th>
<th>INCIDENCE OF PRESCRIBING ERRORS IN HOSPITALIZED PATIENTS IN SAUDI ARABIA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mahmoud MA(^1), Aljadhoy H(^2), Hassan MA(^1), Universiti Sains Malaysia, Penang, Malaysia, (^*)King Saud University, Riyadh, Saudi Arabia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM2</th>
<th>A2</th>
<th>CROSS-CULTURAL VALIDATION OF FOUR COMMONLY USED SYMPTOMS BASED QUESTIONNAIRES TO ASSESS NEUROPATHIC PAIN IN PATIENTS WITH CHRONIC PAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Gudala K(^4), Bansal D(^2), Ghai B(^3), National Institute of Pharmaceutical Education and Research, Mohali, India, (^2)National Institute of Pharmaceutical Education and Research, Mohali, India, (^3)Postgraduate Institute of Medical Education and Research, Chandigarh, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM3</th>
<th>A3</th>
<th>DO ACCEPTED TECHNIQUES FOR INDIRECT COMPARATIVE EFFECTIVENESS REFLECT THE NEED FOR INDIVIDUALIZED PATIENT CARE IN HETEROGENEOUS POPULATIONS? THE CASE OF BRIVARACETAM VERSUS ADJUNCTIVE ANTI-EPILEPTIC MEDICATIONS FOR THE TREATMENT OF ADULT PATIENTS WITH FOCAL SEIZURES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Borghs S(^1), Harvey RC(^2), Srivastava K(^2), Townsend R(^3), Charokopou M(^4), UCB Pharma, Slough, UK, (^2)BresMed Health Solutions LTD, Sheffield, UK, (^3)BresMed Health Solutions, Panjin, India, (^4)UCB Pharma, Brussels, Belgium</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM4</th>
<th>A4</th>
<th>ASSESSMENT OF THE MEDICAL AND SOCIAL BENEFITS OF INCRETIN-BASED THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Petrova G, Zaharieva S, Carukciev D, Medical University - Sofia, Sofia, Bulgaria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM5</th>
<th>A5</th>
<th>A REVIEW EVALUATING THE VALIDITY OF SMARTPHONE SENSORS AND COMPONENTS TO MEASURE CLINICAL OUTCOMES IN CLINICAL RESEARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Byrom B(^1), Lee J(^2), McCarthy M(^2), Muehlhausen W(^3), ICON Clinical Research, Marlow, UK, (^2)mProve Health, Arlington, VA, USA, (^3)ICON plc, Dublin 18, Ireland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM6</th>
<th>A6</th>
<th>HOW TO MEASURE ‘OPIOID RELAPSE’ IN REAL-WORLD CLAIMS DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Montejano LB(^1), Ronquest NA(^2), Willson TM(^1), Wollschaeger BA(^2), Cole AL(^1), Nadipelli VR(^3), Truven Health Analytics, Ann Arbor, MI, USA, (^1)Indivior Inc., Richmond, VA, USA, (^2)Aventura Family Health Center, North Miami Beach, FL, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM7</th>
<th>A7</th>
<th>MORBIDITY ENDPOINTS (ME) IN THE AMNOG PROCESS IN GERMANY: ARE ME LESS IMPORTANT IN ONCOLOGY SUBSTANCES?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Bakker K, Volmer T, SmartStep Consulting GmbH, Hamburg, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM8</th>
<th>A8</th>
<th>DEVELOPMENT OF A SYSTEMATIC REVIEW SEARCH FILTER TO IDENTIFY MEDICATION ADHERENCE STUDIES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Johnson N(^1), Tongbram V(^1), Ndirangu K(^1), Ogden K(^4), Bay C(^4), ICON, New York, NY, USA, (^1)ICON, San Francisco, CA, USA, (^2)ICON, Cambridge, MA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM9</th>
<th>A9</th>
<th>MODEL OBSERVATIONAL BRIDGING STUDY ON THE EFFECTIVENESS OF EZETIMIBE ON CARDIOVASCULAR OUTCOMES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Ferrière J(^1), Dallongeville J(^2), Getsios D(^3), Rossignol M(^4), Abenhaim L(^5), Grimaldi-Bensouda L(^6), Amzal B(^7), Toulouse University, Toulouse, QC, Canada, (^1)Pasteur Institute, Lille, France, (^2)Evidera, Lexington, MA, USA, (^3)McGill University, Montreal, QC, Canada, (^4)Laser Analytica, London, UK, (^5)Laser Research, Paris, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM10</th>
<th>A10</th>
<th>A PREVALENCE STUDY ON GESTATIONAL HYPERTENSION AND ASSOCIATED COMPLICATIONS IN PREGNANT WOMEN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Ahmad M(^1), Masood I(^1), Usman Minhas M(^1), Noman ul Haq N(^2), (^1)The Islamia University of Bahawalpur, Bahawalpur, Pakistan, (^2)University of Balochistan, Quetta, Pakistan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM11</th>
<th>A11</th>
<th>UTILIZING A BYOD MOBILE APP TO COLLECT PATIENT DIARIES AND DOSING INFORMATION IN A PHASE II CLINICAL TRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Butler A(^1), Mui Y(^2), Dow C(^1), (^1)Bracket, Wayne, PA, USA, (^2)Bracket, United States, PA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM12</th>
<th>A12</th>
<th>COMPARING THE EXPANDED DISABILITY STATUS SCALE VERSUS THE MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE AS CLINICAL ENDPOINTS IN MULTIPLE SCLEROSIS CLINICAL TRIALS: A QUANTITATIVE META-ANALYSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Bin Sawad A(^1), Seoane-Vazquez E(^1), Rodriguez-Monguio R(^2), Turkistani F(^1), MCPHS University, Boston, MA, USA, (^2)University of Massachusetts Amherst, Amherst, MA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM13</th>
<th>A13</th>
<th>EVALUATION OF DIFFERENT RULES FOR LINE OF THERAPY (LOT) ASSIGNMENT IN NON- SMALL CELL LUNG CANCER (NSCLC) PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Feinberg BA(^1), Laney J(^1), Lai L(^1), Mujumdar U(^1), (^1)Cardinal Health, Dublin, OH, USA, (^2)Cardinal Health, Locust Grove, GA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRM14</th>
<th>A14</th>
<th>A RISK ANALYSIS MODEL TO EVALUATE SAFE DELIVERY AND USE OF THE FIRST CHEMOTHERAPY INJECTION FOR HOME ADMINISTRATION: OMACETAXINE MEPESUCCINATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Kim S(^1), Stemhagen A(^1), Barralle R(^2), Van Wart Hood J(^3), Pathak A(^3), UBC Corporation, An Express Scripts Company, Blue Bell, PA, USA, (^2)Teva Pharmaceuticals, North Wales, PA, USA, (^3)Teva Pharmaceuticals, Frazer, PA, USA</td>
</tr>
</tbody>
</table>
PRM15  A15  ARE MEANINGFUL DISCUSSIONS ABOUT ADHERENCE IN REIMBURSEMENT SUBMISSIONS OF CHRONIC DISEASES HINDERED BY REPORTING HETEROGENEITY?
Quigley JM¹, Halfpeny NJ², Ward KE¹, O'Rourke JM¹, Thompson JC³, Scott DA¹, ICON Clinical Research UK Ltd, Abingdon, UK, ICON Health Economics, Abingdon, UK, ICON, Abingdon, UK

PRM16  A16  INCORPORATING USER EXPERIENCE DESIGN INTO ELECTRONIC CLINICAL OUTCOME ASSESSMENT SYSTEM DESIGN
Butler A¹, Feaster T², Friedberger G³, Gaughan S⁴, Bracket, Wayne, PA, USA, Bracket, wayne, PA, USA

PRM17  A17  TIMING AND CHARACTERISTICS OF SUDDEN DEATH IN A PATIENT POPULATION ON HEMODIALYSIS
Kumar P¹, Savant K¹, Prabhu RA¹, Dept of Pharmacy practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal India, Manipal India, ³Kasturba Medical College Manipal, Manipal University, Manipal, Udupi, Karnataka, India

PRM18  A18  BENEFIT-HARM ASSESSMENT USING DATA DERIVED FROM NETWORK META-ANALYSIS: AN APPLICATION USING TREATMENTS FOR ACUTE VENOUS THROMBOEMBOLISM
Cameron C, Cornerstone Research Group Inc., Burlington, ON, Canada

PRM19  A19  ASSESSING THE PREDICTIVE VALIDITY OF QUALITY OF EVIDENCE GRADES IN SYSTEMATIC REVIEWS. A META-EPIEMILOGICAL STUDY
Gartlehner G, Danube University Krems, Krems, Austria

PRM20  A20  TRACKING ANTIPSYCHOTIC POLYPHARMACY AND TREATMENT PATTERNS
Levin R, Cosmatos I, Germshede L, United BioSource Corporation, Blue Bell, PA, USA

PRM21  A21  LATEST TRENDS IN DESIGN OF CLINICAL TRIALS FOR STROKE TREATMENT WITH STEM CELLS
Aggarwal S¹, Kumar S¹, Topaloglu H¹, ¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy Research, Washington, DC, USA

PRM22  A22  ESTABLISHING EQUIVALENCE OF ELECTRONIC CLINICIAN-REPORTED OUTCOME MEASURES
Feaster T¹, Fuller R¹, Mcnamara OW², Lenderking WR², Miller DS¹, Sabatino D², Butler A³, Bracket, wayne, PA, USA, ²Cronos CCS, Lambertville, NJ, USA, ³Evidera, Lexington, MA, USA, ⁴Merck, Upper Gwynedd, PA, USA, Bracket, Wayne, PA, USA

PRM23  A23  CURRENT LITERATURE DESCRIBING THE CLINICAL UTILITY AND ECONOMIC VALUE OF CANCER MOLECULAR DIAGNOSTICS
Doshi SP¹, Stanek EJ¹, Mathews C¹, Wat R², Boston Healthcare Associates, Inc., Boston, MA, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Johns Hopkins University, Baltimore, MD, USA

PRM24  A24  FEASIBILITY OF LINKING BENEFIT DESIGN AND ADMINISTRATIVE CLAIMS DATA TO EVALUATE THE IMPACT OF MEDICATION ACCESS AND RESTRICTIVE FORMULARIES ACROSS MULTIPLE THERAPEUTIC AREAS
Henk HJ¹, Lopez JM², Bookhart BK³, Optum, Eden Prairie, MN, USA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, USA, ³Janssen Scientific Affairs, LLC, Raritan, NJ, USA

PRM25  A25  DISCRETE EVENT SIMULATION FOR FACILITATING BETWEEN-STUDY COMPARISONS
Najafzadeh M, Schneeweiss S, Choudhry NK, Wang SV, Gagne JJ, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

PRM26  A26  IDENTIFYING NON-RESPONDERS TO BRACE THERAPIES IN MULTIPLE SCLEROSIS USING ADVANCED PREDICTIVE MODELS
Risson V¹, Rigg J², Bonzani I¹, Medin J¹, Olson MS¹, Novartis Pharma, Basel, Switzerland, ²IMS Health, London, Switzerland, ³IMS Health, Basel, Switzerland, ⁴Novartis Pharma AG, Basel, Switzerland

PRM27  A27  SELECTING NSCLC PATIENTS FOR VACCINATION: A CAUSAL INFERENCE APPROACH
Lorenzo-Luaces P¹, Sanchez L², Saavedra D², Alonso A³, Center of Molecular Immunology, Habana, Cuba, ²Center of Molecular Immunology, Havana, Cuba, ³Leuven University, Leuven, Belgium

PRM28  A28  SENSITIVITY OF CLINICAL ENDPOINTS IN THE ASCO ONCOLOGY VALUE FRAMEWORK AND IMPLICATIONS FOR CLINICAL TRIAL DESIGN
Chawla AS¹, Wood B², Myrick S², Smith G³, Chawla V⁴, Doyle JU¹, Quintiles Advisory Services, Durham, NC, USA, ²Quintiles Advisory Services, New York, NY, USA

PRM29  A29  DO RHINOLOGIC PATIENTS HAVE SEASONAL VARIATION IN GENERIC OR DISEASE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE?
Hyttönen ML¹, Roine RP², Ruuhela R³, Sintonen H⁴, Virkkula P⁵, Ylitalo-Heikkilä M¹, ¹Helsinki University Central Hospital, Helsinki, Finland, ²Helsinki and Uusimaa Hospital District, Helsinki, Finland, ³Finnish Meteorological Institute, Helsinki, Finland, ⁴University of Helsinki, Helsinki, Finland

PRM30  A30  ONE-SIZE-MAY-NOT-FIT-ALL: A RECONSIDERATION OF EXISTING APPROACHES FOR ESTIMATING UTILITIES OF MULTI-MORBIDITY
Mujica-Mota RE, Medina-Lara A, University of Exeter, Exeter, UK

PRM31  A31  CONVERGENT VALIDITY OF NEW DISEASE ASSESSMENT INSTRUMENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN RELATION TO BILAG-2004

PRM32 B1 RESPONSIVENESS AND TEST-RETEST RELIABILITY OF NEW DISEASE ASSESSMENT INSTRUMENTS IN SYSTEMATIC LUPUS ERYTHEMATOSUS (SLE) IN RELATION TO SLEDAI-2K
Narayanan S1, Busch HM2, Collins CE3, Chatham WW4, DeLaRosa O5, Narvaez M6, Hautamaki E7, Gaylis N7, Ipsos Healthcare, Washington, DC, USA, 8Science & Research Institute, Inc., Jupiter, FL, USA, 9University of Alabama, Birmingham, Birmingham, AL, USA, 10Arthritis and Rheumatic Disease Specialties, Aventura, FL, USA, 11University of Alabama, Birmingham, AL, USA

PRM33 B2 ACCOUNTING FOR RATER SEVERITY/LENIENCY IN ENDPOINT MEASURES IN ADULTS WITH SEVERE TBI
Mallinson T1, Pape T2, Gueronn A2,1 The George Washington University, Washington, DC, USA, 2Edward Hines Jr. Veterans Affairs Hospital, Hines, IL, USA

PRM34 B3 THE DIFFUSION OF INDIRECT COMPARISON META-ANALYTIC METHODS IN THE STUDY OF DRUGS: A SYSTEMATIC REVIEW AND CO-AUTHORSHIP NETWORK ANALYSIS
Ban JK, Tadrous M, Cicinelli EA, Dubins DN, Cadarette SM, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

PRM35 B4 LATEST TRENDS IN DESIGN OF PIVOTAL CLINICAL TRIALS FOR HUNTINGTON'S DISEASE
Aggarwal S1, Kumar S2, Topaloglu H3, NOVEL Health Strategies, Chevy Chase, MD, USA, 4Institute for Global Policy Research, Washington, DC, USA

RESEARCH ON METHODS - Cost Methods

PRM36 B5 ECONOMIC AND PRODUCTIVITY CONSEQUENCES ASSOCIATED WITH RHEUMATOID ARTHRITIS AMONG NON-INSTITUTIONALIZED INDIVIDUALS IN THE UNITED STATES
Gaitonde P1, Shaya FT2, University of Maryland, Baltimore, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM37 B6 A CASE FOR MARKET-BASED COSTS IN DETERMINING COST EFFECTIVENESS: THE HEPATITIS C EXAMPLE
Leinwand B1, Hughes KE2, Sorenson C3, Johnsrud M4, Avalere Health, Washington, DC, USA, 5Avalere Health LLC, Washington, DC, USA

PRM38 B7 INDIRECT COSTS CALCULATION METHOD IN MEDIUM-SIZED REGIONAL HOSPITAL
Kamensky V1, Svoboda V, Simackova J, Rogalewicz V, Czech Technical University in Prague, Kladno, Czech Republic

PRM39 B8 ARE CURRENT COST-UTILITY THRESHOLDS IN CHINA USEFUL?
Sun J, Sun L, Shenyang Pharmaceutical University, Shenyang, China

PRM40 B9 EVIDENCE GAPS IN ECONOMIC EVALUATIONS FOR NON-DRUG TECHNOLOGIES: A CANADIAN COST PERSPECTIVE
Budden AJ, Tsai B, Lee K, CADTH, Ottawa, ON, Canada

PRM41 B10 DEVELOPING CONSISTENT MEASURES FOR COST ANALYSES OF DEMENTIA BEHAVIORAL TRIALS: A REVIEW OF FOUR STUDY PROTOCOLS
Varga S1, Prioli K2, Gitlin LN3, Jutkowitz E4, Pizzi LT5, Thomas Jefferson University, Philadelphia, PA, USA, 2Johns Hopkins School of Medicine, Baltimore, MD, USA, 3University of Minnesota, Minneapolis, MN, USA

PRM42 B11 GUIDELINES FOR BUDGET IMPACT ANALYSIS: A LITERATURE REVIEW
Luna LC1, Costa MG2, Tura BR3, Correia MG4, Santos M5, INC, Rio de Janeiro, Brazil, 6Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil

PRM43 B12 COMPARATIVE ASSESSMENT OF COST EFFECTIVENESS OF OPERATIVE METHODS FOR SPINAL DISC HERNIATION TREATMENT
Sassykova A1, Kulkhan T1, Gurtskaya G2, Mauyenova D3, Saduakassova L4, Yermakanova G5, Republican Center for Health Development, Astana, Kazakhstan, 2JSC “Astana Medical University” Astana, Republic of Kazakhstan, Astana, Kazakhstan

PRM44 B13 WEB-BASED BUDGET IMPACT AND PRICING SCENARIOS PLANNING MODEL: EXAMPLE FROM THE UNITED KINGDOM
Rousseau B1, Johnson B1, Topachevskiy O2, Volovyk A3, Adelphi Values, Cheshire, UK, 4Digital Health Outcomes, Brussels, Belgium

PRM45 B14 LINKAGE ANALYSIS OF MULTIPLE-SCLEROSIS PATIENT DATA FROM SOCIAL-MEDIA SURVEYS AND CLAIMS DATABASES IDENTIFIES A REPRESENTATIVE POPULATION FOR REAL-LIFE OUTCOMES RESEARCH
Risson V1, Godge B2, Bonzani I3, Korn JR4, Medin J5, Olson MS6, Novartis Pharma, Basel, Switzerland, 7IMS Health, Basel, Switzerland, 8IMS Health, Waltham, MA, USA, 9Novartis Pharma AG, Basel, Switzerland

PRM46 B15 VALUE ASSESSMENT OF ORPHAN DRUGS FOR TREATMENT OF RARE DISEASES: A SYSTEMATIC REVIEW
Lockhart CM1, Hansen RN, University of Washington, Seattle, WA, USA

PRM47 B16 VALIDATION OF A COST-EFFECTIVENESS MODEL COMPARING ACCURACY OF GENETIC TESTS FOR BRCA
MUTATIONS
Biltaji E1, Bellows B2, Stenehjem D1, Brixner D2, University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA, 2University of Utah, Salt Lake City, UT, USA, 3Personalized Health Care, University of Utah Health Sciences Center, Salt Lake City, UT, USA

PRM48 B17 COMPARING MODELING APPROACHES IN COST-EFFECTIVENESS ANALYSIS USING SECONDARY SURVIVAL DATA: A STUDY OF NIVOLUMAB VERSUS EVEROLIMUS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA
Grewal S. University of Washington, Seattle, WA, USA

PRM49 B18 EVALUATING THE COST EFFECTIVENESS OF PERSONALISED MEDICINE CO-DEPENDENT TECHNOLOGIES: A CONCEPTUAL FRAMEWORK
Akude P, Mahjoub R, McCabe C, Paulden M, University of Alberta, Edmonton, AB, Canada

PRM50 B19 EXPECTED COST ESTIMATION FOR HOSPITALIZATION IN PATIENTS TREATED IN A COLOMBIAN INSURANCE COMPANY
Romero M1, Celis S2, Acero G1, Barrios E3, Salutia Foundation, Bogotá, Colombia, 2Salutia Foundation, Bogota, Colombia, 3Coomeva Group, Cali, Colombia

PRM51 B20 NEW METRICS FOR ECONOMIC EVALUATION IN THE PRESENCE OF HETEROGENEITY: FOCUSING ON EVALUATING POLICY ALTERNATIVES RATHER THAN TREATMENT ALTERNATIVES
Kim D, Basu A, University of Washington, Seattle, WA, USA

PRM52 B21 VALUE OF TRANSFERABILITY AND EFFICIENCY IN HTA

RESEARCH ON METHODS - Databases & Management Methods

PRM53 B22 IDENTIFICATION OF PERSONS WITH CONGENITAL HEMOPHILIA IN A LARGE ELECTRONIC HEALTH RECORD DATABASE
Wang M1, Cyhaniuk A2, Cooper DL3, Iyer NH4, 1Children's Hospital Colorado, Aurora, CO, USA, 2AC Analytical Solutions, Barrington, IL, USA, 3Novo Nordisk Inc., Plainsboro, NJ, USA

PRM54 B23 USE OF DATABASES FOR HEALTH RESOURCE UTILIZATION AND COST ANALYSES IN EU-5: RESULTS FROM A FOCUSED LITERATURE REVIEW
De Cock E1, Cosmatos I1, Kirsch E1, 1United BioSource Corporation, Barcelona, Spain, 2UBC: An Express Scripts Company, Blue Bell, PA, USA, 3UBC: An Express Scripts Company, Dorval, QC, Canada

PRM55 B24 DEVELOPMENT OF A LINKED DATABASE FOR CYSTIC FIBROSIS RESEARCH BY INTEGRATING A PATIENT REGISTRY WITH ADMINISTRATIVE CLAIMS DATA
Jiao T1, Biskupiak JE1, Ye X1, Unnii S1, Dowd C2, Fink A2, Feng L2, Erdo J2, Brixner D1, 1University of Utah, Salt Lake City, UT, USA, 2Cystic Fibrosis Foundation, Bethesda, MD, USA, 3Personalized Health Care, University of Utah Health Sciences Center, Salt Lake City, UT, USA

PRM56 B25 QUANTIFYING THE DELAY TO FINAL ACCEPTANCE WITH EACH RESUBMISSION: ANALYSIS OF REAL-WORLD/HEALTH-ECONOMIC MANUSCRIPTS
Truss N1, Fuchsberger M1, Streng-Ouwehand I1, Nuottamo N1, Polk E1, 1Excerpta Medica, London, UK, 2Excerpta Medica, Amsterdam, The Netherlands

PRM57 B26 LEVERAGING ELECTRONIC MEDICAL RECORD-BASED ANALYSES TO OPTIMIZE THE DESIGN OF AN OBSERVATIONAL PROSPECTIVE STUDY OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Wang X1, Gerhardsson M1, Sveréus A2, Hiller J2, Wong D2, Nasuti P3, Jenner H4, Mckenney A5, Kamaau AW5, Flickinger KM5, AstraZeneca, Gothenburg, MD, USA, 2AstraZeneca, Gothenburg, Sweden, 3IMS Health, London, UK, 4Anolinx LLC, Salt Lake City, UT, USA, 5PAREXEL, Chester Springs, PA, USA

PRM58 B27 DEVELOPMENT OF A NOVEL ADMINISTRATIVE CLAIMS-BASED ALGORITHM TO IDENTIFY LINES OF THERAPY AMONG MULTIPLE MYELOMA PATIENTS IN THE UNITED STATES
Kozma CM1, Slaton T1, Macomson B2, Maiiese EM3, 1CK Consulting Associates, LLC, Saint Helena Island, SC, USA, 2Janssen Scientific Affairs, LLC, Horsham, PA, USA

PRM59 B28 PATIENT-LED RESEARCH: CHARACTERIZING USE OF A NOVEL MEDICAL RECORD TECHNOLOGY AMONGST AN INFLAMMATORY BOWEL DISEASE COHORT
Bedenbaugh A1, Soi S1, Ahmed E1, 1Betterpath, Inc, Douglasville, GA, USA, 2Betterpath, Inc, New York, NY, USA, 3Betterpath, Inc, New York, NY, USA

PRM60 B29 EVALUATION OF EUROPEAN ALZHEIMER'S DISEASE REAL-WORLD DATA SOURCES FOR FUTURE PHARMACOECONOMIC OR OUTCOMES RESEARCH
Lozano-Ortega G1, Wang S1, Chan E2, Bosshard R2, 1ICON, Vancouver, BC, Canada, 2Otsuka Pharmaceutical Europe Ltd, Wexham, UK

PRM61 B30 ANALYSIS METHOD OF GOVERNMENT HEALTH CARE IN BRAZILIAN MUNICIPALITIES, USING PUBLIC AND OFFICIAL SOURCE
Nita ME1, Mussolino F1, Vaz P1, Tolentino AC1, Riveros BS1, IECS, HAOC, and FIPE, Sao Paulo, Brazil, 2HEADS, Sao Paulo,
PRM62  B31  COMPARISON OF DATA TO DECISION MODELS FOR A DATA CONSORTIUM
Kum H, Ohsfeldt R, Texas A&M Health Science Center, College Station, TX, USA

PRM63  C1  WHAT ARE PEER REVIEWERS LOOKING FOR IN REAL-WORLD/HEALTH ECONOMIC PAPERS? ASSESSMENT OF POSITIVE FEEDBACK FROM PEER-REVIEWER COMMENTS
Hartog TE1, Diamond M1, Nottamano N1, Dekker P1, Peters K2, Excerpta Medica, Amsterdam, The Netherlands, Excerpta Medica, London, UK

PRM64  C2  IDENTIFYING BEST PRACTICES FOR USE OF TEXT DATA IN HEALTH ECONOMICS AND OUTCOMES RESEARCH USING NATURAL LANGUAGE PROCESSING
Feinberg BA, Lal L, Garofalo DF, Mujumdar U, Cardinal Health, Dublin, OH, USA

PRM65  C3  PROBABILISTIC RECORD MATCHING USING MACHINE LEARNING TECHNIQUES
Ross JM1, Ferrin Cota RN1, Zaric GS2, Next Level Analytics Inc., London, ON, Canada, Western University, London, ON, Canada

PRM66  C4  INSIGHTS FOR CARE: BUILDING A PSEUDONYMISED, LINKED, CROSS-SETTING REAL-WORLD EVIDENCE LAB IN BIRMINGHAM, UNITED KINGDOM
Foxcroft R1, Chapman D1, Yassa L1, Bidgoli F2, Cooke M2, Bellary S2, Ronte H1, Monitor Deloitte, London, UK, Merck Sharp & Dohme Limited, Hoddesdon, UK, Heart of England NHS Foundation Trust, Birmingham, UK

PRM67  C5  VIRTUAL CONSULTATION SYSTEM: A WEB-BASED PLATFORM TO ASSESS COMPLEX CLINICAL CASES THROUGH SHARING OF DIAGNOSTIC IMAGES AND REPORTS
Saraceno D1, Ortali M1, Covezzoli A1, De Rosa M1, Czauederna P2, CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, Medical University of Gdansk, Gdansk, Poland

PRM68  C6  EFFECTIVENESS AND SAFETY OF MACITENTAN IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
Simbaqueba E1, Gomez LM2, Huergano C3, Palomino RA1, Health-e International, Bogota, Colombia, Biotoscana Farma, Bogota, Colombia, Universidad Nacional de Colombia, Bogota, Colombia

PRM69  C7  AN OPEN-SOURCE ANALYTIC VISUALIZATION PACKAGE FOR COMPLEX TREATMENT PATTERNS IN R
Wilson JB1, Korol E1, Goring SJ2, Tao R1, Goring S1, ICON plc, Vancouver, BC, Canada, Dash Consulting, Vancouver, BC, Canada

PRM70  C8  CURATING AN ELECTRONIC HEALTH RECORD RESEARCH QUERY DEFINITION LIBRARY
Lohnes M1, Parker C2, Kamauu A1, Anolinx LLC, Salt Lake City, UT, USA, Intermountain Healthcare, Logan, UT, USA

PRM71  C9  USING READILY AVAILABLE ADMINISTRATIVE DATA ELEMENTS TO PREDICT FUTURE MEDICATION NON-ADHERENCE AMONG COPD PATIENTS WITH EMPLOYER-SPONSORED INSURANCE
Patel J1, Dalal A1, Stanford R2, Abughosh S1, Johnson ML1, University of Houston, Houston, TX, USA, Novartis, US Health Economics and Outcomes Research, East Hanover, NJ, USA, GlaxoSmithKline, Research Triangle Park, NC, USA

PRM72  C10  ASSESSMENT AND COMPARISON OF COMPETITIVENESS BETWEEN CLINICAL TRIAL PROTOCOLS: A PSEUDOPOPULATION MODEL AND SIMULATION APPROACH
Wilson A1, Krikov S1, Parker C2, Kamauu A1, Paredes RK1, Kamauu AW1, Anolinx LLC, Salt Lake City, UT, USA, University of Utah, Salt Lake City, UT, USA, Intermountain Healthcare, Logan, UT, USA

PRM73  C11  IDENTIFYING THE CAUSES OF READMISSION AMONG DIABETIC PATIENTS USING MACHINE-LEARNING
Katsipis I1, University of Maryland College Park, College Park, MD, USA

PRM74  C12  OPTIMIZATION OF THE GENERAL SURGERY SERVICE OF THE UNIVERSITY HOSPITAL PEDRO ERNESTO
Cunha GN1, Vianna CM2, Oliveira FS1, Mossegui GB1, Assumpção LR1, Rodrigues MP1, UERJ, Rio de Janeiro, Brazil, Universidade Federal Fluminense, Niterói, Brazil

PRM75  C13  THE DISTRIBUTION OF THE EQ-5D-5L INDEX IN PATIENTS POPULATIONS
Feng Y1, Devlin N1, Bateman A2, Zamora B1, Parkin D1, Office of Health Economics, London, UK, Oliver Zangwill Centre, Princess of Wales Hospital, Cambridgeshire, UK, King’s College London, London, UK

PRM76  C14  ASSESSMENT OF THE IMPACT OF PRICE-VOLUME ADJUSTMENT PROGRAM ON PHARMACEUTICAL EXPENDITURE FOR DIABETES DRUGS: EVIDENCE IN SOUTH KOREA
Han E1, Park S2, Myung J1, Lee E1, Yonsei University, Incheon, South Korea, College of Pharmacy, Sungkyunkwan University, Suwon, South Korea, Sungkyunkwan University, Suwon, South Korea

PRM77  C15  PROXY DEFINITIONS IN RETROSPECTIVE BURDEN OF ILLNESS STUDIES: A SYSTEMATIC REVIEW
Frame D1, Pilcher L, Wallace E, Frame Research, LLC, Brooklyn, NY, USA

PRM78  C16  DELIVERING ACTIONABLE RESULTS FOR OBSERVATIONAL STUDIES THROUGH RAPID EVALUATION PROCESSES
Mack C1, Parmenter L1, Velentgas P1, Franke K1, Jablonski R1, Dreyer NA2, Quintiles, Durham, NC, USA, Quintiles Real World & Late Phase, Reading, UK, Quintiles, Cambridge, MA, USA

RESEARCH ON METHODS - Modeling Methods
PRM79  C17  A NOVEL METHOD USING PRESCRIPTION TREATMENT PATTERNS TO ESTIMATE HEART FAILURE PREVALENCE IN CANADA
Jobin-Gervais K1, Zaour N1, Caron J2, Borrelli R3, Fischer AA3, 1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2IMS Health Brogan, Kirkland, QC, Canada, 3IMS Health Brogan, Mississauga, ON, Canada

PRM80  C18  IMPROVING PRECISION BY APPLYING DISEASE PROGRESSION EQUATIONS FROM MULTIPLE SOURCES IN THE ALZHEIMER’S DISEASE ARCHIMEDES CONDITION EVENT (ACE) SIMULATOR
Tafazzoli A1, DosSantos R1, Ishak KJ2, Krotneva S3, Kansal A3, 1Evidera, Bethesda, MD, USA, 2Evidera, Montreal, QC, Canada, 3Evidera, St-Laurent, QC, Canada

PRM81  C19  MODELING ECODEVOLPMENTAL CONTEXT OF STD'S/HIV RISK AND PROTECTIVE BEHAVIORS AMONG AFRICAN AMERICAN ADOLESCENTS
Li Y4, Mgbere O2, Abughosh S1, Chen H1, Cuccaro P4, Essien EJ1, 1University of Houston, Houston, TX, USA, 2Houston Department of Health and Human Services, Houston, TX, USA, 3University of Texas School of Public Health, Houston, TX, USA

PRM82  C20  THE EVOLUTION OF ECONOMIC MODELING IN ALZHEIMER'S DISEASE: WHERE DO WE GO FROM HERE?
Hernandez L, Toro-Diaz H, Evidera, Lexington, MA, USA

PRM83  C21  PROJECTIONS FOR TOTAL JOINT ARTHROPLASTY DEMAND FOR THE NEXT GENERATION
Odum SM1, Van Doren BA1, Curtis B2, Fehring TK3, Mason JB4, 1OrthoCarolina Research Institute, Inc., Charlotte, NC, USA, 2OrthoCarolina Hip & Knee Center, Charlotte, NC, USA, 3OrthoCarolina Hip and Knee Center, Charlotte, NC, USA

PRM84  C22  STRUCTURAL SENSITIVITY ANALYSES OF MORTALITY AND LOCATION OF CARE IN A SIMULATION OF ALZHEIMER’S DISEASE
Kansal A, DosSantos R, Tafazzoli A, Evidera, Bethesda, MD, USA

PRM85  C23  THE COMPARISON OF CARDIOVASCULAR INCIDENCE PREDICTIONS IN TYPE 1 DIABETES UTILIZING ALTERNATIVE RISK PREDICTION MODELS
Foos V1, Lamotte M1, McEwan P1, 1IMS Health, Basel, Switzerland, 2IMS Health, Vilvoorde, Belgium, 3Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM86  C24  CONTRASTING PREDICTIONS OF RENAL DECLINE BETWEEN THE ADPKD OUTCOMES MODEL AND MAYO CLINIC IMAGING CLASSIFICATION OF ADPKD
McEwan P1, Bennett H1, O’Reilly K2, Robinson P3, 1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Otsuka Pharmaceutical Europe Ltd, Wexham, UK

PRM87  C25  WHAT MAKES A GOOD ECONOMIC EVALUATION IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REVIEW OF REIMBURSEMENT SUBMISSIONS TO PCQRD AND NICE
Li CM1, Risebrough NA1, Briggs A2, 1ICON plc (formerly Oxford Outcomes), Vancouver, BC, Canada, 2University of Glasgow, Glasgow, UK

PRM88  C26  DISCRIMINATING AMONG HIGH-RISK HEART FAILURE PATIENTS USING CLUSTERING
Hane C1, Nori VS1, Rumanes L1, Crown W1, Dunlay S2, Sangaralingham LR3, 1Optum Labs, Cambridge, MA, USA, 2Mayo Clinic, Rochester, MN, USA

PRM89  C27  USING TEXT NOTES FROM CALL CENTER DATA TO PREDICT HOSPITALIZATION
Lorenzana A1, Tyagi M, Wang QC, Chawla R, Nigam S, 1Independence Blue Cross, Philadelphia, PA, USA

PRM90  C28  IMAGINARY WORLDS: THE STATUS OF MODELED CLAIMS PUBLISHED IN VALUE IN HEALTH JANUARY 2015 TO DECEMBER 2015
Langley PC1, Schommer J1, Rhee TG2, 1University of Minnesota, TUCSON, AZ, USA, 2University of Minnesota College of Pharmacy, Minneapolis, MN, USA

PRM91  D1  ASSESSING THE IMPACT OF SIMULATED TIME HORIZON ON PREDICTED INCREMENTAL QUALITY ADJUSTED LIFE YEARS IN TYPE 2 DIABETES
Foos V1, Lamotte M1, McEwan P3, 1IMS Health, Basel, Switzerland, 2IMS Health, Vilvoorde, Belgium, 3Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM92  D2  COMPARING DIRECT AND INDIRECT COSTS OF TYPE 2 DIABETES ACROSS THREE AGE RANGES IN THE UNITED STATES
Foos V1, Lamotte M1, McEwan P3, 1IMS Health, Basel, Switzerland, 2IMS Health, Vilvoorde, Belgium, 3Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM93  D3  PHARMACOKINETIC ADHERENCE TO STATINS
Stauffer ME, Morrison A, 1Kaufman AS, ScribCo, Effort, PA, USA

PRM94  D4  QUANTIFYING THE HEALTH ECONOMIC BENEFIT OF KEY THERAPEUTIC OUTCOMES IN THE MANAGEMENT OF TYPE 2 DIABETES AND ASSESSING THEIR INTER-RELATIONSHIP
McEwan P1, Foos V1, Lamotte M1, Evans M1, 1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2IMS Health, Basel, Switzerland, 3IMS Health, Vilvoorde, Belgium, 4University Hospital Llandough, Cardiff, UK

PRM95  D5  UPDATE OF THE MODEL VALIDATION OF THE ECONOMIC AND HEALTH OUTCOMES MODEL OF TYPE 2 DIABETES
MELLITUS (ECHO-T2DM)
Asseburg C1, Willis M1, Johansen P1, Nilsson A1, Neslusan C2, Schroeder M3, The Swedish Institute for Health Economics, Lund, Sweden, 1Janssen Global Services, LLC, Raritan, NJ, USA, 2Janssen-Cilag UK, High Wycombe, UK

PRM96 D6 ALTERNATIVE APPROACHES TO MODELLING HBA1C PROGRESSION IN TYPE 2 DIABETES AND THEIR IMPACT ON HEALTH ECONOMIC OUTCOMES
McEwan P1, Bennett H1, Fellows J1, Yapp R1, Bergenheim K1, Qin L1, Varol N1, Gordon J1, Health Economics and Outcomes Research Ltd, Cardiff, UK, 1AstraZeneca, Mölndal, Sweden, 2AstraZeneca, Gaithersburg, MD, USA, 3AstraZeneca, Cambridge, UK

PRM97 D7 EXTERNAL VALIDATION OF HEALTH ECONOMIC MODELS FOR COMPLEX CHRONIC DISEASES: LESSONS FROM A POPULATION MODEL FOR DIABETIC RETINOPATHY
Herring W1, Mladis DM, RTI Health Solutions, Research Triangle Park, NC, USA

PRM98 D8 PARAMETERIZATION OF A DISEASE PROGRESSION SIMULATION MODEL FOR SEQUENTIALLY TREATED METASTATIC HER2-POSITIVE BREAST CANCER PATIENTS
Ali AA1, Diaby V1, Adunlin K2, Kohn CG3, Montero AJ3, Florida A & M University, Tallahassee, FL, USA, 2Virginia Commonwealth University, Richmond, VA, USA, 3University of Saint Joseph/Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA, 4Cleveland Clinic, Cleveland, OH, USA

PRM99 D9 CAN HOLISTIC MCDA TACKLE ISSUES RAISED BY EVALUATING TREATMENTS FOR RARE DISEASES: AN EXPLORATION FROM THE HTA PERSPECTIVE
Goetghebeur MM1, Wagner M1, O’Neil B1, Samaha D1, Baltussen R1, LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada, 2LASER Analytica, Montreal, QC, Canada, 3Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

PRM100 D10 MAPPING CANINE LEPTOSPIROSIS RISK IN THE UNITED STATES
Mwacalimba KK1, Wright AK1, White A2, Zambrana-Torrelio C2, Allen C2, Rostal M3, Ball E4, Husain I5, Karesh WB6, Daszak P7, Zoetis, Indianapolis, IN, USA, 2Zoetis, Greeley, CO, USA, 3Ecohealth Alliance, New York, NY, USA, 4Zoetis, Florham Park, NJ, USA, 5Celeritas Solutions LLC, New York, NY, USA

PRM101 D11 IMPACT OF IMPLEMENTING INTERNATIONAL REFERENCE PRICING ON PHARMACEUTICAL PRICES FOR UNITED STATES MEDICARE
Weiss J1, Hakim P1, Degun R2, Navigant Consulting Inc, London, UK

PRM102 D12 HOSPITAL PERFORMANCE ON QUALITY MESAURES: APPROACHES TO FAIR CROSS-HOSPITAL COMPARISONS AND VALUE-BASED PAYMENTS
Nygren K1, Suponic S2, 1Navigant Consulting, Lawrenceville, NJ, USA, 2Navigant Life Sciences, Lawrenceville, NJ, USA

PRM103 D13 IS EXENATIDE REALLY LINKED TO ACUTE PANCREATITIS: A NOVEL ANALYTIC EXAMINATION?
Chen J1, Hauptman P2, Turner JS2, Burroughs TE1, Saint Louis University Center for Outcomes Research (SLUCOR), Saint Louis, MO, USA, 2Saint Louis University School of Medicine, Saint Louis, MO, USA, 3Saint Louis University College for Public Health and Social Justice, Saint Louis, MO, USA

PRM104 D14 AN EXPLORATION OF THE HETEROGENEITY IN A NETWORK META-ANALYSIS EXPLAINED BY DOSING DIFFERENCES
Schmitz S1, Kandala N2, Senn S4, Trinity College Dublin, Dublin, Ireland, 2Luxembourg Institute of Health, Strassen, Luxembourg

PRM105 D15 COMPARISON OF PROPENSITY SCORE WITH ZIP MODELS IN ANALYZING ZERO-INFLATED COUNT DATA IN OBSERVATIONAL STUDIES
Tu C1, Koh WY1, University of New England, Portland, ME, USA, 2University of New England, Biddeford, ME, USA

PRM106 D16 VALUE OF INFORMATION METHODS FOR OPTIMAL TIMING OF BIOMARKER COLLECTION
Bansal A1, Basu A2, University of Washington, Seattle, WA, USA

PRM107 D17 QUANTIFYING AND ADJUSTING FOR EFFECT MODIFICATION IN INDIRECT TREATMENT COMPARISONS
Goring SM1, Wilson JB2, Thompson JC2, Scott DA3, ICON, Vancouver, BC, Canada, 2ICON, Abingdon, UK, 3ICON, Oxford, UK

PRM108 D18 SURVIVAL NETWORK META-ANALYSIS: HAZARD RATIOS VERSUS RECONSTRUCTED SURVIVAL DATA
Vickers AD1, RTI Health Solutions, Manchester, UK

PRM109 D19 ESTIMATION OF TRANSITION PROBABILITIES BETWEEN CERVICAL LESIONS FOR THE NATURAL HISTORY OF CERVICAL CANCER AMONG CHINESE WOMEN
Wen Y1, Chen J1, Wang Y1, Li C1, Pan X1, Yang C2, Sichuan University, Chengdu, China

PRM110 D20 COMPARING HOSPITAL PERFORMANCE FOR IN-HOSPITAL MORTALITY IN PNEUMONIA PATIENTS USING TRADITIONAL LOGISTIC REGRESSION AND MULTILEVEL MODELING APPROACH
Sura SD1, Bhasnali A1, Wang X2, Johnson ML1, Aparasu R1, 1University of Houston, Houston, TX, USA, 2University of Houston College of Pharmacy, Houston, TX, USA

PRM111 D21 A NEW TOOL TO AUTOMATE NETWORK META-ANALYSES OF STUDIES EXTRACTED FROM CLINICALTRIALS.GOV
Karcher H1, Wiecek W1, Nikodem M2, Voss E3, Sena A3, Cepeda S4,1LASER Analytica, London, UK, 2LASER Analytica, Krakow, Poland, 3Janssen Research & Development, Raritan, NJ, USA, 4Janssen Research & Development, Titusville, NJ, USA

PRM112 D22 AN OVERVIEW OF STATISTICAL METHODS FOR META-ANALYSES COMBINING INDIVIDUAL PARTICIPANT DATA AND AGGREGATE DATA
Ellis AG1, Dahabreh I1, Wong JB2, Trikalinos TA1, Brown University, Providence, RI, USA, 2Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

PRM113 D23 ESTIMATION OF TRANSITION PROBABILITIES BETWEEN ESOPHAGEAL CANCER AND ITS PRECANCEROUS LESIONS BASED ON A MARKOV MODEL
Chen J, Wang Y, Li C, Wen Y, Pan X, Yang C, Sichuan University, Chengdu, China

PRM114 D24 DEVELOPING GRAPHICAL USER INTERFACE FOR BAYESIAN STATISTICS APPLIED TO MIXED TREATMENT COMPARISON ON R COMMANDER
Correia MG1, Tura BR1, Lanzillotti RS2, Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil, 2Rio de Janeiro State University, Rio de Janeiro, Brazil

RESEARCH ON METHODS - Patient-Reported Outcomes Studies

PRM116 D26 APPLICATION OF ITEM RESPONSE THEORY IN VALIDATING THE PATIENT HEALTH QUESTIONNAIRE (PHQ-9) IN THE AMERICAN GENERAL POPULATION
Gupta S, Witt EA1, Kantar Health, Princeton, NJ, USA

PRM117 D27 ATTRIBUTE IDENTIFICATION OF CAREGIVERS’ TRADEOFFS IN CARE MANAGEMENT DECISION MAKING FOR INDIVIDUALS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS
Majid T1, Asamoah B1, Bridges JF2, dosReis S1, University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PRM118 D28 QUALITATIVE EQUIVALENCE BETWEEN PAPER AND ELECTRONIC TABLET VERSIONS AND USABILITY OF 12 PATIENT-REPORTED OUTCOME INSTRUMENTS FOR RHEUMATOID ARTHRITIS
Eremenco S1, Stringer S1, Gleeson S1, Landrián A1, Falcon I1, Evidera, Inc., Bethesda, MD, USA, 2AbbVie, North Chicago, IL, USA

PRM119 E1 A SYSTEMATIC REVIEW OF DISCRETE CHOICE EXPERIMENTS IN HEALTH-CARE RESEARCH: THE USE OF SINGLE SCENARIO DESIGNS
Müller K1, Tao R1, Goring S1, Lane S1, ICON plc, Vancouver, BC, Canada, 2ICON, Vancouver, BC, Canada, 3ICON PLC, Vancouver, BC, Canada

PRM120 E2 PSYCHOMETRIC VALIDATION OF THE DIABETES KNOWLEDGE TEST IN MEDICAID-ELIGIBLE ADULTS
Simmons D1, McGuigan K, Bateman MT, McCarthy C, Wagner ML, Rutgers, The State University of NJ, Piscataway, NJ, USA

PRM121 E3 A STUDY ON KNOWLEDGE AND AWARENESS ON ORAL CANCER IN A COMMUNITY OF SUIZHOU, CHINA
Vasireddy VK1, Soochow University, Suzhou, China

PRM122 E4 AN ASSESSMENT OF THE VALIDITY AND RESPONSIVENESS OF THE ICECAP-O IN A MULTICENTRE RANDOMIZED CONTROLLED TRIAL OF BLOOD PRESSURE MANAGEMENT
Keeley TJ1, Al-Janabi H1, Fletcher K1, McManus R2, Mant J3, Coast J4, The University of Birmingham, Birmingham, UK, 2The University of Oxford, Oxford, UK, 3University of Cambridge, Cambridge, UK, 4The University of Bristol, Bristol, UK

PRM123 E5 CONSTRUCT VALIDITY OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN US ADULT PEOPLE WITH HEMOPHILIA (PWH): RESULTS FROM THE PAIN, FUNCTIONAL IMPAIRMENT, AND QUALITY OF LIFE (P-FIQ) STUDY
Batt K1, Recht M1, Cooper DL2, Iyer NN3, Kempton CL3, Wake Forest School of Medicine, Winston-Salem, NC, USA, 2Oregon Health & Science University, Portland, OR, USA, 3Novo Nordisk Inc., Plainsboro, NJ, USA, 4Emory University School of Medicine, Atlanta, GA, USA

PRM124 E6 CHALLENGES IN TRANSLATING THE EPWORTH SLEEPINESS SCALE INTO 66 LANGUAGES
Bindi P1, Bayles A2, Acquard C1, Johns M1, Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France, 3Epworth Sleep Centre, Melbourne, Australia

PRM125 E7 THE RELIABILITY AND VALIDITY OF THE CAREGIVER WORK LIMITATIONS QUESTIONNAIRE FOR EMPLOYED CAREGIVERS OF INDIVIDUALS WITH SCHIZOPHRENIA AND/OR SCHIZOAFFECTIVE DISORDER
Lerner D1, Benson C2, Chang H2, Greenhill A1, Rogers W1, Parsons S1, Tufts Medical Center, Boston, MA, USA, 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA

PRM126 E8 DEVELOPING GUIDELINES FOR MIGRATING THE ACTS, A PAPER PRO, TO WEB FORMAT
Marson-Smith HT1, Langel K1, Folkerts K2, Bamber L3, Skerritt B4, ICON Plc, Oxfordshire, UK, 2eClinical Health, Stirling, UK, 3Bayer Pharma AG, Wuppertal, Germany, 4ICON, Dublin, Ireland

PRM127 E9 TASTE HETEROGENEITY OR SOMETHING ELSE? ANALYZING STATED BENEFIT-RISK TRADEOFF PREFERENCES FOR PSORIASIS TREATMENTS
Fairchild AO, Reed SD, Johnson FR, Duke Clinical Research Institute, Durham, NC, USA

PRM128 E10 DEVELOPMENT AND VALIDATION OF A SHORT HEALTH CONFIDENCE SCORE
PRM129 E11 VALUING EQ-5D-5L USING DISCRETE CHOICE EXPERIMENTS WITH DURATION: INVESTIGATING DIMENSION ORDER
Mulhern B1, Norman R2, Viney R1, Lorgelly P1, Lancsar E1, Ratcliffe J2, Brazier J3, University of Technology Sydney, Sydney, Australia, 2Curtin University, Perth, Australia, 3Office of Health Economics, London, UK, 4Monash University, Melbourne, Australia, 5Flinders University, Adelaide, Australia, 6University of Sheffield, Sheffield, UK

PRM130 E12 DEVELOPMENT OF A CONCEPTUAL FRAMEWORK FOR ASSESSING DISEASE-SPECIFIC PATIENT-REPORTED OUTCOMES IN NONALCOHOLIC STEATOHEPATITIS
Palsgrove AC1, Hazra S2, Ferguson B3, Cheng R4, Cole JC5, PPD, Rockville, MD, USA, 2Intercept Pharmaceuticals, Inc., San Diego, CA, USA, 3PPD, San Diego, CA, USA

PRM131 E13 THE TRANSLATION AND PRELIMINARY Linguistic VALIDATION OF THE ASSESSMENT OF OPioid TAKING BEHAVIORS AND ADHERENCE SCALE (AOtBa) IN PATIENTS WITH SICKLE CELL DISEASE
Alsalman AJ1, Jafari MA2, Alabdulaal ZS3, Northern Border University, Rafha, Saudi Arabia, 2King Faisal University, Alahsa, Saudi Arabia, 3Kappa Research Group, Alahsa, Saudi Arabia

PRM132 E14 QUALITATIVE INTERVIEWS VERSUS SOCIAL MEDIA SEARCHES: COMPARELING TWO APPROACHES FOR CONCEPT ELICITATION
Gelhorn HL1, Anand SB2, Parvizi J3, Morrison T4, Yu H5, Pokrzywinski R1, Al-Jassar G2, Cox A6, Dashiell-Aje E1, Chen AF7, Evidera, Bethesda, MD, USA, 2Evidera, London, UK, 3Rothman Institute, Philadelphia, PA, USA, 4Pfizer, Collegeville, PA, USA

PRM133 E15 HEALTH-RELATED QUALITY OF LIFE OF HIV/AIDS PATIENTS ON HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY AT A UNIVERSITY REFERRAL HOSPITAL IN ETHIOPIA
Surur AS1, University of Gondar, Gondar town, Ethiopia

PRM134 E16 EVALUATING HUMANISTIC OUTCOMES FOR ORAL CANCER PATIENTS IN INDIA: A SYSTEMATIC LITERATURE REVIEW
Munir MV1, Vadlamudi NK2, Indian Institute of Public Health - Public Health Foundation of India, Hyderabad, India, 2PAREXEL International, Hyderabad, India

PRM135 E17 US AND LATIN AMERICA: FINDING THE BEST BASE FOR SPANISH ADAPTATIONS
Anderson H1, Gordon-Stables R2, ICON Plc, Abingdon, UK, 2ICON plc, Oxford, UK

PRM136 E18 CONSIDERING CHALLENGES IN ENGLISH TO KOREAN TRANSLATION AND CULTURAL ADAPTATION
Scharf L1, Forsythe C2, Lee J3, ICON Plc, Abingdon, UK, 2ICON plc, Seoul, South Korea

PRM137 E19 ASSESSMENT OF IRT-BASED DIFFERENTIAL ITEM FUNCTIONING BETWEEN LEVELS OF DISEASE BURDEN IN THE QUALITY OF LIFE IMPAIRMENT OF CHRONIC PAIN PATIENTS
Roberts BA1, Davis FN, Gostine ML, Risko R, ProCare Systems, Inc., Grand Rapids, MI, USA

PRM138 E20 USING DISCRETE CHOICE EXPERIMENTS TO VALUE GENERIC PREFERENCE-BASED MEASURES: A SYSTEMATIC REVIEW
Mulhern B1, Norman R2, Viney R1, Stolk E4, University of Technology Sydney, Sydney, Australia, 2Curtin University, Perth, Australia, 4Erasmus MC, Rotterdam, The Netherlands

PRM139 E21 HEALTH-RELATED QUALITY OF LIFE OF SICKLE CELL DISEASE PATIENTS AND FAMILIES IN COLOMBIA
Romero M1, Sanabria M2, Huerfano LM3, Salutia Foundation, Bogotá, Colombia, 2Salutia’s Foundation-Research center in economy, management and health technologies., Bogota, Colombia, 3Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia

PRM140 E22 EVALUATION OF THE PSYCHOMETRIC PROPERTIES OF TWO ELECTRONIC DAILY DIARIES DEVELOPED TO ASSESS BREAST PAIN/TENDERNESS AND VAGINAL BLEEDING/SPOTTING IN POSTMENOPAUSAL WOMEN ON HORMONE THERAPY
Tatlock S1, Abraham L2, Bushmakin AG3, Moffatt M4, Williamson N1, Coon C5, Arbuckle R1, Adelphi Values Ltd, Bollington, UK, 2Pfizer, Inc., Surrey, UK, 3Pfizer Inc, Groton, CT, USA, 4Pfizer Inc, New York, NY, USA, 5Outcometrix, Tucson, AZ, USA

PRM141 E23 DIFFICULTIES FACED IN THE TRANSLATION AND CULTURAL ADAPTATION OF THE WORD ‘PARTNER’ IN SEXUAL HEALTH QUESTIONNAIRES
Oke L1, ICON Plc, Abingdon, UK

PRM142 E25 DEVELOPING A PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH 4 SUBTYPES OF SOFT TISSUE SARCOMA
Skalicky AM1, Ghate SR2, Perez JR2, Rentz A1, 1Evidera, Bethesda, MD, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PRM143 E26 SIMULTANEOUS DEVELOPMENT OF PRO QUESTIONNAIRES FOR USE IN CLINICAL TRIALS AND ‘REAL-WORLD’ SITUATIONS
Shields A1, Stokes J1, Foley C1, Banderas B1, Sundaram M3, 1Adelphi Values USA, Boston, MA, USA, 2AbbVie Inc., North Chicago, IL, USA

PRM144 E27 DEFINING AND CAPTURING PATIENT-CENTRED CARE IN LONG-TERM CONDITIONS: THE DEVELOPMENT OF A PATIENT-REPORTED EXPERIENCE MEASURE
PRM145
RESEARCH ON METHODS - Statistical Methods

PRM152 E34 IMPACT OF RESTRICTED FOLLOW-UP TIMES IN CLINICAL TRIALS ON OVERALL SURVIVAL ESTIMATES: A CASE COMPARISON OF ADVANCED PROSTATE CANCER, ADVANCED LUNG CANCER, AND CHRONIC MYELOID LEUKEMIA USING REGISTRY DATA
Shah D1, Paly V1, Sidhu M1, Briggs A1, ICON Plc, New York, NY, USA, 2University of Glasgow, Glasgow, UK

PRM153 F1 CONTEXTUAL ANALYSIS OF THE EFFECT OF PROSTATE-SPECIFIC ANTIGEN TESTING ON PROSTATE CANCER OUTCOMES AMONG ELDERLY MEN
Jayasekera J1, Onukwuga E1, Tom S1, Harrington D2, Pradel FG1, Naslund M1, 1Georgetown University, Washington, DC, USA, 2University of Maryland, Baltimore, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA, 4University of Maryland School of Medicine, Baltimore, MD, USA

PRM154 F2 PROPOSED CHECKLIST FOR NON-STATISTICIANS TO ASSESS THE QUALITY OF A NETWORK META-ANALYSIS IN THE CONTEXT OF A NICE SUBMISSION
Pacou M1, Gauthier A1, Taieb V1, Belhadi D2, Mesana L3, 1Amaris, Paris, France, 2Amaris, London, UK, 3Amaris, Toronto, ON, Canada

PRM155 F3 INTERVAL-CENSORED SURVIVAL DATA ANALYSIS: LEARNINGS FROM PHASE III TRIAL IN PROSTATE CANCER
Amzal B1, Wiecek W1, Obadia T1, Benzaghou F1, LASER Analytica, London, UK, 2Steubabitech, Paris, France

PRM156 F4 LONG-TERM COST UTILITY ANALYSIS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN INTENSIFICATION THERAPIES IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN IN SPAIN
Prades M1, Lizan L2, Hunt B3, Ramirez de Arellano A4, 1Outcomes'10, Castellon, Spain, 2Outcomes 10, Castellon, Spain, 3Ossian, Basel, Switzerland, 4Novo Nordisk Ltd, Madrid, Spain

PRM157 F5 COMPARING CONFIDENCE INTERVALS OF INCIDENCE RATES
Pati D1, Liu J1, Su Z1, Quintiles Inc, Rockville, MD, USA, 2Quintiles Inc, Cambridge, MA, USA, 3Better Outcomes Corporation, Cambridge, MA, USA

PRM158 F6 LONG-TERM COST EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS GLP-1 ADDED TO BASAL INSULIN AS INTENSIFICATION THERAPIES IN TYPE 2 DIABETES MELLITUS IN SPAIN
Prades M1, Lizan L2, Hunt B3, Ramirez de Arellano A4, 1Outcomes'10, Castellon, Spain, 2Outcomes 10, Castellon, Spain, 3Ossian, Basel, Switzerland, 4Novo Nordisk Ltd, Madrid, Spain

PRM159 F7 REVISITING THE PERFORMANCE OF CONTINUITY CORRECTION METHODS IN META-ANALYSIS OF SPARSE DATA
Parks DC1, Bhattacharyya A1, 1GSK, Phoenixville, PA, USA, 2GSK, King of Prussia, PA, USA

PRM160 F8 SYNTHESIS OF TIME-TO-EVENT DATA FOR COST-EFFECTIVENESS ANALYSIS: PROPORTIONAL HAZARDS OR ACCELERATED FAILURE TIME SCALE?
Parker C1, Padhiar A2, Scott DA3, 1ICON Health Economics, Abingdon, UK, 2ICON Health Economics, Oxford, UK, 3ICON, Oxford, UK

PRM161 F9 TRENDS IN THE USE OF MATCHING-ADJUSTED INDIRECT COMPARISONS IN PUBLISHED LITERATURE AND NICE TECHNOLOGY ASSESSMENTS: A SYSTEMATIC REVIEW
Ndirangu K1, Tongbram V2, Shah D1, 1ICON Plc, New York, NY, USA, 2ICON, New York, NY, USA

PRM162 F10 BAYESIAN ANALYSIS OF SINGLE ARM TRIALS: CONCEPTS AND EXAMPLES
Amzal B1, Benzaghou F2, LASER Analytica, London, UK, 2Steubabitech, Paris, France

PRM163 F11 USE OF ANTIHYPERTENSIVE AGENTS AND RISK OF PARKINSON'S DISEASE: A META-ANALYSIS OF OBSERVATIONAL STUDIES

Mullapudi A, Gudala K, Boya C, Bansal D, National Institute of Pharmaceutical Education and Research, Mohali, India

PRM164 F12 PREVALENCE OF USE OF CONTRACEPTIVE METHODS IN YOUNG POOR PEOPLE FROM A REGION OF COLOMBIA
Alvis Zakuk J1, Salcedo Mejia F2, Alvis Guzman N1, Alvis Zakuk JY1, Alvis Zakuk NR1,1 Alzak foundation, Cartagena, Colombia, 2University of Cartagena, CARTAGENA DE INDIAS, Colombia, 3University of Cartagena, Cartagena, Colombia, 4Univsity of Cartagena, Cartagena, Colombia, 5Mutual Ser EPS, cartagena, Colombia

PRM165 F13 CHECKLIST TO ASSESS THE FEASIBILITY OF A NETWORK META-ANALYSIS
Belhadi D1, Pacou M2, Gauthier A1, Taieb V1, Mesana L3, 1Amaris, London, UK, 2Amaris, Paris, France, 3Amaris, Toronto, ON, Canada

PRM166 F14 MEASURING OPPORTUNITIES TO IMPROVE HEALTH OUTCOMES VIA INDIVIDUALIZED TREATMENT ASSIGNMENT
Patterson-Lomba O, Signorovitch J, Analysis Group, Inc., Boston, MA, USA

PRM167 F15 MATCHING ADJUSTED INDIRECT COMPARISONS TO ASSESS COMPARATIVE EFFECTIVENESS OF THERAPIES: USAGE IN SCIENTIFIC LITERATURE AND HEALTH TECHNOLOGY APPRAISALS
Thom H1, Jugl SM2, Palaka E3, Jawla S4, 1University of Bristol, BRISTOL, UK, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Global Service Center, Dublin, Ireland, 4Novartis Healthcare Pvt. Ltd., Hyderabad, India

PRM168 F16 COMPARISON OF GENERALIZED LINEAR MODELLING APPROACHES AS APPLIED TO NETWORK META-ANALYSIS
Batson S1, Sutton A1, Abrams K1, 1DRG, Bicester, UK, 2University of Leicester, Leicester, UK

PRM170 F17 APPLICATION OF ASSOCIATION RULES IN CLINICAL DATA MINING: A CASE STUDY FOR IDENTIFYING ADVERSE DRUG REACTIONS
Sharma D, Novartis Healthcare Private Limited, Hyderabad, India

PRM171 F18 METHODS OF SAMPLE SIZE CALCULATION IN RETROSPECTIVE BURDEN OF ILLNESS STUDIES
Johnston KM1, Szabo SM1, Donato B2, Bolzani A3, 1Broad Street HEOR, Vancouver, BC, Canada, 2Alexion Pharmaceuticals, Cheshire, CT, USA, 3Redwood Outcomes, Vancouver, BC, Canada

PRM172 F19 MEASURING THE ECONOMIC IMPACT OF SSB TAXES IN BRAZIL: AN INPUT-OUTPUT ANALYSIS
Balbinotto G1, Cardoso L, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

PRM173 F20 META-ANALYSIS FOR ORPHAN DRUGS: AN EXAMPLE WITH BOSUTINIB
Siderova P1, Kamusheva M1, Mitov K1, Petrova G2, 1Medical University - Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria

RESEARCH ON METHODS - Study Design

PRM174 F21 WHAT IS REPORTED IN COST-EFFECTIVENESS ANALYSES OF ANTI-EPILEPTICS?: A DESCRIPTIVE ANALYSIS USING THE CHEERS CRITERIA
Kanaskar A, Mctibe J, Mintzer S, Pizzi LT, Thomas Jefferson University, Philadelphia, PA, USA

PRM175 F22 ASSOCIATION OF DEEP RESPONSES WITH OUTCOMES (CLINICAL / NON-CLINICAL) IN CHRONIC LYMPHOCYTIC LEUKEMIA: A SYSTEMATIC REVIEW
Arora P1, Mott DA, University of Wisconsin-Madison, Madison, WI, USA

PRM176 F23 DEVELOPING BEST PRACTICES FOR MANAGING TREATMENT SWITCHING IN THE DESIGN, CONDUCT, ANALYSIS, AND REPORTING OF ONCOLOGY DRUG CLINICAL TRIALS
Conley RB1, Al Naber J1, Messner DA1, Henshall C2, Huang C3, Rosner GL1, 1Center for Medical Technology Policy, Baltimore, MD, USA, 2Brunnel University, London, UK, 3Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

PRM177 F24 RISK-ADJUSTED HOSPITAL RATES OF READMISSION AND MORTALITY USING COMORBIDITY DATA FROM A CLINICAL REGISTRY VERSUS ADMINISTRATIVE CLAIMS
O'Brien E1, Li S1, Thomas L1, Wang TY1, Peterson ED1, Duke Clinical Research Institute, Durham, NC, USA

PRM178 F25 COMPARISON OF ADAPTIVE RANDOMIZATION DESIGNS FOR BINARY RESPONSE TRIAL
Smolen HJ, Medical Decision Modeling Inc., Indianapolis, IN, USA

PRM179 F26 TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR ALPHA 1 TRYPsin DEFICIENCY DISORDER
Aggarwal S1, Kumar S1, Topaloglu H1, 1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy Research, Washington, DC, USA

PRM180 F27 LATEST TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR HEMOPHILIA A AND B
Aggarwal S1, Kumar S1, Topaloglu H1, 1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy Research, Washington, DC, USA

PRM181 F28 LATEST TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR PARTIAL ONSET OF SEIZURES
Aggarwal S1, Kumar S1, Topaloglu H1, 1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy Research, Washington, DC, USA

PRM182 F29 OBSERVATIONAL STUDIES EVALUATING BIOSIMILAR AGENTS: A FOCUSED LITERATURE REVIEW
Mokiou S1, De Cock E2, 1UBC: An Express Scripts Company, London, UK, 2United BioSource Corporation, Barcelona, Spain
PRM183 F30 IDENTIFYING AND VALUING PATIENT GROUP ENGAGEMENT METHODS
Eisenstein EL1, Levitan B2, Getz KA3, Patrick-Lake B4, Harker M5, Duke Clinical Research Institute, Durham, NC, USA, 2Janssen Research & Development, LLC, Titusville, NJ, USA, 3Tufts University, Boston, MA, USA, 4Duke University, Durham, NC, USA

PRM184 F31 A PATIENT-CENTRIC OUTCOMES RESEARCH STUDY WITH A BRANDED PROTON-PUMP INHIBITOR IN A COMMUNITY PHARMACY SETTING: FEASIBILITY AND IMPLEMENTATION OF A REAL-WORLD OBSERVATIONAL OUTCOMES RESEARCH STUDY
Chaponis Ru1, Bayliss M2, Livote E2, Lopes V3, Hospattankar A4, GlaxoSmithKline, Parsippany, NJ, USA, 2Optum, Lincoln, RI, USA

PRM185 F32 LATEST TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR PERIPHERAL T-CELL LYMPHOMA
Aggarwal S1, Kumar S2, Topaloglu H3, NOVEL Health Strategies, Chevy Chase, MD, USA, 1Institute for Global Policy Research, Washington, DC, USA

PRM186 F33 TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR CLUSTER HEADACHE DISORDER
Aggarwal S1, Kumar S2, Topaloglu H3, NOVEL Health Strategies, Chevy Chase, MD, USA, 1Institute for Global Policy Research, Washington, DC, USA

PRM187 F34 LESSONS FOR REMS FROM A MULTI-PHASE RISKMAP ASSESSMENT
Tave A, Goehring Jr E, Kamani S, Jones JK, The Degge Group, Ltd., Fairfax, VA, USA

PRM188 G1 USE OF HOME HEALTH SERVICES IN MATERNAL AND INFANT STUDIES
Covington D1, Churchill P2, Hurst N2, PPD, Wilmington, NC, USA, 3PPD, Morrisville, NC, USA

PRM189 G2 APPLICATION OF COMMON METHODOLOGY TO DEVELOP ECONOMIC EVALUATIONS WITH A REGIONAL APPROACH IN THREE LATIN AMERICAN COUNTRIES
Sánchez E1, Gaíntu Duarte H2, Fundación IFARMA, Bogotá, Colombia, 1Universidad Nacional de Colombia, Bogotá, Colombia

PRM190 G3 DEVELOPMENT OF AN INNOVATIVE OBSERVATIONAL STUDY TO ASSESS MULTIPLE SCLEROSIS DISEASE PROGRESSION IN REAL WORLD CLINICAL PRACTICE
Khan N1, Weinstock-Guttman B2, Medin J3, Christoffersen P4, Price J5, Bonzani I6, Zivadinov R7, 1IMS Health, Basel, Switzerland, 2SUNY University at Buffalo, Buffalo, NY, USA, 3Novartis Pharma AG, Basel, Switzerland

PRM191 G4 LATEST TRENDS IN DESIGN OF CLINICAL TRIALS FOR REAL-WORLD HEALTH ECONOMIC EVIDENCE GENERATION
Aggarwal S1, Kumar S2, Topaloglu H3, NOVEL Health Strategies, Chevy Chase, MD, USA, 1Institute for Global Policy Research, Washington, DC, USA

PRM192 G5 THE VALIDITY AND RELIABILITY OF COHORT IDENTIFICATION ALGORITHMS FOR REAL-WORLD STUDIES
Zhou Y1, Murray JF2, 1University of Michigan AND Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Carmel, IN, USA

PRM193 G6 COMBINING MULTIPLE DATA SOURCES IN A SINGLE STUDY: STRENGTHS OF HYBRID STUDY METHODOLOGY
Kritikou P1, Stein D2, De Cock E2, Hanson KA3, UBC: An Express Scripts Company, London, UK, 1UBC: An Express Scripts Company, Dorval, QC, Canada, 2United BioSource Corporation, Barcelona, Spain

RESEARCH ON METHODS - Conceptual Papers

PRM194 G7 WHY AREN'T ALL PRO/COA CLINICAL TRIALS USING ELECTRONIC DATA COLLECTION TO OPTIMIZE DATA INTEGRITY AND PATIENT EXPERIENCE?
Holzbaur E, Ross J, Rothrock T, Almac Clinical Technologies, Souderton, PA, USA

PRM195 G8 PURPOSES OF QUALITATIVE METHODS IN HEALTH OUTCOMES RESEARCH: TWO PRACTICAL EXAMPLES
Guillemet J, Gauthier A, Amaris, London, UK

PRM196 G9 INDIRECT TREATMENT COMPARISONS WITH GUIDED MATCHING-BASED ADJUSTMENT: A HYBRID OF THE STC AND MAIC TECHNIQUES
Ishak KJ1, Rael M2, Proskorovsky I3, Evidera, Montreal, QC, Canada, 1Evidera, San Francisco, CA, USA

PRM197 G10 A ROLE FOR PRO-BASED PATIENT TREATMENT SIMULATORS IN OBSERVING PHYSICIAN TREATMENT OF PAIN AND DISCOMFORT
Hu G, Koganov, M.KMK Consulting Inc., Morristown, NJ, USA

PRM198 G11 IMPROVING THE QUALITY OF CARE IN PAEDIATRIC HOSPITAL ENVIRONMENT BY OPTIMIZING BUDGET ALLOCATION BETWEEN INVESTMENT IN VACCINATION AND FUTURE INSTITUTIONAL DEVELOPMENT
Dort T1, Schercroun N2, Standaert B3, naviga S.A. on behalf of GSK Vaccines, Brussels, Belgium, 12Keyrus Biopharma on behalf of GSK Vaccines, Lasnes, Belgium, 3GSK Vaccines, Wavre, Belgium

PRM199 G12 APPLICATIONS OF THE FDA GUIDANCE ON COMMON ISSUES IN DRUG DEVELOPMENT FOR RARE DISEASES
Pan YI, UBC: An Express Scripts Company, Dorval, QC, Canada

PRM200 G13 MITIGATING TREATMENT UNBLINDING IN ELECTRONIC SYSTEMS WITH PATIENT-REPORTED OUTCOME RESULTS
Ross J, Holzbaur E, Rothrock T, Almac Clinical Technologies, Souderton, PA, USA
PRM201 G14 DETERMINING AND IDENTIFYING COSTS FOR ECONOMIC EVALUATIONS: GUIDANCE FROM CANADA
Budden AJ1, Lee KM1, Jacobs P2,3, CADTH, Ottawa, ON, Canada, 1Institute of Health Economics, Edmonton, AB, Canada

PRM202 G15 AN ANALYSIS OF THE CRITERIA USED IN EXISTING OR PROPOSED MCDA MODELS
Piniazhko O1, Nemeth B1, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 1Syreon Research Institute, Budapest, Hungary

PRM203 G16 TO JOIN OR NOT TO JOIN? ANALYSIS OF PROGRESSION-FREE AND OVERALL SURVIVAL USING MULTI-STATE MODELING
Rael M1, Ishak KJ1, Benedict A1, Evidera, San Francisco, CA, USA, 2Evidera, Montreal, QC, Canada, 3Evidera, Budapest, Hungary

PRM204 G17 THE IMPACT OF SOCIOECONOMIC FACTORS IN THE PREVALENCE OF DEPRESSION IN BRAZIL BETWEEN 1998 AND 2008
Balbinotto G, Silveira E, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

PRM205 G18 PACE CONTINUOUS INNOVATION INDICATORS DATA SUPPORT DYNAMIC VALUE ASSESSMENTS OF PHARMACEUTICALS
Thomas S1, Goodman C2, Paddock S1, Shortenhaus SH1, Ferguson J1, Grainger D1, Li R1, Rose Li and Associates, Inc., Bethesda, MD, USA, 2The Lewin Group, Falls Church, VA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Eli Lilly and Company, Sydney, Australia

PRM206 G19 EARLY ASSESSMENT OF THE 10-STEP PATIENT ENGAGEMENT FRAMEWORK FOR PATIENT-CENTERED OUTCOMES RESEARCH STUDIES: THE FIRST 3 STEPS
Oladeinde Y1, Newhouse R1, Lavallee D1, Huang J1, Mullins CD1, University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Indiana University School of Nursing, Indianapolis, MD, USA, 3University of Washington, Seattle, WA, USA, 4Westat, Rockville, MD, USA

PRM207 G20 WHAT’S THE MATTER WITH AVERAGE COST-EFFECTIVENESS RATIOS? A SIMPLE GRAPHICAL EXPLANATION
O’Day K, Campbell DJ, Xcendra, Palm Harbor, FL, USA

PRM208 H1 NETWORK META-ANALYSIS USING OBSERVATIONAL DATA FROM DISTRIBUTED HEALTH DATA NETWORKS: A CONCEPTUAL FRAMEWORK AND ILLUSTRATIVE EXAMPLE
Cameron C1, Fireman B2, Toh D2, Cornerstone Research Group Inc., Burlington, ON, Canada, 2Kaiser Permanente Northern California, Oakland, CA, USA, 3Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

PRM210 H2 UTILIZING SECONDARY DATA SOURCES IN COMBINATION WITH PRIMARY CLINICAL DATA TO OPTIMIZE DATA COLLECTION IN PROSPECTIVE STUDY DESIGNS
Alsayed I, Maguire-Wright K, Flickinger K, Parexel, Waltham, MA, USA

PRM211 H3 USE OF TEXT-MINING TOOLS FOR SYSTEMATIC REVIEWS
Paynter RA1, Bañez L1, Berliner E1, Erinoff E1, Lege-Matsuura JM1, Potter S1, AHRQ Effective Health Care Program, Portland, OR, USA, 2Agency for Healthcare Research and Quality, Rockville, MD, USA, 3ECRI Institute, Plymouth Meeting, PA, USA, 4Vanderbilt University, Nashville, TN, USA

PRM212 H4 METHODS FOR SYNTHESIZING COSTING DATA: AN ILLUSTRATIVE EXAMPLE AND CONCEPTUAL METHODS FRAMEWORK
Solesa I1, Ferko N1, Cheng H1, Clymer JW1, Amaral JF1, Cameron C1, Cornerstone Research Group Inc., Burlington, ON, Canada, 2Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA, 3Ethicon Inc., Cincinnati, OH, USA

PRM213 H5 ASSESSMENT OF THE USE OF HETEROGENEITY OF TREATMENT EFFECT ANALYSES IN CER AND FUTURE DIRECTIONS
McQueston K, Evans E, Ambosio A, Ceesay F, Hughes K, Robb J, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

PRM214 H6 SELECTION OF THE MOST APPROPRIATE EPRO MODE: CONTRIBUTING TO THE SUCCESS OF PATIENT-CENTERED CLINICAL TRIALS
Ross J, Holzbaur E, Rothrock T, Almac Clinical Technologies, Souderton, PA, USA

PRM215 H7 FORMALIZING MODEL TESTING METHODS: THE NEED FOR THE FORMATION OF AN ISPOR TASK FORCE ON MODEL TESTING BASED ON SOFTWARE ENGINEERING BEST TESTING PRACTICES
Dasbach E1, Minayev P1, Kruger M1, Andreev S1, Shvartc V1, Elbashai EH1, Merck & Co. Inc., North Wales, PA, USA, 2MSD IT Global Innovation Network @ Prague, Prague, Czech Republic, 3Merck & Co., Inc., Boston, MA, USA, 4EPAM, St. Petersburg, Russian Federation, 5Merck & Co., Inc., Kenilworth, NJ, USA

PRM216 H8 COMBINING MORBIDITY AND MORTALITY IN A SINGLE MEASURE: COMPARING THE LOAD AND QALY MODELS
Benson T, R-Outcomes Ltd, Thatcham, UK

PRM217 H9 EPRO PRODUCT LIFE CYCLE: GUIDANCE FOR A SUCCESSFUL MANAGEMENT PHASE
Holzbaur E, Ross J, Rothrock T, Almac Clinical Technologies, Souderton, PA, USA

PRM218 H10 SURVEY METRICS FOR SURVEYS USING ADMINISTRATIVE DATA AS THE SAMPLING FRAME
DISEASE - SPECIFIC STUDIES

RESPIRATORY-RELATED DISORDERS - Clinical Outcomes Studies

PRS1 H12 THE RISK OF SEIZURES WITH VARENCLINE USE AMONG PATIENTS WHO HAVE ATTEMPTED TO QUIT SMOKING USING PHARMACOTHERAPY OR NICOTINE REPLACEMENT THERAPY
Chopra DA, Shah AB, Painter JT, University of Arkansas for Medical Sciences, Little Rock, AR, USA

PRS2 H13 MYOCARDITIS AS A FEATURE OF CHURG-STRAUSS SYNDROME COULD BE MANIFESTED WITH EXPOSURE TO LEUKOTRIENE RECEPTOR ANTAGONISTS
Ali AK, Eli Lilly and Company, Indianapolis, IN, USA

PRS3 H14 RADIOGRAPHIC CONTRAST MEDIA-INDUCED ADVERSE REACTIONS WITH COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING IN SOUTH INDIAN TEACHING HOSPITAL: PROSPECTIVE STUDY
Rajesh R1, Anjali T1, Chandrakant S2, Manipal College of Pharmaceutical Sciences, Manipal University, MANIPAL, India, 2Kasturba Medical College, Manipal, Manipal, MANIPAL, India

PRS4 H15 RISK OF CARDIOVASCULAR DISEASES FROM ADD-ON OF INHALED TIOTROPIUM TO COMBINED THERAPY OF INHALED CORTICOSTEROIDS AND LONG-ACTING BETA-AGONISTS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS
Wang M1, Tsai C2, Wu B3, Lin CW1, Wang Y1, National Defense Medical Center, Taipei, Taiwan, 2Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

PRS5 H16 A PROSPECTIVE OBSERVATIONAL PHARMAVIGILANCE STUDY TO EVALUATE INCIDENCE, ONSET, AND SEVERITY OF ADVERSE EFFECTS DURING ANTI-TUBERCULAR THERAPY
Agrawal A1, MUHS, NASHIK, KALYAN, MUMBAI, India

PRS6 H17 ANALYSIS OF COPD COMORBIDITIES AND THEIR IMPACT ON HOSPITAL 30-DAY READMISSION RATES USING ELECTRONIC HEALTH RECORD DATA
Zhang X, Hayashida DK, Peyeri FW, Boston Strategic Partners, Inc., Boston, MA, USA

PRS7 H18 EXAMINING CORTICOSTEROID-INDUCED TYPE 2 DIABETES IN THE COPD MEDICARE POPULATION
Ruban C1, Noone JM2, Marino J1, Shcherbakova N1, Saunders W1, Blanchette CM1, 1University of North Carolina Charlotte, Charlotte, NC, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA, 3Western New England University, Springfield, MA, USA, 4UNC Charlotte College of Health and Human Services - Health Informatics, Chapel Hill, NC, USA

PRS8 H19 EXPLORING THE ASSOCIATION BETWEEN STATINS AND COPD: AN ANALYSIS OF THE 2009-2010 NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
Ghosh S1, Kamal KM1, Covvey JR1, Candrilli SD2, Giannetti V1, 1Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA

PRS9 H20 MORTALITY AND REHOSPITALIZATION RATES AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE US MEDICARE POPULATION
Pandya S1, Du H1, Wang L1, Yuce H2, Baser O1, STATinMED Research, Plano, TX, USA, 1New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, 2Columbia University and STATinMED Research, New York, NY, USA

PRS10 I1 COMPARISON OF SUICIDE ATTEMPTS/BEHAVIORS FOLLOWING SMOKING CESSATION TREATMENTS AMONG SCHIZOPHRENIC SMOKERS
Wang X1, Wu F2, Chen H1, Bordnick P2, Johnson ML1, Essien EJ1, Peters R3, Abughosh S1, 1University of Houston, Houston, TX, USA, 2University of Texas Health Science Center at Houston, Houston, TX, USA

PRS11 I2 IMI GET REAL: STAKEHOLDER VIEWS ON THE EARLY USE OF PRAGMATIC TRIALS DURING MEDICINE DEVELOPMENT TO SUPPORT ASSESSMENT OF NEW INTERVENTIONS
Jonsson P1, Czachorowski M1, Chambers M1, Tomlinson R1, Birch H1, Thwaites R1, Garner S1, 1National Institute for Health and Care Excellence (NICE), Manchester, UK, 2GSK, Brentford, UK, 3GSK, King of Prussia, PA, USA, 4GSK, Brentford, Middlesex, UK, 5Takeda, London, UK, 6National Institute for Health and Care Excellence (NICE), London, UK

PRS12 I3 COMPARISON OF FIRST- AND SECOND-SEASON PALIVIZUMAB PROPHYLAXIS IN PATIENTS WITH CONGENITAL AIRWAY ANOMALIES (CAA) IN THE CARESS DATABASE (2005-2015)
Wang D1, Li A1, Paes BS2, Mitchell I2, Lancelot K2, 1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3University of Calgary, Calgary, AB, Canada

PRS13 I4 BURDEN OF DISEASE AND HEALTH CARE COSTS OF ADULT PATIENTS WITH SEVERE REFRACTORY ASTHMA IN A BIG REAL-WORLD DATA BASE (ARCO)
Pedrini A1, Rossi E2, Calabria S1, Dondi L1, Esposito I2, Martini N1, 1CORE srl - Collaborative Outcome Research, Bologna, Italy, 2CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 3Accademia Nazionale di Medicina, Roma, Italy
### RESPIRATORY-RELATED DISORDERS - Cost Studies

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRS14</td>
<td>PREVALENCE OF THE TYPES OF DRUG RESISTANCE TB IN PATIENTS ATTENDING FATIMA JINNAH TB SANATORIUM IN QUETTA: A RETROSPECTIVE STUDY</td>
<td>ul Haq N¹, Nasim A², Razaque G¹, Ahmed N¹, Mohammad S¹, Riaz S¹, Zeeshan M²¹, University of Balochistan, Quetta, Pakistan, ²University of The Punjab, Lahore, Pakistan</td>
<td></td>
</tr>
<tr>
<td>PRS15</td>
<td>RECURRENT EPISODES OF PNEUMONIA IN ELDERLY PEOPLE FROM PRIVATE BRAZILIAN PERSPECTIVE</td>
<td>Squiassi HB, Ferreira CN, Santana CF, Pfizer, São Paulo, Brazil</td>
<td></td>
</tr>
<tr>
<td>PRS16</td>
<td>PREDICTORS OF ELECTRONIC CIGARETTE USE AMONG INDIVIDUALS WITH ASTHMA</td>
<td>Geneus CJ, Davis RE, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA</td>
<td></td>
</tr>
<tr>
<td>PRS17</td>
<td>EVALUATION OF ASTHMA TREATMENT CURRENTLY GIVEN IN PUBLIC SECTOR HOSPITAL OF BAHAWALPUR, PAKISTAN</td>
<td>Hassan A¹, Ahmad M²¹, Masood I², Rauf A¹, Bahawal Victoria Hospital, Bahawalpur, Pakistan, ²The Islamia University of Bahawalpur, Bahawalpur, Pakistan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRS18</td>
<td>BUDGET IMPACT OF PNEUMONIAS, MENINGITIS AND SEPSIS DISEASE: BRAZILIAN PRIVATE HEALTH CARE DATABASE ANALYSIS</td>
<td>Santana CF, Ferreira CN, Squiassi HB, Pfizer, São Paulo, Brazil</td>
<td></td>
</tr>
<tr>
<td>PRS19</td>
<td>ECONOMIC IMPACT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN COLOMBIA</td>
<td>Tamayo C, Simbaqueba E, Palomino RA, Health-e International, Bogota, Colombia</td>
<td></td>
</tr>
<tr>
<td>PRS20</td>
<td>BUDGET IMPACT ANALYSIS OF BUESONIDE IN THE TREATMENT OF ASTHMA IN ADULT POPULATION IN RUSSIAN FEDERATION</td>
<td>Kulikov A, Makarova E.I.M, Sechenov First Moscow State Medical University, Moscow, Russia</td>
<td></td>
</tr>
<tr>
<td>PRS21</td>
<td>EVALUATING INTERVENTIONS UNDER THE BUNDED PAYMENTS FOR CARE INITIATIVE (BCPI): A CASE STUDY FOR THE COPD MARKET</td>
<td>Nygren K¹, Suponicic S², Navigant Consulting, Lawrenceville, NJ, USA, ²Navigant Life Sciences, Lawrenceville, NJ, USA</td>
<td></td>
</tr>
<tr>
<td>PRS22</td>
<td>THE COSTS OF CESSATION MEDICATIONS AMONG PRIVATE HEALTH PLANS: AN ENVIRONMENTAL SCAN BEFORE THE ENACTMENT OF THE AFFORDABLE CARE ACT</td>
<td>Xu X¹, Asman K², Babd SD¹, Malarcher AM¹, Naavaal S¹, Schauer G¹, King BA¹, ¹Centers for Disease Control and Prevention, Atlanta, GA, USA, ²RTI International, Atlanta, GA, USA</td>
<td></td>
</tr>
<tr>
<td>PRS23</td>
<td>ECONOMIC BURDEN OF AIR LEAK COMPLICATIONS IN THORACIC SURGERY: ESTIMATES FROM A NATIONAL HOSPITAL BILLING DATASET</td>
<td>Yoo A¹, Ghosh SK², Danker W³, Kassis E¹, Kalsekar I¹, ¹Epidemiology &amp; Health Informatics, Medical Devices, Johnson &amp; Johnson Co., New Brunswick, NJ, USA, ²Global Health Economics and Market Access, Ethicon, Inc., Cincinnati, OH, USA, ³Global Health Economics and Market Access, Ethicon, Inc., Somerville, NJ, USA, ⁴Medical Affairs, Ethicon, Inc., Cincinnati, OH, USA</td>
<td></td>
</tr>
<tr>
<td>PRS24</td>
<td>COST OF PNEUMONIA IN OLDER PEOPLE LIVING IN NURSING HOME</td>
<td>Costa N¹, Hoogendijk E², Demougeot L², Rolland Y², Bourrel R², Duboqué M², Vellas B², Molinier L², Cesari M², ¹INSERM, Toulouse, France, ²University of Toulouse, Toulouse, France, ³Regional Health Insurance, Toulouse, France</td>
<td></td>
</tr>
<tr>
<td>PRS25</td>
<td>ESTIMATING ECONOMIC LOSS FROM LUNG CANCER</td>
<td>Undram L¹, Uganbayar G², ¹Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia, ²Private hospital, Ulaanbaatar, Mongolia</td>
<td></td>
</tr>
<tr>
<td>PRS26</td>
<td>BURDEN OF COPD IN CHINA: A SYSTEMATIC LITERATURE REVIEW</td>
<td>Zhang L¹, Zhu B, Ming J, Wang Y, Fudan University, Shanghai, China</td>
<td></td>
</tr>
<tr>
<td>PRS27</td>
<td>ASSESSING THE ECONOMIC BURDEN AND HEALTH CARE RESOURCE UTILIZATION OF US VETERANS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE</td>
<td>Ogbonmo A¹, Tan H¹, Kariburyo MF¹, Xie L¹, Baser O², STATinMED Research, Ann Arbor, MI, USA, ²Columbia University and STATinMED Research, New York, NY, USA</td>
<td></td>
</tr>
<tr>
<td>PRS28</td>
<td>EVALUATING ASTHMA-RELATED EXPENSES AND HEALTH CARE RESOURCE UTILIZATION AMONG CHILDREN IN THE UNITED STATES MEDICAID POPULATION</td>
<td>Zhang Q¹, Zhao Y¹, Keshishian A¹, Xie L¹, Yuce H², Baser O³, STATinMED Research, Ann Arbor, MI, USA, ¹New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, ²Columbia University and STATinMED Research, New York, NY, USA</td>
<td></td>
</tr>
<tr>
<td>PRS29</td>
<td>ASSESSING HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG US VETERANS DIAGNOSED WITH ASTHMA</td>
<td>Ogbonmo A¹, Tan H¹, Kariburyo MF¹, Xie L¹, Baser O², STATinMED Research, Ann Arbor, MI, USA, ²Columbia University and STATinMED Research, New York, NY, USA</td>
<td></td>
</tr>
<tr>
<td>PRS30</td>
<td>ESTIMATION OF DIRECT AND INDIRECT COSTS ASSOCIATED WITH ASTHMA AND COPD: A CANADIAN EMPLOYERS PERSPECTIVE</td>
<td>Ng C¹, Risebrough NA¹, Jayasundara KS², Freeman MA², ICON plc (formerly Oxford Outcomes), Vancouver, BC, USA</td>
<td></td>
</tr>
</tbody>
</table>
Canada, 2GlaxoSmithKline Inc, Mississauga, ON, Canada

**PRS31 J6**  THE BURDEN OF CYSTIC FIBROSIS: PULMONARY EXACERBATIONS AND HEALTH CARE RESOURCE UTILIZATION IN A COMMERCIAL INSURED POPULATION IN THE UNITED STATES

Hassan M1, Bonafe de MM2, Limone B2, Hodgkins P1, Sawicki G1, Vertex Pharmaceuticals Incorporated, Boston, MA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Truven Health Analytics, New York, NY, USA, 4Harvard Medical School, Boston, MA, USA

**PRS32 J7**  OUTCOMES RESEARCH AND PHARMACOECONOMIC STUDY ON TB

Khan MF, University Of Balochistan, Quetta, Pakistan

**PRS33 J8**  COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM BROMIDE FOR PATIENTS WITH SEVERE OBSTRUCTIVE PULMONARY DISEASE IN MEXICO

Herran S3, Baez-Revueltas FB4, Peniche Otero G5, Herrera Rojas J6, Baeza G7, Boehringer Ingelheim, Distrito Federal, Mexico, 8Information Technology Squad, SA de CV, Distrito Federal, Mexico

**PRS34 J9**  INVESTIGATING THE VALUE OF OMALIZUMAB IN THE TREATMENT OF SEVERE PERSISTENT ALLERGIC ASTHMA: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES

Likhar N, Kanukula R, Mothe RK, Vsn M, Dang A, MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, India

**PRS35 J10**  COST-EFFECTIVENESS ANALYSIS OF FORMOTEROL FOR ASTHMA TREATMENT IN RUSSIAN FEDERATION

Kulikov A, Makarova E, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**PRS36 J11**  COST EFFECTIVENESS OF MEPOLIZUMAB IN ADULT ASTHMA PATIENTS

Whittington MD1, McQueen RB2, Chapman RH3, Tice JA4, Ollendorf D5, Campbell JD6, 1University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 2Research in Real Life (RiRL), Cambridge, UK, 3Institute for Clinical and Economic Review, Boston, MA, USA, 4UCSF School of Medicine, San Francisco, CA, USA, 5University of Colorado Anschutz Medical Campus, Denver, CO, USA

**PRS37 J12**  RESOURCE UTILIZATION ASSOCIATED WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS PATIENTS WHO ARE BEING TREATED FOR EXACERBATIONS

Germino R, Liao L, Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA

**PRS38 J13**  SIX-MONTH COST ASSESSMENT AFTER COPD-RELATED HOSPITAL OR EMERGENCY DEPARTMENT VISITS

Xiang P1, Tran M1, Rascati KL2, Stock EM3, Godley P4, Coleman A5, Bogart M6, Stanford R7, Scott & White Health Plan, Temple, TX, USA, 2University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 3Center for Applied Health Research Central Texas Veterans Health Care System jointly with Baylor Scott & White Health, Temple, TX, USA, 4GlaxoSmithKline Research Triangle Park, NC, USA

**RESPIRATORY-RELATED DISORDERS - Patient-Reported Outcomes & Patient Preference Studies**

**PRS39 J14**  WEAKNESSES OF TREATMENT GUIDELINES FOR THE MANAGEMENT OF ANAPHYLAXIS AND HEALTH CARE UTILIZATION FOLLOWING AN ANAPHYLAXIS EVENT

Brown D1, Locklear JC2, Karjalainen M3, Saathoff F4, Lehning U5, Xcenda, LLC, Palm Harbor, FL, USA, 6EMD Serono, Inc., Rockland, MA, USA, 7Allergopharma GmbH & Co. KG, Reinbek, Germany

**PRS40 J15**  PULMONARY EXACERBATIONS, LUNG DYSFUNCTION, AND EQ-5D MEASURES IN ADOLESCENTS AND ADULTS WITH CYSTIC FIBROSIS AND HOMOZYGOTIC F508DEL-CFTR MUTATION

Solem CT1, Vera-Llonch M2, Tal M3, O’Callaghan L4, Phamarit International, Bethesda, MD, USA, 2Vertex Pharmaceuticals Incorporated, Boston, MA, USA

**PRS41 J16**  AN APPROACH TO EVALUATING THE USEFULNESS OF SUPPLEMENTING THE EQ5D DESCRIPTIVE SYSTEM IN OBSTRUCTIVE PULMONARY DISEASE

Law EH, Joo MJ, Vinicky M, Pickard AS, University of Illinois at Chicago, Chicago, IL, USA

**PRS42 K1**  THE ASSOCIATION BETWEEN MATERNAL SMOKING DURING PREGNANCY AND CHILD QUALITY-ADJUSTED LIFE YEARS

Hartman JD1, Craig BM2, Blackburn C3, Simmons V4, 1Moffitt Cancer Center, Tampa, FL, USA, 2University of South Florida, Tampa, FL, USA

**PRS43 K2**  EXPLORING THE QUALITATIVE EXPERIENCE OF CHEST CONGESTION WITH CHILDREN AND ADULTS TO DEVELOP PATIENT-REPORTED OUTCOME ITEMS TO SELF-ASSESS SYMPTOMS OF THE COMMON COLD

Grant L1, Marshall C2, Burrows K3, Khannmo N4, Albrecht H5, Arbuckle R6, Shea T7, Adelphi Values Ltd, Bollington, UK, 8RB, Hull, UK, 9Florida International University, Miami, FL, USA, 10RB, Parsippany, NJ, USA

**PRS44 K3**  RESCUE MEDICATION USE IN COPD: PAYER AND REGULATORY PERSPECTIVE

Sharma S1, Kalra M2, Thakur C3, Punekar YS4, Parexel Consulting, Chandigarh, India, 5GlaxoSmithKline, Uxbridge, UK

**PRS45 K4**  DEVELOPMENT OF A REPORT CARD FOR IDENTIFYING LOCAL SUBLINGUAL IMMUNOTHERAPY EVENTS IN CLINICAL TRIALS

Norquist JM1, Tanzosh T2, Flood E3, Li H4, Iskold B5, Ganser TR6, Marson-Smith HR7, Merck & Co, Whitehouse Station, NJ,
**RESPIRATORY-RELATED DISORDERS - Health Care Use & Policy Studies**

**PRS46 K5**

**THE ASSOCIATION BETWEEN SMOKING STATUS AND QUALITY OF LIFE: FACTORING IN LIFESTYLE VARIABLES**

Brown B, Ndugubu SO, Rascati K, Ford K, The University of Texas at Austin, Austin, TX, USA

**PRS47 K6**

**SYSTEMATIC REVIEW OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION**

Gu S¹, Hu H², Dong H¹, Zhejiang University, Hangzhou, China, Zhejiang Medical College, Hangzhou, China, Zhejiang University, Hangzhou, China

**RESPIRATORY-RELATED DISORDERS - Health Care Use & Policy Studies**

**PRS48 K7**

**PREDICTORS OF LOW PATIENT ACTIVATION WHEN INITIATING C1 ESTERASE INHIBITOR THERAPY FOR HEREDITARY ANGIODEMA**

Cross N¹, Hanna D², Eaddy M³, Nunna S¹, Rane P¹, Lash Group, Frisco, TX, USA, Xcenda, LLC, Palm Harbor, FL, USA, University of Mississippi, University, MS, USA, University of Houston, Houston, TX, USA

**PRS49 K8**

**PATIENT COMFORTABILITY IN ADMINISTERING C1 ESTERASE INHIBITOR THERAPY FOR HEREDITARY ANGIODEMA: AN EVALUATION OF PATIENT ACTIVATION AND ADHERENCE**

Cross N¹, Hanna D², Eaddy M³, Rane P¹, Lash Group, Frisco, TX, USA, Xcenda, LLC, Palm Harbor, FL, USA, University of Houston, Houston, TX, USA

**PRS50 K9**

**THE COVERAGE OF CESSION MEDICATIONS AMONG EMPLOYER-SPONSORED INSURANCE: AN ENVIRONMENTAL SCAN BEFORE THE ENACTMENT OF THE AFFORDABLE CARE ACT**

Xu X¹, Asman K², Malarcher AM¹, Naavaal S¹, Jamal A¹, Neff L¹, Babb SD¹, Centers for Disease Control and Prevention, Atlanta, GA, USA, RTI International, Atlanta, GA, USA

**PRS51 K10**

**BURDEN OF ILLNESS ASSOCIATED WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Singh M¹, Baculea S¹, Quigley JM¹, Bergstrom G², Holmgren U³, ICON Clinical Research UK Ltd, Abingdon, UK, AstraZeneca, Mölndal, Sweden

**PRS52 K11**

**B.E.S.T. ASTHMA PROGRAM (BREATHE EASY. START TODAY.®): A PRIMARY CARE-BASED PROGRAM FOR DISPENSING ASTHMA MEDICATION AND DEVICES REDUCES ACUTE HOSPITALIZATION AND EXPENDITURES IN MEDICAID SUBJECTS**


**PRS53 K12**

**ASSOCIATION BETWEEN ACCESS-TO-CARE FACTORS AND HEALTH CARE RESOURCE UTILIZATION AMONG ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Kim M¹, Ren J¹, Tillis W², Asche CV¹, Kim IK², Kirkness CS¹, University of Illinois College of Medicine at Peoria, Peoria, IL, USA, OSF Saint Francis Medical Center, Peoria, IL, USA, Battelle Memorial Institute, Atlanta, GA, USA

**PRS54 K13**

**EMBRACING PATIENT HETEROGENEITY USING AGENT-BASED MODELING AND PREEMPTIVE CARE PATHWAYS ALLOWS FOR IMPROVED CARE IN THE TREATMENT OF BRONCHIOLITIS OBLITERANS SYNDROME**

Zia A¹, Weimersheimer P², Mesa OA³, Peters C⁴, Jones CO¹, University of Vermont, Burlington, VT, USA, University of Vermont College of Medicine, Burlington, VT, USA, Therakos, Inc., Wokingham, Berkshire, UK, Therakos, Inc., Mallinckrodt Company, West Chester, PA, USA, University of Vermont - College of Medicine, Burlington, VT, USA

**PRS55 K14**

**RELATIONSHIP BETWEEN SEVERITY AND ACUTE INHALER USE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Hur P¹, Albrecht j², Huang T³, Simoni-Wastila L², Moyo P³, Khokhar B³, Harris I², Wei Y², University of Maryland School of Pharmacy, Baltimore, MD, USA, University of Maryland, School of Medicine, Baltimore, MD, USA, University of Maryland, School of Pharmacy, Baltimore, MD, USA, Impaq International, Columbia, MD, USA, University of Florida College of Pharmacy, Gainesville, FL, USA

**PRS56 K15**

**COMPARATIVE EFFECTIVENESS OF SMOKING CESSATION MEDICATIONS AMONG SCHIZOPHRENIC SMOKERS**

Wu J¹, Chen H², Bordnick P¹, Essien EJ¹, Johnson ML¹, Peters RJ¹, Wang X², Abughosh S³, University of Houston, Houston, TX, USA, University of Texas Health Science Center at Houston, Houston, TX, USA

**PRS57 K16**

**TRENDS IN ORAL GLUCOCORTICOID UTILIZATION AMONG OLDER ADULTS WITH RESPIRATORY DISEASE**

Amiche MA¹, Lévesque L², Gomes T³, Adachi JD², Cadarette SM¹, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, McMaster University, Hamilton, ON, Canada

**PRS58 K17**

**ANTIBIOTICS USE PATTERN AND APPROPRIATENESS AMONG CHILDREN IN THE TREATMENT OF COUGH/COLD AND DIARRHEA**

Ahmad A¹, Khan MU¹, Mohanta GP², Parimalakrishnan S², Patel R³, UCSI University, Kuala Lumpur, Malaysia, Annamalai University, Chidambaram, India, Shenandoah University, Winchester, VA, USA

**PRS59 K18**

**PATIENT-CENTERED OUTCOMES ASSOCIATED WITH INITIAL MAINTENANCE THERAPY USE BEHAVIOR AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS WITH EMPLOYER SPONSORED INSURANCE**

Patel J¹, Dalal A², Stanford R³, Aparasu R¹, Abughosh S¹, Johnson ML¹, University of Houston, Houston, TX, USA, Novartis, US Health Economics and Outcomes Research, East anover, NJ, USA, GlaxoSmithKline, Research Triangle Park, NC, USA
PRS60 K19 ASSSESSMENT OF MEDICARE ADVANTAGE PRESCRIPTION DRUG COVERAGE GAP AMONG COPD PATIENTS: ANALYSIS OF HOSPITALIZATION USE
Bhansali A1, Sansgiry SS2, Serna O3, Fleming ML4, Abughosh S5, Kamdar M6, Stanford R7, University of Houston College of Pharmacy, Houston, TX, USA, 1University of Texas of Houston, Houston, TX, USA, 2Cigna HealthSpring, Houston, TX, USA, 3University of Houston, Houston, TX, USA, 4Glaxo Smith Kline, Research Triangle Park, NC, USA, 5GlaxoSmithKline, Research Triangle Park, NC, USA

PRS61 K20 BURDEN OF RESPIRATORY ILLNESS IN A MULTICENTRIC HOSPITAL REGISTRY: THE ARGENTINE-HEALTH CARE COST AND UTILIZATION STUDY
Insuá J, Hospital Universitario Austral, Argentina, Argentina

PRS62 L1 ANALYSIS OF RELATIONSHIP BETWEEN TEMPERATURE DIFFERENCES AND ASThma USING CLAIMS DATABASE
Matsuyama S, Milliman, Tokyo, Japan

PRS63 L2 THE CHANGING EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: IMPLICATIONS FOR THE WORKPLACE
Nguyen T, University of Minnesota, Minneapolis, MN, USA

PRS64 L3 COPD PHARMACOTHERAPY IN BULGARIA AND ITS ADHERENCE TO GOLD GUIDELINES
Petrova G1, Dimitrova M2, Voycheva H3, Georgiev O4, Petrova D5, Medical University - Sofia, Sofia, Bulgaria, 1Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria

PRS65 L4 SOCIOECONOMIC INEQUALITIES IN ACUTE RESPIRATORY INFECTION MORTALITY AMONG CHILDREN IN COLOMBIA
Alvis-Zakzuk N1, Diaz D2, Castillo-Rodríguez L3, Carrasquilla-Sotomayor M4, Castañeda-Orjuela CA5, De la Hoz Restrepo F6, Alvis Guzman N7, Instituto Nacional de Salud, Bogotá, Colombia, 1Instituto Nacional de Salud, Bogotá, Colombia, 7INSTITUTO NACIONAL DE SALUD, Bogotá, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Colombian National University, Bogota, Colombia, 4University of Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoléon Franco Pareja, Cartagena de Indias, Colombia

PRS66 L5 DETERMINANTS AND DISTRIBUTION OF 18-24 YEAR OLD CURRENT WATERPIPE TOBACCO SMOKERS IN THE UNITED STATES: FINDINGS FROM THE NATIONAL ADULT TOBACCO SURVEYS
Kates FR1, Haider MR2, University of Florida, Gainesville, SC, USA, 1University of South Carolina, Columbia, SC, USA

PRS67 L6 IMI GET REAL WORK PACKAGE 1 CASE STUDY: CHALLENGES IN MEASURING CLINICAL EFFECTIVENESS IN COPD AND POTENTIAL USE OF REAL-WORLD EVIDENCE TO REDUCE UNCERTAINTY
Jaksa A1, Adler B2, Rubinstein J3, Birch H4, Tomlinson R5, Chambers M6, Peress E7, Czachorowski M8, Garner S9, Jonsson P10, Chinn C11, Context Matters, New York, NY, USA, 1GSK, Brentford, Middlesex, UK, 2GSK, King of Prussia, PA, USA, 3GSK, Brentford, UK, 4Novartis, Basel, Switzerland, 5National Institute for Health and Care Excellence (NICE), Manchester, UK, 6National Institute for Health and Care Excellence (NICE), London, UK, 7Sanofi, Guildford, UK

PRS68 L7 HEDIS QUALITY MEASURE PERFORMANCE AND OTHER FACTORS PREDICTIVE OF HEALTH CARE COSTS FOLLOWING COPD-RELATED ADMISSION
Tran M1, Xiang P2, Rascati KL3, Stock EM4, Godley P5, Coleman A6, Bogart M7, Stanford R8, Scott & White Health Plan, Temple, TX, USA, 1The University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 2Center for Applied Health Research - Central Texas Veterans Health Care System jointly with Baylor Scott & White Health, Temple, TX, USA, 3GlaxoSmithKline, Research Triangle Park, NC, USA

SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies

PSS1 L8 ASSESSING SEVERITY IN PSORIASIS: CORRELATION OF DIFFERENT MEASURES (PASI, BSA, AND IGA) IN A CANADIAN REAL-WORLD SETTING
Lane S1, Lozano-Ortega G2, Wilson J3, Chamboenot O4, Barbeau M5, Gagné-Henley A6, Barankin B7, Gregory V8, 1ICON PLC, Vancouver, BC, Canada, 2ICON, Vancouver, BC, Canada, 3Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 4Innovaderm Network, Montreal, QC, Canada, 5Toronto Dermatology Centre, Toronto, BC, Canada

PSS2 L9 THE COMPARATIVE EFFECTIVENESS OF ADDING CLOSTRIDIAL COLLAGENASE OINTMENT TO STANDARD OF CARE IN INDIVIDUALS WITH STAGE IV PRESSURE ULCERS
Carter M1, Gilligan A2, Waycaster CR3, Fife CE4, 1Strategic Solutions Inc., Cody, WY, USA, 2Truvan Health Analytics, Ann Arbor, MI, USA, 3Smith & Nephew Inc., Fort Worth, TX, USA, 4Intelliure, The Woodlands, TX, USA

PSS3 L10 A MATCHING ADJUSTED INDIRECT COMPARISON OF SONIDEGIB AND VISMODEGIB IN ADVANCED BASAL CELL CARCINOMA
Odom D1, Mladsi DM2, Purser M3, Kaye JA4, Palaka E5, Charter A6, Jensen JA7, Sellami D8, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Global Service Center, Dublin, Ireland, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals UK Ltd., Surrey, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PSS4 L11 FIRST TREATMENT SUCCESS WITH INJECTABLE CEFOVECIN SODIUM IN DOGS FOR SUPERFICIAL PYODERMA, WOUNDS, AND ABSCESSES IN DIFFERENT DOG POPULATIONS
Wright AK, Fadok V, Amodie D, Zoetis, Greely, CO, USA

PSS5 L12 SYSTEMATIC REVIEW AND META-ANALYSIS OF BRIAKINUMAB, A FULLY HUMAN INTERLEUKIN 12/23 MONOCLONAL ANTIBODY, FOR THE TREATMENT OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
THE PREVALENCE AND INCIDENCE OF HIDRADENITIS SUPPURATIVA IN CANADA: RESULTS FROM A POPULATION-BASED SURVEY

Lachaine J1, Miron A2, Shear N2, Alhusayen R3,4, University of Montreal, Montreal, QC, Canada, 4University of Toronto, Toronto, ON, Canada, 5Sunnybrook Health Sciences Centre, Toronto, ON, Canada

BURDEN OF WET AGE-RELATED MACULAR DEGENERATION IN SINGAPORE IN THE YEAR 2030

Saxena N1, George PP1, Heng BH1, Yong SO2, Lim TH2, National Healthcare Group, Singapore, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore

SENSORY SYSTEMS DISORDERS - Cost Studies

COST AND BUDGET IMPACT OF TOPICAL TREATMENTS FOR THE INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSacea IN THE MANAGED CARE SETTING

Williamson T1, Khalaf K2, Carlton R2, Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 3Xcenda, LLC, Palm Harbor, FL, USA

DIRECT MEDICAL COSTS FOLLOWING PEDIATRIC TYMpanostOMY TUBE PLACEMENT IN THE UNITED STATES

Candrilli SD1, Tam IM2, Moss JR3,4, RTI Health Solutions, Research Triangle Park, NC, USA, 5Otonomy, Inc., San Diego, CA, USA, 6Charlotte Eye, Ear, Nose, and Throat Associates, Matthews, NC, USA

EXAMINE THE BURDEN OF ILLNESS OF US MEDICARE PATIENTS DIAGNOSED WITH CATARACT

Tan H1, Xie L1, Wang Y1, Yuce H2, Baser O3,1, STATinMED Research, Ann Arbor, MI, USA, 4New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, 5Columbia University and STATinMED Research, New York, NY, USA

COST EFFECTIVENESS OF NIVOLUMAB-IPILIMUMAB COMBINATION THERAPY COMPARED TO MONOTHERAPY FOR METASTATIC MELANOMA FROM A US SOCIETAL PERSPECTIVE

Tran DM, McDowell LC, Oh A, Barcelon JA, Keyvani D, Merino O, Wilson L, University of California, San Francisco, San Francisco, CA, USA

COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB AND ADALIMUMAB IN PSORIATIC PATIENTS PREVIOUSLY TREATED WITH ETANERCEPT IN A REAL-WORLD SETTING


COST EFFECTIVENESS OF DOSE OPTIMIZED USTEKINUMAB VERSUS SWITCHING TO ANTI-TNFs FOLLOWING PARTIAL RESPONSE TO USTEKINUMAB EVERY TWELVE WEEKS IN PATIENTS WITH MODERATE TO SEVERE PLaque PSORIASIS

Poulin Y1, Lathia U2, Griffin EA3, Perampaladas K4, Université Laval and Centre de Recherche Dermatologique du Québec métropolitain, Quebec City, UK, 5Janssen Inc., Toronto, ON, Canada, 6Health Thinking Analytics Ltd, Devon, UK

THE EFFECTIVENESS AND COST EFFECTIVENESS OF PIT AND FISSURE SEALANT FOR PREVENTION OF DENTAL CARES IN SCHOOL-AGE CHILDREN IN CHINA

Yang L, Li X, Peking University, Beijing, China

COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COlombiA

Ojeda C1, Hernandez N2, Giraldo CV3, Argote AC4, Coronell S5, Roa M1, Hospital La Samaritana, Bogota, Colombia, 2Private Practice, Bogota, Colombia, 3Universidad El Bosque, Bogota, Colombia, 4Hospital San José Bogota, Bogota, Colombia, 5Cafesalud/Colmedica, Bogota, Colombia, 6Janssen Cilag, Bogota, Colombia

ASSURE-CSU: ASSESSING THE IMPACT OF CHRONIC SPONTANEOUS / IDIOPATHIC URTICARIA ON WORK PRODUCTIVITY AND ACTIVITY

McBride D1, Balp M2, Abuzakouk M3, Berard F4, Canonica GW5, Gimenez-Arnau A6, Grattan C7, Knustl AC8, Hollis K9, Khalil S10, Lacour J11, Lynde C12, Marsland AJ13, Nakonechna A14, Ortiz de Frutos FJ15, Oude Elberink J15, Proctor C16, Sussman G17, Weller K18, Maurer M18, RTI Health Solutions, Manchester, UK, 9Novartis Pharma AG, Basel, Switzerland, 10Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 11Claude Bernard University Lyon, Lyon, France, 12University of Genoa, Genoa, Italy, 13Hospital del Mar, Parc de Salut Mar, Barcelona, Spain, 14Nordfolk and Norwich University Hospital, Norwich, UK, 15University Medical Center Utrecht, Utrecht, The Netherlands, 16RTI Health Solutions, Research Triangle Park, NC, USA, 17Université Nice Sophia Antipolis, Nice Cedex 2, France, 18Lyderm Research Inc., Toronto, ON, Canada, 12Salford Royal Hospital, Salford, UK, 13Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK, 14Hospital 12 Octubre, Madrid, Spain, 15University of Groningen, Groningen, The Netherlands, 16St Michael's Hospital, University of Toronto, Toronto, ON, Canada, 17Charite - Universitätsmedizin Berlin, Berlin, Germany

RESURce UTILIZATION AND QUALITY OF LIFE OF PATIENTS WITH Hidradenitis Suppurativa in Canada: RESULTS FROM A POPULATION-BASED SURVEY

Lachaine J1, Miron A2, Shear N2, Alhusayen R3, University of Montreal, Montreal, QC, Canada, 4University of Toronto, Toronto, ON, Canada, 5Sunnybrook Health Sciences Centre, Toronto, ON, Canada

BIOLOGICS SWITCHING PATTERNS AND ASSOCIATED COSTS IN PSORIASIS PATIENTS IN A LARGE COMMERCIALLY
INSURED POPULATION IN THE UNITED STATES
Tian H, Gilloteau I, Mollon P, McDwyer P, Lotya J, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Novartis Pharma AG, Basel, Switzerland, Novartis Pharmaceuticals AG, Basel, Switzerland, Novartis Ireland Ltd, Elm Park, Ireland

SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PSS20 M6 COMPARISON OF LATANOPROST, TRAVOPROST, AND BIMATOPROST ON ADHERENCE, PERSISTENCE, AND PATTERN OF INITIAL THERAPY IN GLAUCOMA AND OCULAR HYPERTENSION: AN ADMINISTRATIVE CLAIMS DATABASE ANALYSIS
Heo JH, Rascati KL, The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

PSS21 M7 REAL-WORLD COST PER PERSISTING PATIENT: COMPARING PSORIASIS PATIENTS INITIATED ON APREMILAST OR BIOLOGIC THERAPIES
Feldman SR, Kuznik A, Clancy Z, Wake Forest University School of Medicine, Winston-Salem, NC, USA, Celgene Corp & Regeneron Pharmaceuticals, Warren, NJ, USA, Celgene Corporation, Warren, NJ, USA

PSS22 M8 COMPARISON OF PERSISTENCE BETWEEN ADULTS WITH PSORIASIS INITIATING APREMILAST OR BIOLOGICS
Feldman SR, Kuznik A, Clancy Z, Wake Forest University School of Medicine, Winston-Salem, NC, USA, Celgene Corp & Regeneron Pharmaceuticals, Warren, NJ, USA, Celgene Corporation, Warren, NJ, USA

PSS23 M9 TREATMENT PATTERNS AND MEDICATION ADHERENCE OF GLAUCOMA PATIENTS IN SOUTH KOREA
Park KH, Kim CY, Cha J, Kim Y, Seoul National University Hospital, Seoul, South Korea, Yonsei University College of Medicine, Seoul, South Korea, Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea

PSS24 M10 HEALTH UTILITIES ASSOCIATED WITH BEST CORRECTED VISUAL ACUITY LEVELS IN DIABETIC MACULAR EDEMA PATIENTS AND FACTORS INFLUENCING UTILITY VALUES
Park S, Choi i, Lee S, Suh D, Chung-Ang University, Seoul, South Korea

PSS25 M11 PREVALENCE OF METAMORPHOSIA IN PATIENTS WITH VITREOMACULAR TRACTION, WITH OR WITHOUT MACULAR HOLE, AND ITS IMPACT ON QUALITY OF LIFE: THE MEMO STUDY

PSS26 M12 INCREMENTAL BURDEN OF CARDIOVASCULAR COMORBIDITY OR PSORIATIC ARTHRITIS AMONG INDIVIDUALS WITH MODERATE-TO-SEVERE PSORIASIS
Augustin M, Tian H, Gilloteau I, Mollon P, Vietri J, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Novartis Pharma AG, Basel, Switzerland, Kantar Health, Horsham, PA, USA

PSS27 M13 PATIENT PERCEPTIONS OF PSORIASIS: A REVIEW OF THE SURVEY LITERATURE BY GEOGRAPHY
Mordin M, Haydysch E, Graham-Clarke P, Gnanasakthy A, Nikai E, RTI Health Solutions, Ann Arbor, MI, USA, RTI Health Solutions, Research Triangle Park, MI, USA, Eli Lilly Australia, West Ryde, Australia, RTI Health Solutions, Research Triangle Park, NC, USA, Eli Lilly and Company, Brussels, Belgium

PSS28 M14 EVALUATION OF A NOVEL CLINICIAN REPORTED OUTCOME IN NAIL PSORIASIS
Hudgens S, Sundaram M, Williams DA, Clinical Outcomes Solutions, Tucson, AZ, USA, AbbVie Inc., North Chicago, IL, USA

PSS29 M15 THE IMPACT OF PLAQUE PSORIASIS SEVERITY ON WORK PRODUCTIVITY AND DAILY ACTIVITIES
Lane S, Szabo S, Syed I, Chambenoit O, Barbeau M, Ho V, Lynde C, Gregory V, ICON PLC, Vancouver, BC, Canada, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, Vancouver Coastal Health, Vancouver, BC, Canada, Lynderm Research Inc., Toronto, ON, Canada

PSS30 M16 IMPACT OF DRY EYE DISEASE ON QUALITY OF LIFE, WORK PRODUCTIVITY, DAILY ACTIVITIES, AND HEALTH CARE RESOURCE USE IN A SURVEY OF 74,095 AMERICAN ADULTS
Farrand KF, Stillman IÖ, Fridman M, Schaumberg DA, Shire, Wayne, PA, USA, Shire, Lexington, MA, USA, AMF Consulting, Inc., Los Angeles, CA, USA

PSS31 M17 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO ADVANCED DRY AGE-RELATED MACULAR DEGENERATION: RESULTS FROM A PHASE 1/2A CLINICAL TRIAL OF CNT0 2476
Pierson RF, Orr S, Bogert J, Malone T, Crosby RD, Mathias SD, Chang TS, Cell Therapy, Janssen Research & Development, LLC, Spring House, PA, USA, Janssen Global Services, LLC, Raritan, NJ, USA, Neuropsychiatric Research Institute, Fargo, ND, USA, Health Outcomes Solutions, Winter Park, FL, USA, Retina Institute of California, Pasadena, CA, USA

SENSORY SYSTEMS DISORDERS - Health Care Use & Policy Studies

PSS32 M18 ACCEPTABILITY OF AZITHROMYCIN MASS TREATMENT FOR TRACHOMA ELIMINATION IN INJIBARA TOWN AND ADJACENT BANJA DISTRICT OF AWI ZONE, NORTHWESTERN ETHIOPIA
Mekonen ZT, Addis Ababa University, Addis Ababa, Ethiopia

PSS33 M19 REAL-WORLD USE OF SECUKINUMAB AMONG PATIENTS WITH PSORIASIS: PATIENT CHARACTERISTICS AND DOSING

**PUK1 N4** KHA T INDUCES MILD TO MODERATE NEPHROTOXICITY IN RATS: DANGERS OF PSYCHOACTIVE SUBSTANCES IN PERIPHERAL TISSUES  
Sabe ZS, University of Gondar, Gondar, Ethiopia

**PUK3 N6** THE COST-UTILITY OF SOLIFENACIN IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN CHINA  
Fan C1, Liao L2, Wang J3, Zhang H4, Chen B5, Wu J6,1Beijing Medical and Health Economic Research Association, Beijing, China, 2China Rehabilitation Research Center, Beijing, China, 3Beijing Hospital, Beijing, China, 4Astellas Pharma China Inc., Beijing, China, 5Shenyang Pharmaceutical University, Shenyang, China, 6306 hospital of PLA, Beijing, China

**PUK4 N7** COMPARATIVE EFFECTIVENESS OF TACROLIMUS-BASED STEROID SPARING VERSUS STEROID MAINTENANCE REGIMENS WITH KIDNEY TRANSPLANTATION: RESULTS FROM A DISCRETE EVENT SIMULATION  
Desai VC1, Ferrand Y2, Kelton C3, Cavanaugh T4, Caro J5, Goebel J6, Heaton PC7, HealthCore, Andover, MA, USA, 2Clemson University, Clemson, SC, USA, 3University of Cincinnati, Cincinnati, OH, USA, 4McGill University, Montreal, QC, Canada, 5Children's Colorado Hospital, Aurora, CO, USA

**PUK5 N8** THE IMPACT OF HEPATITIS C VIRUS ON KIDNEY-RELATED OUTCOMES AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE  
Rodriguez CV1, Arduino J2, Hsu J3, Rubenstein KB4, Wei R5, Hu H6, Horberg M7, Derose S8, Tartof SY9,1Kaiser Permanente, Rockville, MD, USA, 2Merck, North Wales, PA, USA, 3Kaiser Permanente, Pasadena, CA, USA

**PUK6 N9** ASSOCIATED FACTORS WITH GRAFT LOSS IN KIDNEY TRANSPLANTATION PATIENTS WHO USED MAINTENANCE IMMUNOSUPPRESSIVE REGIMENS CONTAINING CYCLOSPORINE OR TACROLIMUS IN SNS  
Gomes RM1, Lemos LL, Barbosa WB, Costa JD, Acuciro FA, Guerra Jr AA, CCATES, Federal University of Minas Gerais, Belo Horizonte, Brazil

**PUK7 N10** ANEMIA: THE TROUBLEMAKER CHILD OF CHRONIC KIDNEY DISEASE  
Salman M1, Hussain K2, Khan AH3, Adnan AS4, Shehzadi N5, Syed Sulaiman SA6,1University of the Punjab, Lahore, Pakistan, 2Universiti Sains Malaysia, Pulau Pinang, Malaysia, 3Hospital Universiti Sains Malaysia, Kelantan, Malaysia

**PUK8 N11** BUDGET IMPACT ANALYSIS OF MEDICAL CARE FOR CHRONIC RENAL DISEASE PATIENTS IN NEED OF RENAL REPLACEMENT THERAPY VIA PERITONEAL DIALYSIS AND HEMODIALYSIS IN THE RUSSIAN HEALTH CARE ENVIRONMENT  
Yagudina R1, Kulikov A2, Abridrashitova G3, Serpik VG1M. Sechenov First Moscow State Medical University, Moscow, Russia

**PUK9 N12** COST OF ILLNESS ANALYSIS OF NOCTURIA IN GERMANY, SWEDEN, AND THE UNITED KINGDOM  
Weidlich D1, Andersson FL2, Guest J1, Catalyst Health Economics Consultants, Northwood, UK, 2Ferring Pharmaceuticals A/S, Copenhagen, Denmark

**PUK10 N13** CHARACTERIZING HEALTH CARE UTILIZATION, DIRECT COSTS, AND COMORBIDITIES ASSOCIATED WITH INTERSTITIAL CYSTITIS: A RETROSPECTIVE CLAIMS ANALYSIS  
Tung A1, Hepp Z2, Bansal A3, Devine B4,1University of Washington, Seattle, WA, USA, 2Allergan, plc, Irvine, CA, USA

**PUK11 N14** COST EFFECTIVENESS OF ONABOTULINUMTOXINA VERSUS PTNS AND SNS FOR THE TREATMENT OF OVERACTIVE BLADDER FROM THE US PAYER PERSPECTIVE  
Hepp Z1, Yehoshua A2, Gultyaev D3, Lister J4, Boer R5, Khalaf K6,1Allergan, plc, Irvine, CA, USA, 2LA-SER Analytica, Lorrach, Germany, 3Xcenda, LLC, Palm Harbor, FL, USA
COST-EFFECTIVENESS ANALYSIS OF MEDICAL CARE FOR CHRONIC RENAL DISEASE PATIENTS IN NEED OF RENAL REPLACEMENT THERAPY VIA PERITONEAL DIALYSIS AND HEMODIALYSIS IN THE RUSSIAN HEALTH CARE ENVIRONMENT

Yagudina R, Kulikov A, Abdrashtitova G, Serpik VG, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

ECONOMIC EVALUATION OF SEVELAMER VERSUS CALCIUM-BASED BINDERS IN TREATING HYPERPHOSPHATEMIA AMONG PATIENTS WITH END-STAGE RENAL DISEASE IN CHINA

Yang L, Peking University, Beijing, China

ECONOMIC AND QUALITY-OF-LIFE IMPACT OF A PELVIC FLOOR PHYSICAL THERAPY PROGRAM FOR WOMEN WITH URINARY INCONTINENCE IN A MIDDLE LOW-INCOME NEIGHBORHOOD IN MEDELLIN, COLOMBIA

Martinez W, Orozco J, Stolen K, Bogut L, Cuartas M, Metrosalud, Medellin, Colombia, Medtronic PLC, Medellin, Colombia, Medtronic PLC, Minneapolis, MN, USA, Medtronic PLC, Minneapolis, MN, Colombia, Medtronic PLC, Bogota, Colombia

COMPARISON OF ARTERIOVENOUS FISTULA (AVF) MAINTENANCE AND ASSOCIATED COSTS BETWEEN TRADITIONAL SURGICAL AVF CREATION AND A NEW ENDOVASCULAR APPROACH

Yang S, Arnold RJ, Yu TM, Glickman M, Layton AJ, Rajan DK, Lok C, Quorum Consulting, Inc, San Francisco, CA, USA, Eastern Virginia Medical School, Virginia Beach, VA, USA, University of Toronto, Toronto, ON, Canada, University Health Network-Toronto General Hospital, University of Toronto, Toronto, ON, Canada

THE ECONOMIC BURDEN AFTER RENAL TRANSPLANTATION IN EUROPE

Muduma G, Hawkew NA, Astellas Pharma UK, Chertsey, UK, Creativ-Ceutical, Luxembourg, Luxembourg

HEALTH IN THE TRIAD OF INEQUALITY, SOCIOECONOMIC GRADIENT, AND CONSUMPTION PATTERN

Ayerga TJ, Bayero University, Kano, Nigeria

ASSESSING CHANGE IN HEALTH-RELATED QUALITY OF LIFE WITH MIRABEGRON ADD-ON THERAPY TO SOLIFENACIN IN INCONTINENT PATIENTS WITH OVERACTIVE BLADDER: AN ANALYSIS OF EQ 5D-5L AND OAB-5D DATA FROM THE BESIDE CLINICAL TRIAL


REAL-WORLD, CROSS-SECTIONAL, DESCRIPTIVE STUDY OF THE QUALITY OF LIFE OF PATIENTS WITH ANEMIA AND CHRONIC KIDNEY DISEASE ACROSS EUROPE

Goldsmith D, Eriksson D, Teitsson S, Jackson J, van Nooten F, Guy’s and St Thomas’ NHS Foundation Hospital, London, UK, Quantify Research, Stockholm, Sweden, Adelphi Group, Bollington, UK, Astellas Pharma BV, Leiden, The Netherlands

HUMANISTIC BURDEN AFTER RENAL TRANSPLANTATION IN EUROPE: SYSTEMATIC LITERATURE REVIEW

Muduma G, Hawkew NA, Astellas Pharma UK, Chertsey, UK, Creativ-Ceutical, Luxembourg, Luxembourg

ECONOMIC AND UTILIZATION TRENDS AMONG ESRD PATIENTS WITH ANEMIA: IV IRON AND ERYTHROPOIESIS STIMULATING AGENTS

White A, Kim D, Coyle R, Coyle D, Young H, University of North Texas, Fort Worth, TX, USA, Mercer University, Atlanta, GA, USA, University of Georgia, Athens, GA, USA

REIMBURSEMENT-BASED ECONOMIC EVALUATION OF DRUGS FOR THE TREATMENT OF OVERACTIVE BLADDER

Lee KM, Coyle D, Coyle K, Loncar M, CADTH, Ottawa, ON, Canada, University of Ottawa, Ottawa, ON, Canada, Brunel University, Uxbridge, UK

A SYSTEMATIC REVIEW OF INTERNATIONAL POLICIES, BARRIERS, AND STRATEGIES TO INCREASE PERITONEAL DIALYSIS ADOPTION

Ariza JG, Cataño A, Brabata C, BAXTER, BOGOTA, Colombia, BAXTER, MIAMI, FL, USA

EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN-RECEPTOR BLOCKERS INHIBITORS ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE IN MEDICARE PART D ENROLLEES

Han Y, Balkrishnan R, Erickson SR, Hirth RA, Saran R, University of Michigan, Ann Arbor, MI, USA, University of Virginia School of Medicine, Charlottesville, VA, USA